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 Abstract 
Introduction 
Laparoscopic colorectal surgery and enhanced recovery programs have been 
shown to improve patient outcomes and reduce length of stay following surgery. 
The use of regional analgesia is usually a fundamental element of an enhanced 
recovery program. A proposed benefit of regional analgesia in colorectal 
surgery is suppression of the post-operative stress response. No data is 
available to indicate if this is applicable in laparoscopic colorectal surgery. In 
addition there is no direct evidence addressing whether there is an appropriate 
type of fluid, crystalloid or colloid, to use in goal-directed fluid therapy. The aim 
of this study was to examine the effects the choice of analgesia and intravenous 
fluid had on physiological and biochemical outcomes following laparoscopic 
colorectal surgery in patients within an enhanced recovery program. 
 
Methods 
A randomized clinical trial (NCT 01128088) was conducted between 2010-2011 
at a single institution. All patients underwent laparoscopic colorectal surgery for 
benign or malignant conditions within an established enhanced recovery 
program. Patients were randomly assigned to receive either a spinal or 
morphine PCA as their primary post-operative analgesia. In addition, patients 
were randomly allocated to receive either 6% Volulyte or Hartmann’s solution, 
which was administered as directed by an oesophageal Doppler monitor in 
order to achieve stroke volume optimisation. Blood was taken to measure 
aspects of the stress response at pre-op, 3, 6, 12, 24 and 48 hour time 
intervals. Various other physiological and patient outcomes were measured. 
 Results 
One hundred and twenty patients were analysed in the study. There was no 
significant difference in patient characteristics between the groups. No 
significant difference was seen between the analgesia groups at pre-op, 3, 6, 
12, 24 or 48 hours in the levels of insulin, IL-2, 4, 6, 8, 10, 12, TNF-α, VEGF or 
IFN-γ. Median cortisol (468 nmol/l (IQR: 329-678) vs 701 nmol/l (IQR: 429-820); 
p=0.004) and glucose (6.1 mmol/l (IQR: 5.4-7.5) vs 7 mmol/l (IQR: 6-7.7); 
p=0.012) levels were significantly lower at 3 hours post-op in the spinal group 
and thereafter the same.  
 
Patients receiving Hartmann’s solution received significantly greater volumes of 
fluid in comparison to those receiving 6% Volulyte (20.98ml/kg (IQR: 16.68-
25.73) vs 13.95ml/kg (IQR: 11.76-18.1); p<0.0005). There was no significant 
difference in the median length of stay between either fluid (6% Volulyte 2.75 
days [IQR: 2.08-3.6] vs Hartmann’s 2.29 days [IQR: 2.01-3.59]; p=0.807) or 
analgesia (spinal 2.25 days [IQR: 1.89-3.13] vs PCA 2.9 days [IQR: 2.09-3.93]; 
p=0.059) groups. The number of complications was no different between the 
two types of fluids but patients receiving spinal analgesia (20% vs 37%, 
p=0.013) had a significantly reduced number. 
 
 
 
 
 
 
 Conclusion 
Following laparoscopic colorectal surgery within an enhanced recovery program 
the use of spinal analgesia in comparison to morphine PCA significantly 
reduces the levels of cortisol and glucose at 3 hours only. This difference does 
not translate to a reduction in length of stay. There is no effect on other aspects 
of the stress response at various post-operative time intervals. A significantly 
greater quantity of Hartmann’s solution is required to achieve stroke volume 
optimisation in comparison to 6% Volulyte. This, however, did not make any 
difference to the incidence of post-operative complications or length of stay. 
Either fluid is acceptable in the quantities given in this study. 
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1 Introduction 
1.1 The principles of Enhanced Recovery after Surgery 
(ERAS) 
Fast track or enhanced recovery programmes originated in the 1990s. Their aim 
was to improve peri-operative care in patients undergoing open colorectal 
surgery, by utilization of a multi-modal rehabilitation programme. The main 
pioneer and protagonist of the concept was a surgeon, Henrik Kehlet from 
Copenhagen, Denmark. During the 1990s he had concerns that current peri-
operative care principles led to delays in patient recovery and potentially 
increased the rate of post-operative complications in elective open colorectal 
surgery. The average length of stay following elective open colorectal surgery 
with standard peri-operative care ranged from 8-12 days, with post-operative 
morbidity in 20-30% of patients  (Kehlet 2008). The limiting factors to early 
discharge were pain, nausea, ileus, fatigue and the use of nasogastric tubes 
and drains  (Kehlet, & Mogensen 1999). 
 
With the use of several peri-operative innovations, such as continuous epidural 
analgesia, early oral feeding and enforced mobilization Kehlet showed that the 
length of stay was reduced to a median of five days following elective open 
colorectal surgery  (Møiniche et al 1995). With additional modifications to the 
multi-disciplinary approach of peri-operative care the length of stay was further 
reduced to a median of two days in both open and laparoscopic colorectal 
surgery  (Bardram et al 1995; Kehlet, & Mogensen 1999) . Further research and 
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the formation of the international ERAS group, resulted in the identification of 20 
key elements that are recommended to deliver optimal peri-operative care, as 
seen in Table 1.1  (Lassen et al 2009). 
Table 1.1 The twenty elements of the Enhanced Recovery Programme 
1 Preadmission information and counseling 
2 Avoidance of pre-operative bowel preparation 
3 Pre-operative carbohydrate loading and minimal starvation 
4 Avoidance of pre-anaesthetic medications 
5 Thromboembolic prophylaxis 
6 Administration of prophylactic antibiotics 
7 Standardised anaesthetic protocol to include a mid-thoracic epidural 
8 Prevention of nausea and vomiting 
9 Laparoscopic resection where the skill is available 
10 Minimal length abdominal incisions 
11 No routine use of nasogastric tubes 
12 Prevention of intra-operative hypothermia 
13 Careful perioperative fluid management using goal-directed techniques 
14 No routine use of abdominal drains 
15 Short period of urinary drainage 
16 Prevention of post-operative ileus 
17 Post-operative analgesia with a continuous thoracic epidural and 
avoidance of opiate analgesia 
18 Postoperative nutritional care 
19 Early mobilization 
20 Audit 
 
These recommendations are based on the best available evidence and the 
most relevant elements will be discussed below.  
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It is important to prepare patients prior to admission by providing written 
information, tours of the post-operative surgical wards and most importantly to 
use patient pathways which highlight the post-operative goals that patients are 
expected to achieve. Correct preparation of patients has been shown to reduce 
pain levels and anxiety  (Kiecolt-Glaser et al 1998; Egbert et al 1964).  
 
The use of a mechanical bowel preparation, such as sodium picosulphate, 
should be avoided as it has not been shown to reduce the consequences of an 
anastomotic leak  (Contant et al 2007; Jung et al 2007). Mechanical bowel 
preparation can produce significant fluid and electrolyte disturbances and may 
also actually increase the risk of anastomotic leaks  (Bucher et al 2005).  
 
In addition to minimizing pre-operative starvation to six hours for solids and two 
hours for clear fluids the administration of an oral carbohydrate drink the night 
before and the morning of surgery is beneficial. Oral carbohydrate loading can 
be safely administered  (Nygren et al 1995) pre-operatively and reduces post-
operative insulin resistance, which minimizes the catabolic state and 
subsequent nitrogen losses following surgery  (Ljungqvist et al 2000; Ljungqvist 
et al 2002; Wang et al 2010). Along with preservation of the anabolic state, oral 
carbohydrate preloading reduces the length of stay following elective colorectal 
surgery  (Noblett et al 2006b). 
 
The ERAS group recommended the use of mid-thoracic epidural analgesia 
(TEA) with a mixture of local anaesthetic (bupivacaine) and low dose opiate 
(fentanyl), started prior to the first skin incision and continued at 4-10 ml/hr for 
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the next 48 hours  (Lassen et al 2009). There are a number of proposed 
benefits with TEA usage. With the use of TEA there is a reduction of pulmonary 
complications due to an increase of the functional residual capacity  (Moraca et 
al 2003). TEA can also reduce gastrointestinal ileus, provide excellent pain 
control and allow early mobility  (Kehlet, & Holte 2001; Fotiadis et al 2004; 
Marret et al 2007). TEA will also reduce the neuro-humoral stress response that 
occurs following surgery. These effects are produced by a blockade of 
sympathetic afferents and efferents that traverse the epidural space.  To be fully 
effective it is recommended that the epidural is continuous for 48 hours after 
surgery  (Holte, & Kehlet 2002a). TEA also reduces the amount of systemic 
morphine that may be required for breakthrough pain, which is known to cause 
immune suppression  (Afsharimani et al 2011).  
 
Peri-operative fluid therapy is a further critical stage in the ERAS programme. 
There has been much debate in the literature regarding the correct volume of 
fluid to give during major surgery. The argument usually lies around “liberal” 
versus “restrictive“ fluid regimes  (Rahbari et al 2009; Holte et al 2007; 
Brandstrup et al 2003; Bundgaard-Nielsen et al 2009). Current 
recommendations from the ERAS group are that a state of normovolaemia 
should be targeted during the intra-operative period  (Lassen et al 2009). The 
most appropriate method of achieving correct fluid balance is to use 
individualized goal-directed fluid therapy (GDFT), guided by changes in the 
measured stroke volume or corrected flow time in response to fluid infusion.  
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Oesophageal Doppler monitoring or LiDCO rapid are two examples of methods 
that easily allow GDFT to be monitored  (Montenij et al 2011; Bundgaard-
Nielsen et al 2007). Recent guidance from the National Institute for Health and 
Clinical Excellence recommend the use of an oesophageal Doppler for fluid 
management in major surgery (MTG 3). The aim of achieving a normovolaemic 
state in an individual patient is to prevent fluid overload and subsequent weight 
gain, which will be expected to reduce post-operative complications and length 
of stay  (Noblett et al 2006a). 
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1.2 The importance of ERAS 
Evidence has now started to highlight the importance of ERAS programmes in 
colorectal surgery. There have been six randomised controlled trials 
investigating the effect of ERAS programmes on open colorectal surgery, where 
the primary outcome measure was length of stay  (Khoo et al 2007; Serclová et 
al 2009; Muller et al 2009; Gatt et al 2005; Anderson et al 2003; Delaney et al 
2003b). They have all shown that the use of ERAS generates a significant 
reduction in the length of stay in comparison to standard peri-operative care. A 
reduction of the post-operative complication rate was also shown in some of 
these studies  (Serclová et al 2009; Muller et al 2009; Khoo et al 2007). These 
randomised trials and a number of controlled clinical trials have been analysed 
in six reviews  (Adamina et al 2011; Rawlinson et al 2011; Varadhan et al 2010; 
Eskicioglu et al 2009; Wind et al 2006b; Gouvas et al 2009).  
 
A comprehensive meta-analysis used the above six randomised controlled 
trials, with a total of 452 patients  (Varadhan et al 2010). It showed that the use 
of ERAS protocols in open colorectal surgery reduced the length of stay by 2.5 
days. If greater than four elements of the ERAS protocol were implemented, 
length of stay was reduced by greater than two days, accompanied by a 50% 
reduction of complication rates. In addition to reduced length of stay, there was 
no compensatory increase in the readmission rate. The same conclusion was 
also drawn by Adamina et al, who reviewed the same randomised controlled 
trials  (Adamina et al 2011). 
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Despite the important effect that ERAS protocols have on patient recovery and 
outcome there is still a disappointingly low uptake of the programme in the UK 
and further afield, or of individual elements within it. A questionnaire sent to all 
the members of the Association of Coloproctology of Great Britain and Ireland 
(ACPGBI) identified some interesting facts  (Arsalani-Zadeh et al 2010). There 
was a 64% response rate, of whom under 50% of respondents used a pre-
operative oral carbohydrate load, and over 30% still used a mechanical bowel 
preparation for left-sided resections. There was, however, an 86% use of 
epidurals for post-operative pain control. A postal survey conducted by the 
ERAS group on its member countries identified that perioperative routines for 
colon cancer surgery in northern Europe differed widely and there was 
considerable deviation from the best available evidence  (Lassen et al 2005). 
 
One of the difficulties with ERAS protocols is the multimodal nature of the 
programme spanning the whole patient pathway, which can lead to problems 
with adherence to all the elements.  Patients not enrolled as part of an ERAS 
trial have been recognised to have poorer compliance with the elements of 
ERAS protocols, particularly oral carbohydrate loading, in comparison to those 
patients in ERAS trials  (Ahmed et al 2010). This had an effect in non-ERAS 
trial patients, who showed a slower return of normal diet and lower use of non-
opiate postoperative analgesia. A review conducted on ERAS trials, which 
focused on compliance, identified that with increasing adherence to the ERAS 
elements there was a reduction in length of stay, but a concomitant rise in the 
readmission rate  (Ahmed et al 2011). A real-time review of compliance to the 
individual elements of the ERAS protocol in one hospital showed a variation of 
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28% to 100%  (Walter et al 2011). While it is important to embrace the concept 
and principles of an ERAS programme the real-time implementation of it is 
recognised as an additional difficult hurdle.  
 
Studies have aimed to identify factors that will predict deviation from the ERAS 
protocol and subsequent delay in discharge. A lower American Society of 
Anesthesiologists (ASA) classification, low use of oral postoperative opiates and 
interestingly, a reduced length of time the epidural was in use resulted in a 
reduced length of stay  (Ahmed et al 2010). If the epidural was in use for less 
than 24 hours patients were twice as likely to have a reduced length of stay. A 
single-centre study from Yeovil District Hospital showed an association between 
an increased length of stay and increasing age, the number of procedures 
performed and deviation from the ERAS protocol  (Boulind et al 2011). This 
study highlighted patients’ failure to mobilise, a surrogate marker for failed 
ERAS elements, as a red flag for delayed discharge. Similar findings were seen 
from the LAparoscopy and/or FAst track multimodal management versus 
standard care (LAFA) trial group where failure to comply with enforced 
mobilisation and oral intake were independent predictors of delayed discharge  
(Vlug et al 2011a). 
 
The majority of trials focus on the primary outcome or ERAS programmes as 
the length of stay. A more important issue, however, is the occurrence of 
postoperative complications, which obviously has a direct effect on the length of 
stay. Gustafsson et al reviewed over 900 patients in a single-centre cohort 
study who underwent colorectal cancer surgery within an ERAS programme 
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over a six year period  (Gustafsson et al 2011). They identified that with 
increased adherence to the ERAS protocol there was a significant reduction in 
the rate of postoperative complications. A 27% increase in overall adherence to 
the ERAS protocol produced a 27% reduction in relative risk of 30-day morbidity 
and 47% reduction in symptoms delaying discharge. The major independent 
factors associated with increased morbidity if omitted were oral carbohydrate 
loading and the use of restrictive fluid regimes on the day of surgery. For every 
additional litre of fluid given, the risk of postoperative symptoms delaying 
recovery increased by 16%, and the risk of complications increased by 32%. 
 
The importance of reducing postoperative complications is not just linked to 
delays in discharge but can have a profound effect on long-term survival. Khuri 
et al looked at long-term survival in a cohort of over 100,000 patients 
undergoing a number of different surgeries  (Khuri et al 2005). Across the whole 
cohort the occurrence of any 30-day complication reduced median patient 
survival by 69%. 
 
It is clear that ERAS protocols when followed well can reduce length of stay and 
complication rates in colorectal surgery, which can have a profound effect on 
long-term survival. All that has been discussed so far pertains to open 
colorectal surgery. Laparoscopic colorectal surgery provides additional benefits 
to patients and some elements of the ERAS protocol need to be tailored to this 
minimal access technique. 
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1.3 ERAS in the era of laparoscopic colorectal surgery 
Laparoscopic colorectal surgery has a number of distinct advantages over open 
colorectal surgery. There is a reduction in length of stay and morbidity, as well 
as an earlier return to normal gut function, less pain and more rapid recovery  
(Abraham et al 2004; Aly 2009; Breukink et al 2006). There is no difference in 
the adequacy of resection, in terms of margins and lymph node harvest, 
achieved with laparoscopic surgery  (Bonjer et al 2007; Kuhry et al 2008), 
indeed there have been suggestions of a potential increase in long-term 
survival in certain groups  (Lacy et al 2008; Day et al 2011; Day et al 2013). 
 
A number of studies have identified a significant reduction in length of stay with 
laparoscopic colorectal resection  (Delaney et al 2003a; Clinical Outcomes of 
Surgical Therapy Study Group 2004; Tjandra, & Chan 2006; Stage et al 1997; 
Neudecker et al 2009; Lacy et al 2002). There is evidence that there is a 
significant improvement in the length of stay when ERAS and laparoscopic 
surgery are combined  (Senagore et al 2003b; Lovely et al 2012; Haverkamp et 
al 2011; Lloyd et al 2010; Feroci et al 2011). With this combination it is possible 
to achieve extremely short hospital stays of one day  (Levy et al 2009; Delaney 
2008).  The previous section showed that application of ERAS protocols to 
open colonic surgery can achieve substantial reductions in length of stay  
(Kehlet, & Mogensen 1999). The remaining question is whether the use of 
ERAS protocols as used in open surgery will produce similar outcomes with 
laparoscopic surgery. 
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There have been a few case-controlled studies  (Junghans et al 2006; Polle et 
al 2007; MacKay et al 2007; Raymond et al 2009) and three randomised 
controlled trials  (Basse et al 2003; Basse et al 2005; King et al 2006) 
comparing laparoscopic surgery with ERAS to open surgery with ERAS. There 
have been two systematic reviews  (Vlug et al 2009; Khan et al 2009) 
conducted on these studies and both have drawn the same conclusion that 
there is not enough data to identify any difference. There is considerable 
heterogeneity in the above studies, however, to make any meaningful review 
extremely difficult. There are currently three large randomized controlled trials 
underway to address this issue: the EnROL, LAFA  (Wind et al 2006a) and 
TAPAS  (Reurings et al 2010) studies. One of these, the LAFA trial  (Vlug et al 
2011b), has recently published its findings. 
 
The LAFA trial randomized 427 patients into four groups to receive either 
laparoscopic or open surgery with either standard care or ERAS care  (Vlug et 
al 2011b). The laparoscopic fast-track (ERAS protocol) group had a median 
length of stay of 5.0 days, which was significantly shorter than the 7.0 days in 
the open fast-track group. There were no differences detected in postoperative 
morbidity between the four groups but with regression analysis laparoscopy 
was identified as the only independent factor that reduced hospital stay and 
morbidity. 
 
Thus, laparoscopic surgery and ERAS protocols may work synergistically to 
achieve short length of stays following colorectal resection. The majority of 
research on ERAS and laparoscopic surgery involves the application of ERAS 
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protocols that are little changed from those used in open surgery. An example 
of this is the strong recommendation for the use of a thoracic epidural, for its 
various effects described in section 1.3. While its use in open surgery is 
undisputed, there is evidence that it may be unnecessary in laparoscopic 
surgery  (Levy et al 2010).  
 
Delaney et al showed that extremely short lengths of stay can be achieved 
using a morphine PCA within an enhanced recovery program following 
laparoscopic surgery  (Delaney 2008). The use of spinal analgesia is another 
alternative to the epidural, with its short-acting nature and good pain control 
lending itself well to laparoscopic surgery. There has been one retrospective 
review  (Virlos et al 2010) and one randomized controlled trial  (Levy et al 2011) 
comparing spinal with PCA, and spinal with epidural or PCA respectively. Virlos 
et al showed a significantly shorter length of stay with spinal analgesia in 
comparison with PCA  (Virlos et al 2010). Levy et al showed significantly shorter 
length of stays with spinal analgesia or PCA compared with epidural analgesia  
(Levy et al 2011). In addition there has been a randomised trial  (Hübner et al 
2014) which identified a reduced number of complications but no difference in 
length of stay in patients receiving an opiate PCA rather than an epidural. 
 
One of the proposed benefits of thoracic epidural use is suppression of the 
stress response during the postoperative period  (Fotiadis et al 2004). As very 
short length of stays can be achieved with laparoscopic surgery one may be 
able to presume that the magnitude and duration of the stress response is less. 
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This would, therefore, render the use of an epidural analgesia less vital. There 
is currently no evidence to address this issue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  29 
1.4 The stress response in surgery 
The stress response is an overarching term encompassing the multiple 
physiological responses that patients undergo following trauma or injury. 
Surgery is a potent stressor. The origins of the term “stress response” stem 
from the work of Sir David Cuthbertson, a clinical chemist in Glasgow, over 80 
years ago  (Cuthbertson 1932). While investigating the reason for non-union of 
long bone fractures he noticed a dramatic increase in the loss of nitrogen, 
potassium and creatine in these patients when compared to healthy controls. 
He hypothesized that the increased loss of intracellular constituents was 
secondary to a breakdown of tissue causing a net protein catabolism. He 
identified an elevated basal metabolic rate occurring at the same time as this 
peak in tissue catabolism. This is the concept of the stress response. 
 
The stress response following an injury can be divided into two distinct phases: 
the “ebb” and “flow” phases. The ebb phase is first and represents the patient’s 
survival response to the stimulus of injury/surgery, with a net decrease in 
energy requirements. This represents a period of survival and is proportional to 
the degree of magnitude of the stimulus applied.  
 
The second phase, the flow phase, represents a hyper-metabolic period during 
which there is net catabolism and a raised basal metabolic rate proportional to 
the degree of injury  (Kohl, & Deutschman 2006). During this time period, of 
variable length, the body undergoes repair and, when successfully achieved, 
the homeostatic state is returned. This represents the normal response 
following surgery. 
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Occasionally, however, the hyper-metabolic phase can continue unchecked, 
and this leads to a systemic inflammatory response syndrome (SIRS) and then 
multi-organ dysfunction syndrome (MODS). In this abnormal state, patients 
require a high level of care and experience significant morbidity and mortality. 
Over the years there has been considerable research to prevent the 
development of SIRS and then MODS following surgical interventions. In 
addition the benefit of the stress response at all has been brought into question 
and much work, therefore, has been aimed at attenuating it, with the theory that 
this may promote rapid recovery  (Kehlet 1997). 
 
The stress response is composed of a number of different, individual 
physiological responses. They are best divided into endocrine/metabolic, 
inflammatory and immune responses. Each of these will be discussed 
separately, focusing on the useful measureable markers of the post-surgical 
stress response.  
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1.4.1 Endocrine and metabolic response 
There are a number of endocrine and subsequent metabolic changes that occur 
as a result of surgery. There is a general increase in the secretion of pituitary 
hormones and activation of the sympathetic nervous system, which leads to 
hormone secretion from target organs.  
 
The hypothalamic activation of the sympathetic nervous system (SNS) leads to 
a release of catecholamines from the adrenal medulla causing a tachycardia 
and hypertension. A number of organs also receive stimulation as a result of 
direct SNS stimulation as well as that achieved by circulating catecholamines. 
The posterior pituitary produces increased amounts of arginine vasopressin, 
which functions as an anti-diuretic hormone. There are also increases in the 
secretion of growth hormone and prolactin with reduction in the amount of total 
and free tri-iodothyronine (T3) following surgery  (Desborough 2000). Growth 
hormone promotes protein synthesis and lipolysis and inhibits glucose uptake 
by cells  (Kohl, & Deutschman 2006).  
 
As a result of surgery there is also activation of the hypothalamic-pituitary-
adrenal axis (HPA) axis. The hypothalamus releases corticotrophin-releasing 
factor (CRF), which stimulates the anterior pituitary to release 
adrenocorticotrophic hormone (ACTH) into the circulation. This stimulates the 
adrenal cortex to release cortisol, a glucocorticoid. Cortisol promotes protein 
breakdown and prevents protein synthesis leading to a net nitrogen loss, which 
has a detrimental effect on post-operative recovery and healing  (Lattermann et 
al 2001). There is also an increase in gluconeogenesis and lipolysis with 
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resultant increases in blood glucose levels. In addition, cortisol has anti-
inflammatory effects by reducing circulating lymphocyte numbers, suppressing 
natural killer cell activity as well as reducing chemotaxis of neutrophils  
(O'Connor et al 2000).  
 
Insulin, a polypeptide of two amino acid chains joined by two disulphide bridges, 
is a key anabolic hormone. Insulin is released from the beta cells of the 
pancreas in response to elevated amino acid and glucose levels following food 
intake. Insulin promotes the uptake of glucose into muscle and adipose cells 
and the formation of glycogen and triglycerides. Protein catabolism and lipolysis 
are inhibited by the actions of insulin  (Desborough 2000). As a result of surgery 
there is a reduction of insulin levels, as well as development of insulin 
resistance at the cellular level. The GLUT 4 transport protein was first described 
by James et al  (James et al 1988) as an additional insulin sensitive transport 
protein in extrahepatic tissues, predominantly in skeletal muscle and adipose 
tissue. Insulin resistance in the post-operative period is thought to be due to a 
disturbance in the GLUT 4 transport protein  (Ljungqvist et al 2000). This, along 
with the effects of cortisol, leads to a state of hyperglycaemia during the 
postoperative period.  
 
A dose-dependent response to the degree of insulin resistance and subsequent 
hyperglycaemia occurs secondary to the severity of surgery and related blood 
loss  (Thorell et al 1993; Thorell et al 1994; Thorell et al 1999). Insulin 
resistance is also driven by postoperative elevated levels of interleukin-6 (IL-6), 
cortisol, glucagon, catecholamines and growth hormone (Ljungqvist et al 2000). 
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The severity of insulin resistance that occurs equates with increases in 
postoperative length of stay and possible complications (Awad et al 2013; 
Thorell et al 1999).  
 
Insulin and cortisol are therefore valuable and important markers of the 
postoperative endocrine and metabolic stress response. Their use in this 
context have been validated in a number of previous studies (Brandt et al 1978; 
Thorell et al 1999; Kehlet 2000; Lattermann et al 2001; Ljungqvist et al 2002; 
Lattermann et al 2003; Wang et al 2010; Ozawa et al 2000; Crema et al 2005; 
Buyukkocak et al 2006b) and furthermore are readily measureable in venous 
blood samples in a hospital laboratory setting. 
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1.4.2 Inflammatory response 
The inflammatory response to surgery involves a change in the levels of various 
cytokines, and in consequence is also closely linked to postoperative changes 
in immune function. Cytokines are small protein molecules that are produced by 
cells in response to a stimulus and act upon other cells to exert their effect. The 
two major groups of cytokines are type 1 and 2. Type 1 cytokines are 
composed of a four α-helices, which produce predominately cellular immune 
responses. Examples of Type 1 cytokines are IL-2, IL-4, IL-6, IL-9, IL-12 and 
GM-CSF. Type 2 cytokines signal humoral responses. Examples of these are 
interferon-γ and IL-10 (Leonard, & Lin 2000). There is also an additional 
functional classification of cytokines categorized by their association with either 
T helper 1 (TH1) or T helper 2 (TH2) cells. These groups contain cytokines from 
both the type 1 and 2 classification. 
 
Following surgery the cytokine cascade is activated as part of the acute phase 
response and is diverse in both its production of cytokines and also their 
function. Activation is secondary to the release of local products following cell 
lysis, as well as to humoral factors and to activation of the sympathetic nervous 
system (Ben-Eliyahu 2003). Pro-inflammatory cytokine release is initiated by 
macrophages and monocytes at the initial site of injury, the operative field, as 
part of the acute phase response. These early cytokines are TNF-α and 
Interleukin-1β, which primarily stimulate a fever and tachycardia, but 
subsequently stimulate the release of other mediators such as IL-6 (Ni 
Choileain, & Redmond 2006). IL-6 is responsible for the release of a number of 
acute phase proteins, ie: CRP and procalcitonin. If the pro-inflammatory 
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response was left unchecked a profound systemic inflammatory response state 
would occur ultimately leading to multi-organ failure and potentially death.  
 
Therefore, IL-6 is also responsible for activating the anti-inflammatory response 
by stimulating the release of prostaglandin E2 from macrophages, which in turn 
leads to the release of IL-10 (Ayala et al 1994), a potent anti-inflammatory 
cytokine. It is this careful balance of pro and anti-inflammatory mediators that is 
required to enable an optimal post-operative recovery following surgery. The 
actions of the cytokines thus released are essentially either pro-inflammatory or 
anti-inflammatory, as such the amounts released and their relative proportions 
will determine the subsequent host response.  
 
A description of the cytokines that have been analysed in this study is given 
below, and the relevance they are thought to have in the postoperative acute 
phase response. These cytokines have been chosen for analysis because they 
provide a good representation of both the pro- and anti-inflammatory 
responses, that occur both immediately postoperatively and thereafter. 
 
1.4.2.1 Interleukin 2 (IL-2) 
This is a type 1 cytokine that is released from CD4 (TH1) T lymphocytes and 
acts as a primary promoter of T lymphocyte proliferation, immunoglobulin 
production and gut barrier integrity  (Lin et al 2000). Following surgery there is a 
reduction in the levels of IL-2, which contributes to the suppression of cell-
mediated immunity (CMI) that occurs after surgery (Ben-Eliyahu 2003). The 
degree of suppression is related to the extent of tissue trauma from surgery, as 
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has been demonstrated by comparing laparoscopic versus open 
cholecystectomy  (Brune et al 1999). 
 
1.4.2.2 Interleukin 4 (IL-4) 
This is a type 1 cytokine produced by activated TH2 cells and also from mast 
cells, macrophages and B lymphocytes. It has an anti-inflammatory effect. IL-4 
down-regulates the effect of pro-inflammatory mediators on macrophages, and 
increases the susceptibility of cells to the anti-inflammatory effects of 
glucocorticoids  (Lin et al 2000). The levels of IL-4 rise during the postoperative 
period  (Ishikawa et al 2009). 
 
1.4.2.3 Interleukin 6 (IL-6) 
This is a type 1 cytokine produced by most tissues in response to stimulation by 
TNF-α and IL-1, which are early mediators in the postoperative inflammatory 
response. IL-6 is predominately pro-inflammatory in its action but does have 
some anti-inflammatory action by attenuating TNF-α and IL-1 activity. It also 
promotes the release of prostaglandin E2 from macrophages, which suppresses 
IL-2 production, and leads to an increase in IL-10 levels (Ni Choileain, & 
Redmond 2006). IL-6 levels increase postoperatively peaking at 4-6 hours after 
the initial stimulus (Lin et al 2000), and are proportional to the degree of 
operative severity (Jawa et al 2011). IL-6 stimulates the hepatic acute phase 
response producing a rise in C-reactive protein levels (Jawa et al 2011). The 
HPA axis is also activated by circulating levels of IL-6, in addition to spinal 
afferent signals from the site of surgery (Ben-Eliyahu 2003). IL-6 has been used 
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as a marker of the postoperative inflammatory response in numerous studies to 
date (Sammour et al 2010; Evans et al 2009; Wichmann et al 2005; Ozawa et al 
2000; Leung et al 2000; Harmon et al 1994; Kato et al 1997; Chachkhiani et al 
2005; Kamińska et al 2000). 
 
1.4.2.4 Interleukin 8 (IL-8) 
This is a pro-inflammatory cytokine that is released following surgery from T and 
B lymphocytes, macrophages and epithelial cells, and is temporally related to 
IL-6 release  (Lin et al 2000). It acts as a chemo-attractant and potent activator 
of neutrophils (Sietses et al 1999a). IL-8 levels are thought to rise in the 
postoperative period  (Sietses et al 1999a; Ben-Eliyahu 2003; Kato et al 1997). 
There is some contradictory evidence in one study following laparoscopic 
colonic resection, where a fall in levels was measured  (Wu et al 2003).  
 
1.4.2.5 Interleukin 10 (IL-10) 
This is a type 2 cytokine produced by T (TH2) and B lymphocytes as well as 
macrophages, and has an anti-inflammatory function  (Lin et al 2000). IL-10 is a 
modulator of the initial inflammatory response driven by TNF-α and IL-6, 
attenuating this effect. Prolonged activity of IL-10 can, however, lead to 
suppression of monocyte function, and thus increase the risk of sepsis. There is 
an increase in IL-10 levels during the post-operative period, which lags behind 
those of the pro-inflammatory cytokines (Ni Choileain, & Redmond 2006). In 
addition to IL-10 release secondary to local factors the SNS also triggers 
production following surgery (Ben-Eliyahu 2003). IL-10 has been shown to 
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exhibit a measurable rise following colorectal surgery  (Kamińska et al 2000) 
and major surgery  (Mahdy et al 2002). 
 
1.4.2.6 Interleukin-12 (IL-12) 
This is a type 1 cytokine released from B lymphocytes, neutrophils and 
macrophages and has a pro-inflammatory function  (Lin et al 2000). It has two 
functions. It promotes cell-mediated immunity by differentiation of T helper cells. 
IL-12 also mediates the activity of natural killer cells  (Inoue et al 2005) and as 
such has been suggested to have a possible anti-tumour role (O'Hara et al 
1998). Following surgery there is a recognised reduction in IL-12 levels (Ben-
Eliyahu 2003). 
 
1.4.2.7 Interferon gamma (IFN-γ) 
This is a type 2 cytokine released from TH1 cells, natural killer cells and 
macrophages (Lin et al 2000). TH1 cells are stimulated to release IFN-γ by the 
action of IL-2, IL-12 and IL-18. It is usually detectable by six hours and can 
persist for a number of days (Lin et al 2000). IFN-γ is pro-inflammatory in its 
function, acting by stimulating macrophages. IFN-γ has been detected in the 
postoperative period (Ben-Eliyahu 2003; Evans et al 2009).  
 
1.4.2.8 Tumour necrosis factor alpha (TNF-α) 
This cytokine is one of the first to be released as a result of surgery in the acute 
phase response. It has a short half-life of around 20 minutes but still produces a 
profound response (Lin et al 2000). It is mostly produced by activated 
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macrophages, but also originates from a number of other cells. It is pro-
inflammatory in its action, and really initiates the acute phase response: 
stimulating the HPA axis, the liver to produce CRP, cell apoptosis, fever and T 
cell proliferation. TNF-α is detectable following surgery but has variable levels of 
response (Evans et al 2009; Kamińska et al 2000), which is probably a 
reflection of its very short half-life. 
 
1.4.2.9 Vascular endothelial growth factor (VEGF) 
This is actually a growth factor rather than a cytokine but is nevertheless very 
relevant in the context of cytokine release after surgery. VEGF is released in 
response to inflammation in order to stimulate angiogenesis (Angelo, & 
Kurzrock 2007). It is also released by solid tumours, and is associated with a 
poor prognosis, secondary to the development of metastases and immune 
suppression  (Evans et al 2006). One study has shown an association between 
high preoperative levels of VEGF and a poor prognosis in colorectal cancer  
(Kwon et al 2010). Little is known about the alteration to VEGF levels following 
surgery, but one study has shown a significant reduction in levels in colon 
cancer patients during the postoperative period  (De Vita et al 2004).  
 
The postoperative inflammatory response is a complex interaction of many 
cytokines, and those discussed above aim to provide a reflection of the acute 
phase response following surgery. This network of cytokines has an effect on 
the levels, function and actions of immune cells. These will be discussed in the 
next section. 
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1.4.3 Immune response 
The immune response following surgery is closely associated with the changes 
that occur to cytokine levels, as described in the previous section. Surgery is 
known to be a potent suppressor of the immune system during the 
perioperative, and into the postoperative period; described as far back as 1971   
(Park et al 1971). Alteration of the immune system is predominately driven by 
changes to cytokine levels, but also results from sympathetic nervous system 
activation of the adrenal medulla causing a release of catecholamines  (Buunen 
et al 2004). Changes occur to both the innate and adaptive immune system as 
a result of surgery.  
 
The predominant effect of surgery is to cause immunosuppression by reduction 
and alteration of cell mediated immunity (CMI). There is a reduction in 
neutrophil chemotaxis and subsequent phagocytosis of bacteria following 
surgery  (Sietses et al 1999a; Marana et al 2000). There is also a reduction in 
the levels and function of natural killer (NK) cells postoperatively  (Sietses et al 
1999a; Marana et al 2000; Ben-Eliyahu 2003; Ayers, & Lee 2010). NK cells are 
granular lymphocytes that form part of the innate cellular response and kill cells 
infected with intracellular organisms. They also destroy tumour cells  (Salama, 
& Platell 2008). A high number of NK cells in the inflammatory infiltrate of 
colorectal tumours is associated with a better prognosis  (Salama, & Platell 
2008). Research looking at tumour metastasis formation using rats showed that 
surgical stress suppressed NK activity sufficiently enough to enhance tumour 
development  (Ben-Eliyahu et al 1999). 
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Following surgery there is a reduction of monocyte function and subsequent 
immune competence. This is reflected by a reduced expression of human 
leukocyte antigen-DR (HLA-DR) on the surface of monocytes  (Buunen et al 
2004). Expression of HLA-DR is associated with the adequate presentation of 
antigens and specific immune responses  (Veenhof et al 2012).  
 
Changes that occur in lymphocyte levels and function are thought to have the 
most profound effect on CMI. Overall lymphocyte levels are reduced following 
surgery  (Ni Choileain, & Redmond 2006; Evans et al 2009), and the ability of B 
lymphocytes to mature into plasma cells and secrete antibodies is suppressed 
with surgery (Sietses et al 1999a). The T lymphocytes that have been 
predominately investigated are the sub-types of T helper cells (CD4) and T 
cytotoxic cells (CD8)(Salama, & Platell 2008). Naïve T helper cells recognize 
antigens associated with major histocompatibility complex (MHC) proteins class 
2 and differentiate into either T helper cells type 1 (Th1) or T helper cells type 2 
(Th2). IL-12 released from macrophages is thought to promote differentiation 
into Th1 cells. IL-4 promotes the formation of Th2 cells  (Salama, & Platell 2008). 
Th1 cells promote CMI (through activation of CD8 cells) and therefore cytotoxic 
activity. CD8 cytotoxic cells recognize antigen presenting cells with MHC class 
1 and associated antigens, thus becoming activated and affecting cytotoxic 
activity. 
 
Following surgery there is a reduction in the levels of Th1 cells and therefore the 
ratio of Th1:Th2 cells is altered. This leads to an imbalance whereupon the 
humoral immune effects of Th2 cells dominate, and the important CMI effects of 
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Th1 cells are reduced  (Ishikawa et al 2009). The pro-inflammatory changes in 
cytokine levels as a result of surgery will drive this response.  
 
The degree of CMI suppression following surgery is of vital importance in 
determining surgical outcome. Suppression of CMI is associated with increased 
postoperative complications, infections and cancer recurrence. A reduction in 
CMI is known to increase the occurrence of postoperative infections  (Sietses et 
al 1999a). More important, however, in the context of this study, is the 
association between CMI suppression and the potential increased risk of 
tumour recurrence. 
 
There are three ways in which surgery is thought to promote the spread of 
malignant disease. Surgery can promote metastatic tumour formation by the 
release of tumour cells into the circulation, known to be an independent 
predictor of cancer recurrence  (Peach et al 2010). Secondly, following removal 
of the primary tumour, the suppressive effect that it may have exerted on any 
secondary deposits present will be removed. Thirdly, as previously discussed, 
surgery causes the release of a number of cytokines and growth factors which 
can promote micro-metastatic formation  (Ben-Eliyahu 2003).  
 
Minimization of CMI suppression, therefore, during the operative and 
postoperative period would seem paramount in oncological resection to prevent 
disease recurrence. Minimizing surgical trauma, as has been explained above, 
will minimize the degree of CMI suppression that occurs (Ordemann et al 2001). 
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1.5 Attenuation of the inflammatory and immune 
response: Laparoscopic versus open colorectal 
surgery 
  
There is a significant inflammatory response and period of immunosuppression 
following surgery. Much effort has been applied to develop suitable techniques 
that will minimise this response to improve patient outcomes. Preoperative oral 
carbohydrate loading, for example, not only reduces the length of stay (Noblett 
et al 2006b), but also attenuates the level of postoperative insulin resistance  
(Wang et al 2010) and reduces the level of cortisol rise on day one (Mathur et al 
2010). As discussed earlier, enhanced recovery protocols reduce length of stay 
and patient morbidity. There is also evidence that ERAS can minimise the 
postoperative stress response.  
 
Cell-mediated immunity, following open or laparoscopic colorectal surgery, is 
better-preserved in patients within an ERAS programme (Wichmann et al 2007). 
Wichmann et al showed a significantly reduced depression of circulating T cells 
and T-helper cells and a faster return to preoperative levels of natural killer cells 
in patients receiving ERAS care; compared to standard care; there was no 
difference in C-reactive protein (CRP) or IL-6 levels between the groups. They 
also showed that length of stay was significantly shorter in the fast-track care 
group. However, there was no mention of sub-analysis between the 
laparoscopic and open cohorts. 
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Ren at al concluded that an ERAS protocol attenuated the surgical stress 
response (Ren et al 2011). They randomized 597 consecutive patients 
undergoing colorectal surgery to either ERAS (n=299) or standard 
postoperative care (n=298). While there were elevated levels of cortisol, IL-6, 
TNF-α, IL-1β and IFN-γ following surgery, there were no significant differences 
detected between the two groups. The only significant difference was with the 
degree of insulin resistance, which was lower on day one in the ERAS group.  
The authors’ assertion that ERAS protocols reduced the inflammatory response 
must be treated with caution.  
 
The majority of work investigating inflammatory and immune changes following 
colorectal surgery focuses on the operative technique, comparing laparoscopic 
with open surgery. The hypothesis is that minimising the surgical insult will 
reduce the inflammatory response and the associated suppression of cell-
mediated immunity that occurs following colorectal surgery. This has 
implications for reducing the number of postoperative infections (Kimura et al 
2010) and the potential to affect tumour recurrence  (Ben-Eliyahu 2003). 
 
Initial research focused on comparing laparoscopic and open techniques in 
simple procedures such as cholecystectomy (Brune et al 1999) or Nissen’s 
fundoplication (Sietses et al 1999b). The evidence suggested a slight reduction 
in the inflammatory response (Kehlet 1999) and preservation of human 
leukocyte antigen-DR (HLA-DR) expression (Sietses et al 1999b) with the 
laparoscopic technique. Laboratory studies comparing laparoscopic to open 
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colonic resection in rats have identified some preservation of immune function 
with laparoscopy  (Kuntz et al 1998; Kuntz et al 2000).  
 
1.5.1 Benign colorectal conditions 
Clinical research with benign colorectal conditions shows evidence of 
attenuation of the stress response with laparoscopy.  When laparoscopic 
abdominal rectopexy is compared with an open procedure there is significantly 
reduced cortisol, CRP and urinary catecholamine levels, but not IL-6 levels  
(Solomon et al 2002). Hildebrandt et al (Hildebrandt et al 2003) showed a 
significant attenuation of the postoperative increase of IL-6, IL-10 and CRP 
following laparoscopic colonic resection for either Crohn’s disease or colonic 
carcinoma compared to those patients undergoing an open resection.  
 
Harmon et al (Harmon et al 1994) conducted a non-randomised prospective 
study comparing laparoscopic and open colectomy for benign and malignant 
colonic conditions. Whilst there was no difference in IL-1 or cortisol levels there 
was a significant blunting of the IL-6 rise in the laparoscopic group. There is 
evidence to suggest cell-mediated immunity is preserved, as measured by 
delayed type hypersensitivity testing of an intradermal injection of antigens, 
following laparoscopic colorectal resection  (Whelan et al 2003). Wichmann et al  
(Wichmann et al 2005) also showed a reduced inflammatory response (IL-6 and 
CRP) and preservation of NK cell numbers with laparoscopy in a non-
randomised study of 70 patients with a variety of colorectal disease. 
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There is contradictory evidence, however, from Dunker et al (Dunker et al 2003) 
who conducted a randomised trial for either Crohn’s disease, ulcerative colitis or 
FAP resections. There was no significant difference between the laparoscopic 
or open groups in the IL-6, CRP levels or HLA-DR expression following surgery.  
 
1.5.2 Colorectal cancer  
There have been many trials comparing laparoscopy and open surgical 
techniques to their effect on the inflammatory or immune response in colorectal 
carcinoma resection. These will be summarised in detail below. 
 
Fukushima et al (Fukushima et al 1996) conducted a non-randomised 
prospective study comparing gasless laparoscopic-assisted versus open 
sigmoid colectomy for colon cancer. 14 patients were studied (seven in each 
group) and no significant differences were measured for CRP, glucagon, and 
urinary catecholamines. However, IL-6 levels were significantly higher in the 
laparoscopic-assisted group on the day of surgery. There was a significant 
correlation, however, between length of surgery and the IL-6 rise and the 
laparoscopic cases tended to be longer than the open cases.  
 
Ozawa et al (Ozawa et al 2000) conducted a non-randomised prospective trial 
comparing laparoscopic colectomy versus open procedures for colon cancer. 
Sixteen patients were included in the study, divided equally between the two 
groups. Blood samples were measured preoperatively, and also at 2, 4, 6, 8, 
24, 48 and 72 hours postoperatively from the time of skin incision. There was 
no significant difference between the groups for patient characteristics except 
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that operative time was longer in the laparoscopic group but blood loss was 
less. Mean IL-6 levels were significantly lower in the laparoscopic group at all 
times, but only significantly so at 4-hours.  There were no significant differences 
in the ACTH and ADH levels and the rise of cortisol levels was similar in both 
the groups. Samples were stored at -20°C so care must be taken in 
interpretation of the results, as the ideal storage temperature is -70°C to prevent 
denaturation of the cytokines (Tworoger, & Hankinson 2006).  
 
Mehigan et al (Mehigan et al 2001) conducted a non-randomised prospective 
trial comparing laparoscopic versus open colorectal resection for cancer with a 
curative intent. 23 patients were enrolled (13 laparosocpic versus 10 open). 
Blood samples were measured preoperatively and at 4, 8, 10, 24, 48, 168 hours 
after induction of anaesthesia. The two groups were comparable apart from a 
significantly longer operative time and reduced blood loss for the laparoscopic 
group. There was a significant rise of IL-6 and CRP levels in both groups but no 
difference between the groups. There was a reduction in CD3 (marker for all T 
cells), CD4 (marker for T helper cells), CD8 (marker for T cytotoxic cells), CD16 
(marker for NK cells) and CD19 (marker for B cells) labelled lymphocytes in 
both groups but no significant difference between the groups. This study 
therefore provided no supportive evidence that immune function is better 
preserved after laparoscopic resection for colorectal cancer. 
 
Nishiguchi et al (Nishiguchi et al 2001) conducted a non-randomised 
prospective trial comparing laparoscopic and open colorectal resection for 
cancer. 27 patients were enrolled (15 laparosocpic versus 12 open). Blood 
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samples were measured preoperatively and at 6, 24, 48, 72, 120, 168 hours 
from the start of surgery. The two groups were comparable for patient 
characteristics with a significantly longer operative time and reduced blood loss 
in the laparoscopic group. The IL-6 levels were significantly less in the 
laparoscopic group at day-one as were the CRP levels on day-two. There was 
no difference between the groups in total white cell count, but the lymphocyte 
sub-set was significantly greater on day-two in the laparoscopic group. In 
summary, there was a reduction in the inflammatory response and perhaps a 
preservation of immune function, in the laparoscopic group. 
 
Hu et al (Hu et al 2003) conducted a non-randomised prospective study 
comparing laparoscopic and open total mesorectal excision for rectal cancer. 49 
patients were enrolled (20 laparoscopic vs 25 open were analysed). Blood 
samples were taken at preoperatively and at days one and five after surgery, 
and stored at -20°C. The two groups were comparable for patient 
characteristics and resection pathology. There was no significant difference 
seen between the two groups for IL-2, IL-6 or TNF-α or for CD3+ CD56, CD3- 
CD56 and IgG, IgM or IgA. There was no difference in the measured 
inflammatory or immune response between the laparoscopic or open technique 
in rectal cancer resection.  
 
Kirman et al (Kirman et al 2003) conducted a non-randomised prospective trial 
comparing laparoscopic and open resection for colon cancer. 51 patients were 
enrolled (24 laparoscopic vs 27 open); blood samples were taken 
preoperatively and on day one and day three and stored at -80°C. The two 
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groups had comparable patient characteristics. The number of CD3 cells 
expressing CD31 were measured which represent migrating T cells. In order for 
CD3 T cells to effect tumour cell killing effectively migration from the circulation 
to the periphery is important. There was a significant reduction in the 
percentage and actual number of T cells expressing CD31 in the measured T 
cell population on day-one and day-three compared to the preoperative level in 
the open group only. There was no evidence if there was a difference between 
the two groups. It was concluded that there is preservation of T cell migratory 
function with laparoscopic surgery. However, care must be taken with this 
conclusion as only intra- and not inter-group analyses were made. 
 
Evans et al (Evans et al 2009) conducted a non-randomised prospective trial 
comparing laparoscopic, mini-laparotomy (abdominal incision <15cm) and open 
resection of colorectal cancer. 72 patients were enrolled, one was excluded due 
to a benign pathology (20 laparoscopic vs 21 mini-laparotomy vs open). Blood 
samples were taken preoperatively and at 3 or 24 hours and five days after 
surgery and stored at  -80°C. The three groups were comparable for patient 
characteristics and tumour pathology. IL-6 levels were significantly lower in the 
laparoscopic group compared with the open group at 3 hours but not at 24 
hours or five days, no difference was detected in comparison to the 
minilaparotomy group. There was no difference in the rise of IL-10 between the 
three groups and IL-2, IL-4, TNF-α and IFN-γ were undetectable in all three 
groups. There was a significant reduction in the percentage of lymphocytes in 
the total white cell count in the three groups compared with preoperative levels, 
with a return to normal at day-five in the laparoscopic group only. There were 
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no significant inter-group differences in the lymphocyte count. The CD4/CD8 
ratio was significantly higher in the laparoscopic patients compared to the other 
groups at day-five. This trial showed some attenuation of the inflammatory 
response in the laparoscopic group and perhaps an earlier return to normality 
for immune function. 
 
Huang et al (Huang et al 2010) conducted a non-randomised prospective trial 
comparing laparoscopic and open resection for colorectal cancer. 68 patients 
were enrolled (35 laparoscopic vs 33 open). Blood samples were taken 
preoperatively and at days one, four and seven after surgery. The groups were 
comparable for patient characteristics and tumour pathology. There was a 
similar operative time with significantly reduced blood loss and median length of 
stay in the laparoscopic group. There was an increase in CRP in both groups 
but no difference between the groups. The only significant difference between 
groups was detected on day-four when lymphocyte, CD4 and CD8 counts were 
significantly greater in the laparoscopic group. There was no significant 
difference between the two groups in CD45RO T cells and NK cell counts. This 
trial demonstrated a more rapid return to normal for some elements of the 
adaptive immune system in those patients receiving laparoscopic surgery. 
 
Han et al (Han et al 2010) conducted a non-randomised prospective trial 
comparing laparoscopic and open resection of stage-3 colorectal cancer. 74 
patients were enrolled (35 laparoscopic and 39 open). Blood samples were 
taken preoperatively and at days one and five after surgery. The two groups 
were comparable for patient characteristics and tumor pathology. There was a 
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significantly longer operative time in the laparoscopic group. There was no 
difference in CRP levels between the two groups. The total lymphocyte count, 
CD4 and CD8 levels were not significantly different between the groups. On day 
five HLA-DR expression was significantly better in the laparoscopic group. A 
multivariate analysis was performed and identified operative time and operative 
technique as the significant factors that correlated with the HLA-DR difference 
between the groups on day five. Minimal immunological advantage was 
detected in the laparoscopic group, although this may be secondary to the time 
intervals measured. The first postoperative measurement was on day-one and 
so any changes occurring earlier than this would have been missed. 
 
Stage et al (Stage et al 1997) conducted a randomised clinical trial (RCT) 
comparing laparoscopic and open colonic resection of cancer; 34 patients were 
randomized. There were five exclusions leaving 15 laparoscopic and 14 open 
patients for analysis. Blood samples were taken preoperatively and at days one, 
three and ten after surgery and stored at -20°C. The two groups were 
comparable for patient characteristics and tumour pathology, with a reduced 
length of stay and longer operative time in the laparoscopic group. There was a 
significantly greater increase in CRP and IL-6 levels in the laparoscopic group 
at day-one. This is a contradictory result from other studies and may be a 
spurious finding secondary to improper cytokine storage, the small numbers, or 
the significantly longer operative time with the laparoscopic group. 
 
Hewitt et al (Hewitt et al 1998) conducted an RCT comparing laparoscopic and 
open colorectal resection for cancer. Twenty-five patients were enrolled, with 
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nine exclusions due to protocol violation, leaving eight laparoscopic and eight 
open patients. Blood samples were taken preoperatively and at 4, 8, 20, 48 
hours and seven and 21 days after surgery and stored at -70°C. The two 
groups were comparable for patient characteristics and tumour pathology. 
There were no significant differences in the levels of IL-6, lymphocytes, CD4, 
CD8 (or their ratio), NK cells, HLA-DR expression between the two groups. 
There was no obvious benefit with laparoscopy but the operative time was 
significantly longer at nearly a median of 1 hour. As shown previously, length of 
operative time correlates with an increased IL-6 response (Fukushima et al 
1996) so therefore any benefit gained with laparoscopy will be nullified if a 
timely procedure is not performed. 
 
Leung et al (Leung et al 2000) conducted a RCT comparing laparoscopic and 
open resection of rectosigmoid cancer. 34 patients were enrolled (17 
laparoscopic vs 17 open) with comparable patient characteristics. Blood was 
drawn at preop, 2, 8, 24, 48, 72 hours and one and four weeks after surgery 
and stored at -70°C. There was a significant reduction in IL-6 and IL-1β at 2 
hours and CRP at 48 hours in the laparoscopic group. There was no difference 
between the groups for TNF-α. This RCT has demonstrated a reduced 
inflammatory response in the early postoperative period with laparoscopic 
surgery, with no difference in disease recurrence at a median follow up of 20 
months. 
 
Schwenk et al (Schwenk et al 2000) conducted a RCT comparing laparoscopic 
and open colorectal resection for cancer. 60 patients were randomized with 30 
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in each arm. The groups were comparable. Blood samples were taken 
preoperatively and at incision, after resection and at 1 and 4 hours, and one, 
two, four and seven days after surgery and stored at -70°C. There was a 
significantly reduced CRP and IL-6 response after laparoscopic surgery, but not 
for IL-10. Thus, there was a reduced inflammatory response detected with 
laparoscopy. 
 
Tang et al (Tang et al 2001) conducted a RCT comparing laparoscopic and 
open resection for colorectal cancer as part of the CLASICC trial (Guillou et al 
2005). 236 patients were enrolled into the immune study. After exclusions and 
missing data there were 80 laparoscopic and 81 open patients with complete 
data that were suitable for analysis. The two groups were comparable for 
patient characteristics and tumour pathology. Blood samples were taken 
preoperatively and on day three and assayed immediately. There was no 
difference between the groups for T cell, B cell, CD4:CD8 ratio, IgG, IgM, IgA, 
C3, C4 or NK cells numbers. This trial with large numbers demonstrated no 
measured advantage in preservation of immune function with laparoscopy. 
However, the only postoperative measurement was performed on day-three, 
which may have missed any changes occurring in the critical immediate 
postoperative phase. 
 
Ordemann et al (Ordemann et al 2001) conducted a RCT comparing 
laparoscopic and open resection of colorectal cancer. 40 patients were enrolled 
with 20 in each arm; the groups were comparable. Blood samples were drawn 
preoperatively and at 1 and 4 hours and one, two, four and seven days after 
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surgery and analysed immediately. There was a reduced increase in white cell 
count in the laparoscopic group on days one to four. There were no changes in 
the CD4 or CD8 levels in the two groups or in their ratio. HLA-DR expression 
was significantly reduced in the open group on day-four only. IL-6 levels were 
significantly higher in the open group at 4 hours and day-one, and TNF-α levels 
were significantly higher from 1 hour to day-two in the open group. This trial 
identified a reduced inflammatory response and some preservation of immune 
function in the laparoscopic group. 
 
Delgado et al (Delgado et al 2001) conducted a RCT comparing laparoscopic 
and open colonic resection for cancer. 140 patients were randomized but after 
exclusions (conversion, steroids, missing samples) there were 39 laparoscopic 
and 58 open patients suitable for analysis. The groups were comparable for 
patient characteristics and tumour pathology. The laparoscopic group had a 
significantly reduced length of stay and blood loss but a longer operative time. 
Blood samples were drawn preoperatively and at 4, 12, 24 and 72 hours after 
surgery and stored at -20°C. There were no significant differences in cortisol or 
prolactin levels between the groups. The IL-6 levels were significantly lower in 
the laparoscopic group at 4, 12 and 24 hours as was the CRP level at 72 hours. 
The laparoscopic group exhibited a reduced inflammatory response in the 
postoperative period. However, the open group had significantly more 
complications (predominantly wound infections), which could have contributed 
to these differences.  
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Wu et al (Wu et al 2003) conducted a RCT comparing laparoscopic and open 
colonic resection for cancer as part of the COLOR trial (Hazebroek, & Color 
Study Group 2002). 26 patients were enrolled (12 laparoscopic and 14 open) 
with comparable patient characteristics and tumour pathology. Blood samples 
were taken preoperatively and at 2 hours, one and four days after surgery and 
stored at -80°C. There were significantly lower IL-6 and IL-8 levels at 2 hours 
only in the laparoscopic group. TNF-α was undetectable and no difference 
between the groups was seen in CRP levels. There were no significant 
differences detected between the two groups in the levels of white cell count, 
CD4, CD8, the ratio, NK cells, CD14, CD19 or in HLA-DR expression. This trial 
demonstrated a transiently reduced inflammatory response in the laparoscopic 
group and no difference in postoperative immune suppression. 
 
Leung et al (Leung et al 2003) conducted a RCT comparing laparoscopic and 
open resection of rectosigmoid cancer. 40 patients were enrolled with 20 in 
each arm. The groups were comparable for patient characteristics and tumour 
pathology. Blood samples were drawn preoperatively and at one, three and 
eight days after surgery. There was no difference between the groups for NK 
cells, white cell count, lymphocytes, T cells, CD4 or B cells at any time point. 
NK-like T cell numbers were significantly depressed in the open group at day-
one and eight compared with the laparoscopic group. In addition CD8 levels 
were significantly lower in the open group at day-eight. There may be some 
preservation of immune function at day-eight in the laparoscopic group although 
the relevance of these data is unclear. 
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Hasegawa et al (Hasegawa et al 2003) conducted a RCT comparing 
laparoscopic and open colonic resection for T2 or T3 cancers. 59 patients were 
randomized and, after exclusion of T4 tumours and metastatic disease, 24 
laparoscopic and 26 open patients were analysed. The groups were 
comparable for patient characteristics and tumour pathology. Blood samples 
were taken preoperatively and at day one, four and seven after surgery. CRP 
levels were significantly less in the laparoscopic group on day-one and -four. No 
differences were seen in the white cell count, NK cell number or IL-6 levels 
between the groups. As the first postoperative samples were taken 24 hours 
after surgery, any early inflammatory changes would have been missed.  
 
Wu et al (Wu et al 2004) published data from a RCT comparing laparoscopic 
and open resection of colon cancer as part of the COLOR trial. It is unclear 
whether this is in fact the same patient cohort that was published in a previous 
study by the same group (Wu et al 2003). 26 patients were randomized (12 
laparoscopic and 14 open); the groups were comparable. Blood samples were 
drawn preoperatively and at 2 hours, one and four days after surgery and 
stored at -80°C. There were no significant differences in VEGF or endostatin 
levels between the groups. This was a limited study to investigate local wound 
healing rather than the overall inflammatory response or immune function. 
 
Zhao et al (Zhao et al 2005) conducted a RCT comparing laparoscopic and 
open colorectal resection for cancer. 60 patients were randomized with equal 
numbers in each arm; the groups were comparable. Blood samples were drawn 
preoperatively and at day three and seven after surgery. There were 
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significantly different levels of lymphocyte and CD8 cell counts and IgM on day-
three. No differences were seen in CD4, CD45RO, IgG, IgA, NK cells or CRP 
levels between the groups. There may be some preservation of immune 
function on day-three with laparoscopy but again there is no data to represent 
that critical immediate postoperative period. 
 
Veenhof et al (Veenhof et al 2011) conducted a RCT comparing laparoscopic 
and open TME (Total Mesorectal Excision) of rectal cancer as part of the 
COLOR 2 trial (Color II Study Group et al 2009). 40 patients were randomized 
(22 laparoscopic and 18 open) and the groups were comparable. Blood 
samples were drawn preoperatively and at 2, 24 and 72 hours after surgery and 
stored at -80°C. There were no differences between the groups for cortisol, 
prolactin, growth hormone, CRP or IL-8. IL-6 was significantly reduced and 
HLA-DR expression was better preserved in the laparoscopic group but only at 
two hours. This trial found that there was a transient reduction in the 
inflammatory response, and perhaps systemic immune function with 
laparoscopy, in the immediate postoperative period only. 
 
Kim et al (Kim et al 2011) conducted a RCT comparing laparoscopic and open 
sigmoidectomy for sigmoid cancer. 81 patients were randomized and after 
exclusions (steroids, anastomotic leak, transfusion, metastases) 38 
laparoscopic and 19 open patients were analysed. The groups were 
comparable. Blood samples were taken preoperatively and at day one after 
surgery. There were no differences between the groups for CRP, IL-6, VEGF or 
insulin-like growth factor binding protein-3 (IGFBP-3). As samples were only 
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taken 24 hours after surgery any attenuation in inflammatory response 
occurring earlier will have been missed.  
 
Veenhof et al (Veenhof et al 2012) conducted a RCT comparing laparoscopic 
and open colonic resection for cancer with or without ERAS (fast track) care 
within the LAFA trial (Wind et al 2006a). 79 patients were randomized as 19 
laparoscopic fast track (LFT), 23 laparoscopic standard (LS), 17 open fast track 
(OFT) and 20 open standard (OS). The groups were comparable. Blood 
samples were drawn preoperatively and at 1, 2, 24 and 72 hours after surgery 
and stored at -80°C. There were significant reductions in postoperative IL-6 and 
CRP levels and preservation of HLA-DR expression in those patients receiving 
laparoscopy. Those patients receiving ERAS care had reduced growth hormone 
levels. The type of surgery had no influence on this result. There was no 
difference in cortisol or prolactin between the groups. This well-constructed 
study with appropriate time intervals demonstrated a reduced inflammatory 
response with laparoscopy and preservation of the adaptive immunity as 
reflected by HLA-DR expression.  
 
In summary there have been nine non-randomised and 15 RCTs conducted on 
patients with colorectal cancer comparing the effects of laparoscopy and open 
resection. Many of the studies contain small numbers and power calculations 
are sparse. There was considerable heterogeneity in study design and the 
inflammatory or immune variables measured. Table 1.2 itemizes the trials 
discussed above with a summary of relevant results. The results in favour of 
laparoscopy are highlighted in red and those in blue favour open surgery, with 
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those in black indicating no difference. Overall there may be some preservation 
of immune function and perhaps a reduced inflammatory response in 
laparoscopic surgery in the non-randomised trials. The RCTs show more 
evidence of a reduced inflammatory response and some immune preservation 
in favour of laparoscopy but overall it is difficult to draw useful conclusion. 
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Table 1.2: Summary of trials into the stress response in colorectal surgery 
Trial Year Trial details Patient Cohorts (Lap vs open) 
Relevant 
Exclusions Analgesia 
Inflammatory 
markers 
Cellular immunity 
markers 
Long term 
outcome 
data 
Fukushima et al  
(Fukushima et al 
1996) 
1996 Non-randomised 
Sigmoid cancer 
(7 vs 7) None 
Not 
mentioned 
IL-6! 
CRP, glucagon, 
urinary 
catecholamines" 
Nil None 
Ozawa et al  
(Ozawa et al 
2000) 
2000 Non-randomised 
Colon cancer 
(8 vs 8) 
Major 
complications Epidural 
IL-6# 
ACTH, ADH, 
Cortisol" 
Nil None 
Mehigan et al  
(Mehigan et al 
2001) 
2001 Non-randomised 
Colorectal 
cancer 
(13 vs 10) 
Major 
complications 
Steroids 
Not 
mentioned CRP, IL-6" 
CD3, CD4, CD8, 
CD16, CD19" None 
Nishiguchi et al  
(Nishiguchi et al 
2001) 
2001 Non-randomised 
Colorectal 
cancer 
(15 vs 12) 
None Not mentioned IL-6, CRP# 
Leukocytes" 
Lymphocytes (CD3)! None 
Hu et al  (Hu et 
al 2003) 2003 
Non-
randomised 
Rectal cancer 
(20 vs 25) None 
Not 
mentioned IL-2, IL-6, TNF-α" 
CD3+ CD56, CD3- 
CD56" 
IgG, IgM, IgA" 
None 
Kirman et al  
(Kirman et al 
2003) 
2003 Non-randomised 
Colon cancer 
(24 vs 27) Steroids 
Not 
mentioned nil CD3 CD31! None 
Evans et al  
(Evans et al 
2009) 
2009 Non-randomised 
Colorectal 
cancer 
(20 lap vs 21 
minilap vs 30 
open) 
Steroids Not mentioned 
IL-2, IL-4, TNF-α, IFN-
γ undetectable 
IL-6# 
IL-10" 
CD4/CD8 ratio! 
Lymphocytes! 
NK cells" 
None 
Huang et al  
(Huang et al 
2010) 
2010 Non-randomised 
Colorectal 
cancer 
(35 vs 33) 
Steroids 
Major 
complications 
Diabetes 
Not 
mentioned CRP" 
Lymphocytes, CD4, 
CD8 day 4! 
CD45RO, NK cells" 
None 
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Trial Year Trial details Patient Cohorts (Lap vs open) 
Relevant 
Exclusions Analgesia 
Inflammatory 
markers 
Cellular immunity 
markers 
Long term 
outcome 
data 
Han et al  (Han 
et al 2010) 2010 
Non-
randomised 
Stage 3 
Colorectal 
cancer 
(35 vs 39) 
Major 
complications 
Transfusion 
Not 
mentioned CRP" 
Lymphocytes, CD4, 
CD8" 
HLA-DR day 5! 
None 
Stage et al*§  
(Stage et al 
1997) 
1997 RCT 
Colorectal 
cancer 
(15 vs 14) 
None Epidural CRP, IL-6! nil None 
Hewitt et al*§  
(Hewitt et al 
1998) 
1998 RCT 
Colorectal 
cancer 
(8 vs 8) 
Steroids 
Diabetes 
Transfusion 
Morphine 
PCA IL-6" 
Lymphocytes, CD4, 
CD8, ratio, NK cells, 
HLA-DR" 
None 
Leung et al*§  
(Leung et al 
2000) 
2000 RCT 
Rectosigmoid 
cancer 
(17 vs 17) 
None Pethidine PRN IL-1β, IL-6, CRP# nil 
No local 
recurrence 
3 lap + 1 
open develop 
mets 
Schwenk et al*§  
(Schwenk et al 
2000) 
2000 RCT 
Colorectal 
cancer 
(30 vs 30) 
None Morphine PCA 
IL-6, CRP# 
IL-1RA, IL-10" nil None 
Tang et al*  
(Tang et al 
2001) 
2001 RCT 
Colorectal 
cancer 
(80 vs 81) 
None Not mentioned nil 
T cell, B cell, 
CD4:CD8, NK cell, C3, 
C4, IgG, IgM, IgA" 
None 
Ordemann et 
al*§  (Ordemann 
et al 2001) 
2001 RCT 
Colorectal 
cancer 
(20 vs 20) 
None Morphine PCA IL-6, TNF-α# 
WCC# 
CD4, CD8, ratio" 
HLA-DR day 4! 
None 
Delgado et al*§  
(Delgado et al 
2001) 
2001 RCT Colon cancer (39 vs 58) Steroids 
Morphine 
PCA 
IL-6, CRP# 
Cortisol, prolactin" nil None 
Wu et al*§  (Wu 
et al 2003) 2003 RCT 
Colon cancer 
(12 vs 14) None 
Not 
mentioned 
IL-6, IL-8# 
CRP" 
WCC, CD4, CD8, 
ratio, NK cells, CD14, 
CD19, HLA-DR" 
None 
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Trial Year Trial details Patient Cohorts (Lap vs open) 
Relevant 
Exclusions Analgesia 
Inflammatory 
markers 
Cellular immunity 
markers 
Long term 
outcome 
data 
Leung et al*  
(Leung et al 
2003) 
2003 RCT 
Rectosigmoid 
cancer 
(20 vs 20) 
None PRN pethidine nil 
NK like cells day 1,8! 
CD8 day 8! 
WCC, lymphocytes, 
CD4, NK cells, B 
cells" 
None 
Hasegawa et 
al*§  (Hasegawa 
et al 2003) 
2003 RCT 
Colorectal 
cancer 
(24 vs 26) 
None Epidural CRP day 1,4# IL-6" WCC, NK cells" 
No port site 
mets at 
20mths 
Wu et al§  (Wu 
et al 2004) 2004 RCT 
Colon cancer 
(12 vs 14) None 
Not 
mentioned VEGF, endostatin" nil None 
Zhao et al*  
(Zhao et al 
2005) 
2005 RCT 
Colorectal 
cancer 
(30 vs 30) 
None Not mentioned CRP" 
Lymphocyte, CD8, 
IgM! 
CD3, CD4, NK cells, 
CD45RO, IgG, IgA" 
None 
Veenhof et al  
(Veenhof et al 
2011) 
2011 RCT Rectal cancer (22 vs 18) None 
Not 
mentioned 
IL-6# 
CRP, IL-8, cortisol, 
prolactin, GH" 
HLA-DR! None 
Kim et al  (Kim 
et al 2011) 2011 RCT 
Sigmoid cancer 
(38 vs 19) 
Major 
complications 
Steroids 
Transfusion 
Pethidine 
PRN 
IL-6, CRP, VEGF, 
IGFBP-3" nil None 
Veenhof et al  
(Veenhof et al 
2012) 
2012 RCT Colon cancer (42 vs 37) Steroids Epidural 
IL-6, CRP, GH# 
Cortisol, prolactin" HLA-DR! Too early 
Favours laparoscopy, favours open, No difference 
*Included in Liu et al  (Liu et al 2011) immune function review 
§Included in Sammour et al  (Sammour et al 2010) humoral response review 
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1.5.3 Meta-analyses 
Sammour et al (Sammour et al 2010) performed a systematic review and meta-
analysis of humoral factors measured in surgery for benign and malignant 
colorectal disease (papers are denoted § in the table 1.2). 13 studies conducted 
up to 2006 were identified in the literature as appropriate for further analysis. A 
meta-analysis was performed on IL-6 data on day-one after surgery, as this was 
the predominant inflammatory marker measured, in 11 trials. Overall, there was 
a significantly higher level (p=0.04) of IL-6 in the open groups (n=187) 
compared with the laparoscopic groups (n=165) on day-one. Figure 1.1 shows 
the forest plot analysis (Sammour et al 2010) of serum and plasma IL-6 levels 
for both groups, it is important to note the heterogeneity in the results. TNF-α, 
IL-8, IL-10 and IL-1 were not analysed as they were only measured in a few 
trials. In summary there is a reduced inflammatory response, as represented by 
smaller increases of IL-6 levels in the early postoperative period, in patients 
receiving laparoscopic procedures. 
 
Figure 1.1: Forest plot analysis of plasma and serum IL-6 on day one. SD= 
standard deviation, CI= Confidence Interval, Std= Standardised. 
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Liu et al (Liu et al 2011) have performed a systematic review and meta-analysis 
to assess postoperative immune function in patients with colorectal cancer 
(papers are denoted * in table 1.2). 11 RCT’s conducted up to 2009 were 
identified as appropriate for further analysis. Due to considerable heterogeneity 
in the measured variables between these trials meta-analysis was performed on 
only a few variables. CD4 at day one to three showed no difference, and CD8 at 
days one to three showed significant advantage towards laparoscopy (however, 
only two studies with a total of 42 patients). Analysis of 110 patients showed no 
difference in CD4:CD8 ratio. 80 patients in this analysis, however, come from 
the study by Tang et al (Tang et al 2001) with the caveats discussed above. 
Figure 1.2 show the forest plot analysis for CD4, CD8 and CD4:CD8 ratio from 
Liu et al (Liu et al 2011). 
 
Figure 1.2: Forest plot analysis for CD4, CD8 and CD4:CD8 ratio for 
laparoscopic versus open surgery on post-operative day one-three. The 
mean difference estimates for individual trials are shown in boxes, error 
bars indicate 95% confidence intervals and summary of effects is shown 
as a diamond  (Liu et al 2011). 
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This meta-analysis showed no difference in IL-6 levels after surgery, but only 
two studies were included with a total of 51 patients. CRP was significantly 
lower in the laparoscopic group at days zero to one, figure 1.3 shows the forest 
plot analysis and associated data (Liu et al 2011). Other immune parameters 
were too heterogeneous to be suitable for a meta-analysis and so only 
descriptive data were provided. The overall conclusion is that there may be 
some preservation of immune function as reflected by CD8 levels and a 
reduced inflammatory response (CRP) in patients undergoing laparoscopic 
procedures, but the evidence is limited. 
 
Figure 1.3: Forest plot analysis of CRP levels in the laparoscopic and 
open surgery groups for colorectal cancer. The mean difference estimates 
for individual trials are shown in boxes, error bars indicate 95% 
confidence intervals and summary of effects is shown as a diamond  (Liu 
et al 2011). 
 
There are however limitations to analysis of published data. The heterogeneity 
of patient groups and the measured variables limits any meaningful analysis. 
There may be a reduced inflammatory response in the first few hours to days 
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after laparoscopic surgery compared to the open technique and this may result 
from reduced abdominal wall trauma.  
 
Another reason to measure changes in immune function after laparoscopic 
resection of colorectal cancer stems from the desire to identify whether patient 
survival is improved and if so why this might be. Circulating tumour cells have 
been detected in peripheral and portal blood during the operative (Wind et al 
2009) and postoperative periods (Peach et al 2010). Detection of circulating 
colorectal tumour cells is an independent predictor of cancer recurrence  
(Peach et al 2010). It may therefore be hypothesised that cell-mediated 
immunity, which combats isolated tumour cells and micro-metastases, is 
optimally functional during the operative and postoperative period to reduce the 
chance of disease recurrence. The reduced trauma that laparoscopy provides 
would logically seem to lead to better functioning of CMI, compared to open 
procedures. However, as seen from the conflicting results of the above studies 
this may not, in fact, be true.  
 
The majority of trials described above were conducted in the early days of 
laparoscopic colorectal surgery, when operative times were significantly longer 
than today. There is evidence that with increasing operative time there is an 
increase in the stress response (Fukushima et al 1996). Any benefits gained by 
laparoscopy in these trials may therefore be negated by this increased time.  
 
It is difficult to draw any conclusions about the survival benefit of laparoscopy 
given that none of these trials have provided any useable long-term outcome 
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data. There is some evidence that laparoscopy could provide a survival benefit 
in selected patient cohorts (e.g. stage-3 patients)(Lacy et al 2008). However, it 
will now be difficult to conduct further prospective trials randomising patients to 
either laparoscopy or open surgery due to patient and surgeon preferences. 
This is evident in the EnROL trial that struggled to reach the required numbers 
and the investigators have had to reduce the power of the study in order to 
reach a conclusion. We await the long-term data from the LAFA trial.  
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1.6 Analgesia and the stress response in colorectal 
surgery 
Section 1.3 has summarised the debate in the medical literature surrounding 
the ideal postoperative analgesia for colorectal surgery. The majority of 
research has focused on open colorectal surgery and evidence indicates that a 
thoracic epidural is the ideal choice, as recommended by the ERAS group  
(Lassen et al 2009). One of the many proposed benefits of epidural usage is 
suppression of the stress response following surgery (Fotiadis et al 2004). This 
evidence may not, however, translate to laparoscopic colorectal surgery.  
 
1.6.1 Epidural analgesia 
Epidural analgesia, when using a combination of opioids and local anaesthetics, 
causes a spinal afferent block, which effects the HPA axis. This leads to a 
reduction in the levels of cortisol and catecholamines, as well as lowering the 
levels of other pituitary mediators released following a surgical stimulus (Kehlet 
2000). There is also a reduction of insulin resistance and resultant 
hyperglycaemia and a preservation of nitrogen balance in the postoperative 
period (Holte, & Kehlet 2002b). For these proposed benefits to be applied 
optimally to the patient the epidural should run continuously for 48 hours  
(Kehlet, & Holte 2001). It is suggested that there is no effect on the 
postoperative inflammatory response with the use of such a neural blockade  
(Kehlet 2000; Moore et al 1994).  
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There is some evidence, however, which suggests that a neural block may alter 
the postoperative inflammatory response. Beilin et al (Beilin et al 2003b) 
showed a trend, although not significantly different, towards a reduction in pro-
inflammatory cytokines (IL-1, IL-6) with the use of an epidural compared to PCA 
(patient-controlled analgesia) or intermittent opiates. The study included 115 
patients undergoing abdominal surgery covering different specialities.  
 
These authors conducted a further study to compare the effect of epidural 
analgesia commenced at the start of surgery, with epidural analgesia started on 
completion of surgery, both running for 48 hours (Beilin et al 2003a). In a group 
of 41 women undergoing open hysterectomies they identified significant 
changes in the cytokine response in those patients with epidurals commenced 
intra-operatively. There were significant reductions in IL-1β, IL-6 and IL-10 
production from stimulated peripheral blood mononuclear cells (PBMC) and less 
of a reduction in IL-2. No significant differences were seen in TNF-α levels. This 
highlights that the inflammatory response can be altered by blockade of the 
spinal afferents, but only if commenced prior to the injury. 
 
Ahlers et al (Ahlers et al 2008) also compared pre-emptive epidural versus 
postoperative commencement in a heterogenous surgical group. They identified 
significantly higher levels of IL- 10 in patients with no intraoperative epidural but 
no difference in IL-12 or HLA-DR expression. IL-10 provides an anti-
inflammatory effect, so it is questionable whether this effect is indeed beneficial.  
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Moselli et al (Moselli et al 2011) conducted a randomized clinical trial in 35 
patients undergoing open colon resection for cancer. Patients were randomized 
to either epidural analgesia commenced during surgery (EA) or to intravenous 
opiates intraoperatively followed by an epidural during the postoperative period 
(IA). The EA group showed significantly reduced levels of IL-1β, IL-2, IL-6, IL-
12, GM-CSF, IFN-γ and TNF-α at 3hours and 24 hours after incision. In addition 
the EA group had significantly elevated levels of IL-4 and IL-10 at the same 
time intervals. In essence patients receiving an epidural during surgery and 
subsequently reduced opiates (EA group) had significant attenuation of the 
postoperative inflammatory response. 
 
Proponents of epidural usage in colorectal surgery suggest that suppression of 
the stress response will reduce postoperative morbidity (Kehlet 2000) and 
potentially shorten length of stay (Kehlet, & Mogensen 1999). There is, 
however, very little evidence for this. A meta-analysis  (Marret et al 2007), and 
further separate review, (Gendall et al 2007) both compared epidural to 
intravenous opiates for postoperative analgesia in open colorectal surgery. 
These trials showed no difference in length of stay.  
 
It is important to remember that work conducted on the effect of postoperative 
analgesia on the stress response following colorectal surgery has been on 
patients receiving open surgery. While this evidence shows that epidural 
analgesia may reduce elements of the stress response in open colorectal 
surgery and improve outcome, it is not necessarily applicable in laparoscopic 
colorectal surgery.  
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Senagore at al (Senagore et al 2003a) published a small RCT comparing PCA 
to thoracic epidural for postoperative analgesia in laparoscopic segmental 
resections. They showed an improvement in postoperative pain in the epidural 
group, but there was no significant difference in the postoperative length of stay 
between the groups. 
 
A recent, randomised trial conducted at the MATTU (Levy et al 2011) on 
laparoscopic colorectal resection showed those patients receiving an epidural 
analgesia had a significantly increased length of stay compared with those 
patients receiving a spinal analgesia or PCA. In addition an observational study  
(Virlos et al 2010) comparing spinal with epidural analgesia in laparoscopic 
colorectal surgery showed a significantly reduced length of stay with the use of 
spinal analgesia.  
 
If epidural analgesia is advocated in order to reduce the postoperative stress 
response and subsequent morbidity this should translate to a reduction in 
length of stay. The current available evidence, however, shows that this does 
not seem to apply in laparoscopic colorectal resection. When considering which 
mode of analgesia to use, the complications associated with the use of epidural 
analgesia therefore become more relevant. The risks of analgesic failure, 
hypotension leading to fluid overload, reduced mobility and rare epidural 
abscesses become more pertinent (Gendall et al 2007). There are suitable 
alternatives, namely spinal analgesia and PCA, that may be safer and reduce 
length of stay. These may be more appropriately used in the majority of 
laparoscopic colorectal resections. On this basis patients undergoing 
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laparoscopic colorectal surgery at The Royal Surrey County Hospital receive 
either a PCA or spinal analgesia as the primary postoperative method of pain 
relief. 
 
1.6.2 Spinal analgesia 
There are very few data investigating the effect of spinal analgesia on the 
postoperative stress response in any specialty. Bar-Yosef et al (Bar-Yosef et al 
2001) have conducted laboratory research into the effect of spinal analgesia in 
rats undergoing a laparotomy. They identified a beneficial reduction in lung 
tumour retention, and a subsequent reduction in development of lung 
metastases in those rats receiving spinal analgesia compared to those that did 
not. A similar benefit was also seen with systemic opiates but to a lesser 
degree. Interestingly there was no preservation of natural killer cell activity with 
either opiates or spinal analgesia compared to anaesthesia alone. 
 
There have been only two small studies measuring the stress response in 
patients receiving spinal analgesia (Buyukkocak et al 2006b; Buyukkocak et al 
2006a). These compared general anaesthesia or spinal analgesia alone in 
patients undergoing haemorrhoidal or perianal surgery. There was no difference 
in the stress response as measured by CRP, cortisol, IL-6 or TNF-α, but 
postoperative measurements were only taken at 24 hours, which as previously 
discussed, may result in missing any significant effect. Further work by the 
same group (Buyukkocak et al 2006b) identified a reduced cortisol response at 
three hours in patients receiving spinal analgesia, but no effect on CRP was 
detected. 
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1.6.3 Morphine PCA 
The use of morphine for postoperative analgesia is another alternative. It 
provides excellent postoperative analgesia but does have the side effect of 
significant nausea and gastrointestinal ileus. In addition it is recognized to 
significantly depress the HPA axis and reduce NK, T and B cell levels as well as 
reduce macrophage and monocyte function (Kurosawa, & Kato 2008; 
Afsharimani et al 2011). Morphine usage could thus potentially amplify the 
postoperative period of immunosuppression. This could have hypothetical 
consequences on cancer recurrence and survival. Regional analgesia may 
abrogate the postoperative immunosuppression by the direct effects of the 
neural block, but also secondary to a reduction in post-operative morphine 
requirements. 
 
What is currently unknown is the exact nature of the stress response following 
laparoscopic colorectal surgery in benign and particularly malignant disease. In 
addition the effect spinal or morphine PCA analgesia may have on the stress 
response is unknown. 
 
 
 
 
 
 
  74 
1.7 Perioperative fluid therapy in colorectal surgery 
There is controversy and continuing debate surrounding the administration of 
perioperative fluid therapy in surgery, particularly colorectal surgery. The 
dispute surrounds whether a “liberal” or “restrictive” perioperative fluid regime is 
the most appropriate in reducing postoperative morbidity. It is important that 
perioperative fluid therapy is carefully utilized as it can have profound effects on 
patient outcomes. Too little fluid can potentially cause hypotension with 
inadequate tissue perfusion and oxygenation. Conversely, too much fluid could 
potentially produce tissue oedema effecting lung function, producing 
postoperative ileus and also affecting anastomotic healing (Bamboat, & 
Bordeianou 2009; Noblett, & Horgan 2010; Bundgaard-Nielsen et al 2009) as 
well as an increase of postoperative nausea and vomiting and length of stay  
(Lobo et al 2002). 
 
There have been a few studies to investigate the most appropriate perioperative 
fluid regime in colorectal surgery using different endpoints and have focused on 
either hospital stay or postoperative morbidity (Holte et al 2007; Kabon et al 
2005; Nisanevich et al 2005; Brandstrup et al 2003), with two reviews to 
analyse these data (Rahbari et al 2009; Bundgaard-Nielsen et al 2009). Both 
articles recognized a significant heterogeneity between the studies, principally 
in the definition of “restrictive” or “liberal” fluid regimes, but also in study design. 
Thus, meaningful conclusions are difficult to draw; however there is a significant 
reduction of postoperative morbidity in patients receiving a restrictive 
perioperative fluid strategy.  
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An additional, recent randomised trial has been published which was not 
included in the above reviews (Abraham-Nordling et al 2012). This study 
investigated the effects of restrictive or standard fluid therapy on the day of 
operation in patients undergoing colorectal surgery. Whilst there was no 
difference in the length of stay between the two groups there was a significant 
reduction in the number of complications in the restrictive group. However, once 
again, the definitions of “restrictive” and “standard” could easily be called 
“standard” and “liberal” by the definitions laid out in the studies above. 
 
Patients that are managed in a state of fluid balance are less likely to have a 
post-operative complications and are more likely to be discharged sooner  
(Varadhan, & Lobo 2010). It is becoming clear that the more appropriate 
technique for delivering perioperative fluids is to follow an individualized goal-
directed approach rather than a standard protocol. This is acknowledged in both 
of the above reviews (Rahbari et al 2009; Bundgaard-Nielsen et al 2009) and 
one of the reviewed trials (Holte et al 2007). A goal-directed approach to fluid 
therapy can be delivered in a number of ways. 
 
There are a number of methods to calculate the cardiac output. Fick in 1870 
was the first to describe a simple formula to estimate the cardiac output. It was 
not until the 1970s that the Swan-Ganz pulmonary artery catheter (PAC) was 
designed, enabling cardiac output calculation using the thermodilution 
technique. The importance of improving oxygen delivery in high-risk surgical 
patients was identified by Shoemaker et al, who, by producing supranormal 
(>600 ml/min/m2) DO2 values using a Swan-Ganz catheter in high-risk surgical 
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patients, was able to reduce mortality (Shoemaker et al 1988). The PAC is 
relatively impractical in the operating theatre and is associated with some 
significant complications for elective surgical cases. There have been several 
new technologies developed aimed at cardiac output optimization in an elective 
surgical setting.  
 
Measurement of the arterial pressure waveform can provide an estimation of 
cardiac output. The PiCCO system is a method of arterial pulse contour 
analysis using thermodilution to provide calibration. The LiDCO system is a 
method of arterial pulse power analysis using a lithium dilution method to 
provide calibration. Both of these methods require multiple lines and as such 
are relatively impractical for elective surgery. The FloTrac and LiDCOrapid 
systems only require a single peripheral arterial line to provide cardiac output 
measurement and as such are more practical.  
 
Bio-impedance estimation of cardiac output is truly non-invasive requiring the 
attachment of skin electrodes to measure impedance of the thorax upon 
passage of an electrical current. The change in impedance allows stroke 
volume to be calculated. A further development in this technology, Cheetah 
NICOM, measures the bio-reactance to electrical current and is both easier to 
use and more accurate.  
 
Oesophageal Doppler monitoring is a further relatively non-invasive technique 
to calculate cardiac output and associated parameters. It has been validated as 
a method that reduces post-operative length of stay and critical care admissions 
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across a range of specialties. It has been validated in cardiac surgery (Mythen, 
& Webb 1995; McKendry et al 2004), in orthopaedic surgery (Sinclair et al 
1997; Venn et al 2002), in gynaecological and urological surgery (Gan et al 
2002) and colorectal surgery (Gan et al 2002; Conway et al 2002; Wakeling et 
al 2005; Noblett et al 2006a). The CardioQ oesophageal Doppler monitor has 
now been recommended by NICE with major or high-risk surgery to reduce 
post-operative complications and length of post-operative hospital stay (NICE 
medical technology guidance 3).  
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1.8 The use of oesophageal Doppler monitoring in 
colorectal surgery 
The use of the oesophageal Doppler monitor (ODM) to guide the administration 
of fluid during the perioperative phase of colorectal surgery has been 
investigated by eight randomised clinical trials. All of these trials have 
randomised patients into two groups, one receiving perioperative fluid therapy 
via a “standardized” method and the other aiming to optimize perioperative fluid 
delivery by the use of the ODM.  
 
Gan et al (Gan et al 2002) randomised 100 patients undergoing elective major 
abdominal surgery of which approximately 30% had general surgery, presumed 
to be colorectal surgery. All patients received a pre-induction fluid bolus of 
lactate-Ringer’s solution and a background infusion of lactate Ringer’s solution 
at 5 ml/kg/hr throughout the operation. The treatment group had 200 ml boluses 
of colloid (6% hydroxyethyl starch in saline) administered as guided by the FTc 
value and stroke volume (SV) recorded on the ODM. The ODM group had 
significantly increased SV, CO and FTc variables at the end of surgery 
compared to the control group. The length of stay was significantly shorter in 
the ODM group. The ODM group also showed an earlier time-to-toleration of an 
oral diet. There was significantly less postoperative nausea and vomiting in the 
ODM group but no differences in other complications. All patients had open 
surgery and were not part of an enhanced recovery programme.  
 
Conway et al (Conway et al 2002) randomized 57 patients undergoing elective 
major bowel resections. It is not clear if patients received a pre-induction bolus 
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of fluid and it does not state what fluid was administered during the operation by 
the anaesthetist in the two groups. The bolus fluid used was 6% hydroxyethyl 
starch, but it is not clear if this was in a balanced solution or saline: it has been 
presumed to be saline given the time the trial was conducted. Boluses were 
administered as determined by the recorded FTc. The SV, FTc and CO 
increased significantly in the ODM group compared with the control group. 
There were significantly fewer intensive care admissions in the ODM group but 
there was no difference in length of stay or in time-to-tolerating oral diet. All 
patients had open surgery and were not part of an enhanced recovery 
programme. 
 
Wakeling et al (Wakeling et al 2005) randomized 128 patients undergoing 
elective colorectal resection. All patients received oral bowel preparation prior to 
surgery and a pre-induction fluid load of 1000-2000 ml of Hartmann’s solution 
the night before surgery. The control group had a background crystalloid 
infusion with additional colloid boluses as determined by the anaesthetist 
guided by standard haemodynamic parameters including central venous 
pressure. The ODM group received a background crystalloid infusion and 
boluses of 250 ml colloid, either Haemaccel or Gelofusine, as guided by the SV 
recorded with the ODM. The ODM group had significantly higher SV, CO and 
DO2 at the end of surgery compared with the control group. The length of stay 
was significantly shorter in the ODM group, and an earlier return to full diet and 
opening bowels. The ODM group had significantly fewer gastrointestinal 
complications, presumed to be ileus or postoperative nausea and vomiting, but 
no other differences in complications were detected. The trial also measured 
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CRP and IL-6 during the postoperative period but detected no difference 
between the groups. All patients in this trial had open surgery and none were 
part of an enhanced recovery programme. 
 
Noblett et al (Noblett et al 2006a) randomized 108 consecutive patients 
undergoing elective colorectal resections. Fluid loading pre-induction was not 
conducted as part of the protocol but, if administered, was included in the total 
volume of fluid recorded. The ODM group received a background crystalloid 
infusion guided by the blinded anaesthetist with additional colloid boluses 
(Volplex) given by the researcher as guided by FTc and SV recorded by the 
ODM. The control group received background crystalloid and colloid bolus 
therapy as felt appropriate by the anaesthetist guided by standard 
haemodynamic parameters. The ODM group had a significantly reduced length 
of stay and earlier return to diet but no difference in time-to-first bowel 
movement. The control group required significantly more patients to be 
admitted to intensive care and a greater number required intraoperative 
inotropic support.  There was no difference in the volume of fluid administered 
between the groups but the ODM group received 58% of the total volume within 
the first 40 minutes of surgery. In addition the ODM group had significantly 
higher SV, CI and FTc values at the end of surgery compared to the control 
group. Noblett et al also measured IL-6 levels during the postoperative period 
and detected significantly reduced levels in the ODM group at six hours after 
surgery but not at 24 hours, in keeping with the results by Wakeling et al  
(Wakeling et al 2005). 76% of patients in this trial had open surgery and none 
were part of an enhanced recovery programme. 
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Senagore at al (Senagore et al 2009) randomized 64 patients undergoing 
laparoscopic colectomy, within an established enhanced recovery programme, 
into three groups. All patients received oral bowel preparation prior to surgery 
and a pre-induction fluid bolus of 5 ml/kg lactated Ringer’s solution. All groups 
had a background infusion of lactated Ringer’s solution at a rate of 5 ml/kg/h for 
the duration of surgery. The control group had additional fluid administered as 
determined by the anaesthetist guided by standard haemodynamic parameters. 
The other two groups had either 200 ml boluses of lactated Ringer’s solution or 
6% hydroxyethyl starch in a balanced solution administered to optimise the FTc 
as guided by the ODM.   
 
The control group had a significantly shorter length of stay compared to the two 
goal directed groups, albeit by only a short length of time, approximately 6 and 
10 hours earlier. The goal-directed starch group had a higher rate of 
complications but no mention was made of statistical significance. No data are 
provided on ODM readings between the groups. The ODM group with lactated 
Ringer’s solution received a significantly greater total volume and normalized 
volume (i.e. per ml/kg/hr) than the other two groups. The standard group 
received significantly more intravenous fluid during the total hospital stay 
compared to the other groups. Interestingly the total volume of intravenous fluid 
administered appeared quite large, ranging from 12 to 19 litres across the 
groups. The ODM groups are at the upper end of this range. It is difficult to be 
more precise as no absolute data values are provided and only graphical 
representations are given. Excessive intravenous fluid will lead to weight gain 
and subsequently lengthen hospital stay. The conclusion from this study seems 
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to be that ODM guided fluid administration may increase the length of stay and 
cause potentially more complications. It is worth noting, however, that these 
total volumes of fluid would be considered excessive for a patient enrolled 
within an enhanced recovery programme in the UK. 
 
Challand et al (Challand et al 2011) randomized 179 patients undergoing 
elective colorectal resections. All patients underwent preoperative 
cardiopulmonary exercise testing to ascertain their anaerobic threshold. 
Patients were classified “fit” if the value was greater than 11 mlO2/kg/min. All 
patients were managed within an established enhanced recovery programme. 
1-2 litres of Hartmann’s solution was administered preoperatively if patients 
received oral bowel preparation, otherwise no pre-induction loading was given. 
The standard group had fluid administered, as felt appropriate by the 
anaesthetist, guided by standard haemodynamic parameters. The ODM group 
received a background infusion of Hartmann’s solution and additional 200 ml 
colloid (Voluven) boluses as guided by SV measurements. 
 
The ODM group had significantly higher SV, CI and FTc readings at the end of 
surgery compared to the control group. There was no significant difference in 
length of stay between the groups. However in the “fit” sub-group the ODM 
group had a significantly longer length of stay and greater number of patients 
admitted to critical care. There was no difference in bowel function and return to 
normal diet between the groups. The ODM group received additional fluid as 
per protocol. Unfortunately no statistical analysis was performed on the total 
volume of fluid administered between the groups. It would appear that in a “fit” 
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cohort of patients ODM guided fluid administration maybe detrimental within an 
enhanced recovery programme. This is somewhat contradictory to most of the 
evidence presented so far. It is worth noting that the trial did incorporate both 
open and laparoscopic resections, which does introduce a degree of 
heterogeneity to the groups. 
 
Brandstrup et al (Brandstrup et al 2012) randomized 150 patients undergoing 
open and laparoscopic elective colorectal surgery within an enhanced recovery 
programme. No bowel preparation was used in any of the patients. The “zero 
balance” group only had fluid given as Voluven in order to replace blood 
volume-for-volume, aiming for no weight change. The ODM group had 200 ml 
boluses of Voluven as guided by the SV. No significant differences were 
detected between the groups for the rate of complications or the length of stay. 
The ODM group had significantly higher SV values compared to the zero 
balance group and received a significantly greater volume of intraoperative 
fluid. 
 
There has been one meta-analysis (Abbas, & Hill 2008) conducted on five trials  
(Szakmany et al 2005; Conway et al 2002; Gan et al 2002; Wakeling et al 2005; 
Noblett et al 2006a). This does include one trial (Szakmany et al 2005) without 
colorectal resections but nevertheless major abdominal surgery. They 
concluded that ODM-guided fluid administration reduced length of stay, had 
fewer complications and ICU admissions, earlier return of bowel function and 
improved cardiac output. On balance the authors felt that ODM usage improves 
short-term outcomes in patients undergoing major abdominal surgery. 
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A subsequent critical appraisal (Srinivasa et al 2011) has been conducted on 
five trials (Senagore et al 2009; Conway et al 2002; Gan et al 2002; Wakeling et 
al 2005; Noblett et al 2006a), all with colorectal resections, but no meta-analysis 
was conducted. The authors’ conclusions are that while cardiac indices are 
improved with ODM usage in colorectal surgery, procedure-specific evidence of 
clinical benefits is scarce. They question the benefit that ODM-guided fluid 
administration may provide in patients who are already optimized within an 
enhanced recovery programme. Indeed the latest three trials (Brandstrup et al 
2012; Challand et al 2011; Senagore et al 2009) add weight to this conclusion, 
as has been discussed above.  
 
As a result of the conclusions in the Srinivasa (Srinivasa et al 2011) review a 
randomised trial was conducted to address this question (Srinivasa et al 2013). 
74 patients undergoing elective colectomy within an enhanced recovery 
programme were equally randomised to receive GDFT or ‘standard’ fluid 
restriction. Both groups received a background crystalloid fluid infusion, with the 
GDFT group having additional boluses guided by an ODM and the control 
group also having additional colloid boluses (up to 500ml) as felt appropriate by 
the anaesthetic team. No difference was noted in the rate of complications, 
length of stay or surgical recovery score between the groups. 
 
Table 1.3 provides a summary of the trials using the ODM to provide goal-
directed fluid therapy in colorectal surgery. There is reasonable heterogeneity 
between the studies. All the studies used a background crystalloid infusion with 
colloid boluses in the ODM group. In patients optimised within an enhanced 
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recovery programme, with no oral bowel preparation and oral carbohydrate 
loading as standard, a more appropriate technique may be to administer fluids 
only with ODM bolus therapy and no concurrent background infusion.  
 
There was no current evidence to suggest whether colloid or crystalloid would 
be the most appropriate bolus fluid to use with ODM when this study was 
designed and conducted. One question now remaining is which fluid, crystalloid 
or colloid, to use with the ODM in patients undergoing laparoscopic colorectal 
surgery within an enhanced recovery programme. 
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Table 1.3: Summary of trials using ODM to provide GDFT in colorectal surgery 
Trial Year Sample size 
Background 
crystalloid 
infusion 
Bolus fluid ERAS Lap 
Total volume of all 
fluid (ml), mean 
Total volume  
of all fluid 
(ml/kg/hr), 
mean 
Outcomes 
(pertaining to 
ODM group) 
Control ODM Control ODM 
Gan  (Gan 
et al 2002) 2002 100 
Yes- lactated 
Ringer’s 
solution 
6% 
hydroxyethyl 
starch in saline 
No 0 4657 5252 15.8 15.6 
!LOS/PONV 
Earlier diet 
"SV/CO/FTc 
Conway  
(Conway 
et al 2002) 
2002 57 
Probably- 
presumably 
crystalloid 
6% 
hydroxyethyl 
starch 
No 0 3770 4516 23.3 29.4 
LOS and time to 
diet no 
difference 
"SV/FTc and 
CO 
Wakeling  
(Wakeling 
et al 2005) 
2005 128 Yes- ?which 
Gelatin 
(Gelofusine/ 
Haemaccel) 
No 0 4500 (median) 
5000 
(median) No data 
No 
data 
!LOS/time to 
diet/bowels 
open and GI 
complications 
"SV/CO/DO2i 
Noblett  
(Noblett et 
al 2006a) 
2006 108 Yes- ?which Gelatin (Volplex) No 24% 3834 3638 No data 
No 
data 
!LOS/time to 
diet/need for 
inotropes/ICU 
admissions/IL-6 
"SV/FTc/CI 
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Trial Year Sample size 
Background 
crystalloid 
infusion 
Bolus fluid ERAS Lap 
Total volume of all 
fluid (ml), mean 
Total volume  
of all fluid 
(ml/kg/hr), 
mean 
Outcomes 
(pertaining to 
ODM group) 
Control ODM Control ODM 
Senagore  
(Senagore 
et al 2009) 
2009 64 
Yes- lactated 
Ringer’s 
solution 
6% 
hydroxyethyl 
starch in 
balanced 
solution 
Yes- 
but 
bowel 
prep 
given 
100% 2850 HES:3300 Cry:3800 18 
HES: 
17 
Cry: 
23 
"LOS and rate 
of complications 
Challand  
(Challand 
et al 2011) 
2011 179 Yes- Hartmann’s 
6% 
hydroxyethyl 
starch in saline 
(Voluven) 
Yes 36% 
3946 (fit 
sub-
group) 
5339 (fit 
sub-
group) 
No data No data 
"LOS and 
critical care 
admissions.  
"SV/CI/Fc 
Brandstrup  
(Brandstru
p et al 
2012) 
2012 150 
Yes-saline or 
lactated 
Ringer’s 
6% 
hydroxyethyl 
starch in saline 
(Voluven) 
Yes 47% 1491 1876 No data No data 
No change in 
LOS and rate of 
complications 
"SV and CO 
Srinivasa  
(Srinivasa 
et al 2013) 
2013 74 Yes- PlasmaLyte 
Colloid- 
unspecified Yes 15% 4311 6335 No data 
No 
data 
No change in 
LOS, surgical 
recovery or rate 
of complications 
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1.9 Which fluid, crystalloid or colloid? 
While the current recommendations available from the ERAS group (Lassen et 
al 2009), GIFTASUP guidelines (Powell-Tuck et al 2009) and NICE (NICE 
2011) advise the use of goal-directed perioperative fluid therapy (GDFT) they 
make no indication as to what the ideal fluid is. This should not really be a 
surprise as there is sparse evidence in the literature to address this question. 
Colloids and crystalloids behave in different ways and it is not clear which class 
of fluid provides the optimal benefit to the patient with GDFT, or indeed if there 
is any difference in benefit. The majority of research conducted on GDFT and 
particularly on the ODM, has used a colloid as the bolus fluid of choice, 
generally with a concurrent background crystalloid infusion. 
 
Crystalloids, in general Ringer’s lactate or Hartmann’s solution, are solutions of 
inorganic ions dissolved in water. The solution is named Hartmann’s or Ringer’s 
lactate, depending on the country you reside in, and is termed Hartmann’s in 
the UK. These are physiological solutions, and are preferred to isotonic 0.9% 
saline, which can produce hyperchloraemic acidosis in large volumes.  
 
Colloids are fluids containing homogenous noncrystalline substances with large 
molecules dispersed in a second substance (usually 0.9% saline or a 
physiological solution)(Grocott et al 2005). Colloids are either semi-synthetic 
(gelatins, dextrans or hydroxyethyl starches) or human plasma derivatives 
(albumin, fresh frozen plasma).  
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Gelatins originate from bovine collagen and are then succinylated to have an 
approximate size of 30 kDa. Examples of these are Gelofusin® or Haemaccel®. 
Dextrans are manufactured from sucrose by the bacteria Leuconostoc and are 
usually 40 or 70 kDa in size. The third generation of semi-synthetic colloids are 
hydroxyethyl starches which are synthesized from amylopectin found in maize 
and undergo hydroxyethyl substitution. They have a variable molecular weight 
either high (450-480 kDa), Hespan® and Hextend®, medium (200 kDa), 
Pentaspan® or low (70-130 kDa), Voluven® or Volulyte®. They also have a 
variable level of molar hydroxyethyl substitution, for example, Voluven® or 
Volulyte® has a substitution of 0.4. 
 
Crystalloids and colloids function in different ways, as one would expect from 
their differing composition. They also have differing potential pitfalls with their 
usage. Crystalloids, due to their composition, require greater volumes to be 
administered to produce the same effect as colloids. This has the potential 
problem of generating tissue oedema with increasing doses, which could affect 
gastrointestinal function, postoperative mobility and anastomotic healing. This 
has been seen in a randomised trial where the use of Ringer’s lactate in a 
group of patients undergoing noncardiac surgery had an increased incidence of 
postoperative nausea and vomiting compared to those receiving a starch based 
colloid (Moretti et al 2003). 
 
There are potential concerns with the use of colloids in surgery (Morris, & 
Rogerson 2011). There is a risk of anaphylactic reactions, however these are 
increasingly rare with the newer generation of starches. There are also 
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increased coagulation problems producing an increased risk of bleeding. 
Colloids are associated with the development of acute kidney injury, which is a 
particular problem with the larger molecular colloids. In addition colloids are 
significantly more expensive than crystalloids.  
 
The endothelial glycocalyx is a layer of proteoglycans and glycoproteins that 
coats the vascular endothelium and contributes substantially to the integrity of 
the vessel (Chappell et al 2008; Doherty, & Buggy 2012). Disruption of this 
layer, as can happen in surgery secondary to the release of inflammatory 
mediators, can increase the permeability of the endothelium to fluid. This may 
have implications if the fluid that is allowed to pass across is a colloid rather 
than a crystalloid, with a potentially longer lasting tissue oedema effect and the 
resultant sequelae from this.  There is, however, some evidence to suggest that 
there may be a reduced inflammatory response (TNF-α and IL-6) with the 
administration of hydroxylethyl starch colloids (130/0.4)(Chen et al 2013). 
 
There is currently very sparse evidence to allow a recommendation regarding 
the correct fluid to use in GDFT, particularly in laparoscopic colorectal surgery 
and within an enhanced recovery programme. One trial by Senagore et al  
(Senagore et al 2009) showed no benefit with the use of colloid for GDFT, but 
identified a need to investigate further the use of crystalloid and GDFT in an 
enhanced recovery setting. Looking at other specialties the Cochrane group 
have identified that there is no advantage with the use of colloid compared to 
crystalloid in abdominal aortic surgery (Toomtong, & Suksompong 2010) or in 
fluid resuscitation in the critically ill patient (Perel, & Roberts 2007).  
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There is some experimental evidence using pigs and Wistar rats. A study has 
compared the effect of low or high volume colloid or crystalloid infusion on 
anastomotic burst pressure in Wistar rats (Marjanovic et al 2010). They 
identified that those rats infused with high volume crystalloid had an increased 
likelihood of anastomotic disruption under testing compared to low volume 
crystalloid or low and high volume colloid. In addition the high volume crystalloid 
rats had reduced hydroxyproline concentrations at the anastomotic site, a 
reflection of reduced submucosal integrity. Kimberger et al (Kimberger et al 
2009) anaesthetised 27 pigs and performed a colonic anastomosis. They were 
randomized to three groups of, either restricted Ringer’s lactate, GD Ringer’s 
lactate or GD HES 6% (130/0.4) colloid. The pigs receiving GD colloid therapy 
had significantly increased microcirculatory blood flow and tissue oxygen 
tension compared to the other groups.  
 
There has been some clinical research conducted using CVP as the goal for 
fluid therapy and measuring tissue oxygen tension in the deltoid muscle 
following major abdominal surgery (Lang et al 2001). Those patients receiving 
HES 130/0.4 colloid had significantly higher tissue oxygen tension compared to 
those receiving Ringer’s lactate, particularly on the morning after surgery. The 
study was small and no differences were seen in complications or mortality 
between the groups. 
 
However, there is little evidence to draw any conclusions regarding which fluid 
to use with GDFT. A recent review article by Morris and Rogerson (Morris, & 
Rogerson 2011) attempted to address this issue and drew the same conclusion. 
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There is a call for research to investigate if there is any benefit to be gained with 
the use of either colloid or crystalloid fluid in GDFT.  It is important that any 
future studies incorporate an established enhanced recovery programme as this 
is likely to affect the outcome.  
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1.10 Aims, Hypotheses and Objectives 
Aims: 
Modification of the enhanced recovery programme for laparoscopic colorectal 
surgery is progressing. There are two key elements that required further 
clarification: 
• The exact nature of the post-operative stress response following 
laparoscopic colorectal surgery and any variation there may be with the 
use of regional or opiate analgesia.   
• Is there an optimal fluid to be used when performing goal-directed fluid 
therapy using an oesophageal Doppler monitor.  
 
The following hypotheses were tested to address these questions. 
 
Hypotheses: 
H0: The choice of analgesia used has no effect on the post-operative stress 
response following laparoscopic colorectal surgery 
H1: Spinal analgesia will produce a retardation of the post-operative stress 
response in comparison to PCA analgesia. 
 
H0: The choice of analgesia has no effect on the amount of opiates required 
following laparoscopic colorectal surgery 
H1: The use of spinal analgesia will reduce the amount of morphine required 
post-operatively compared to PCA analgesia. 
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H0: The choice of analgesia used has no effect on the length of stay following 
laparoscopic colorectal surgery 
H1: Spinal analgesia will produce a reduction in the length of stay compared to 
PCA analgesia. 
 
H0: The choice of fluid to use with GDFT in laparoscopic colorectal surgery has 
no effect on the number of complications. 
H1: 6% Volulyte administered by GDFT will produce a reduction in post-
operative complications compared to using Hartmann’s solution. 
 
H0: The use of GDFT with either Hartmann’s or 6%Volulyte to optimize patients 
is unnecessary and a predictive narrow volume range can be administered 
instead 
H1: GDFT is necessary to guide fluid administration due to large patient 
variability in the volumes of fluid required. 
 
H0: The choice of fluid to use with GDFT in laparoscopic colorectal surgery has 
no effect on the length of stay. 
H1: 6% Volulyte when used with GDFT will produce a reduction in the length of 
stay compared to the use of Hartmann’s. 
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Objectives: 
The hypotheses were tested by: 
1. Randomising patients to four equal groups to receive either spinal or PCA 
as the primary mode of analgesia and to use either Hartmann’s solution or 
6% Volulyte solution with the oesophageal Doppler monitor. 
 
2. Measuring the levels of insulin, cortisol, glucose, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12, IFN-γ, TNF-α and VEGF before surgery and at 3, 6, 12, 24 and 48 
hours from the start of surgery. 
 
3. Measuring the volume of fluid administered to optimise stroke volume as 
guided by GDFT with an oesophageal Doppler monitor and recording the 
outputs obtained from the monitor. 
 
4. Recording the clinical outcomes of patients following surgery.   
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2 Materials, Methods and Patients 
2.1 Patient selection and preparation 
2.1.1 Patient Identification 
All patients with suspected benign (diverticular disease, inflammatory bowel 
disease or endometriosis) or malignant (predominantly adenocarcinoma) 
disease of the colon and rectum were reviewed in the outpatient clinic at The 
Royal Surrey County Hospital. An appropriate history and examination was 
performed and relevant subsequent investigations arranged. Initial 
investigations involved routine blood tests, computerised tomography (CT), 
colonography and colonoscopy. 
 
Patients with suspected neoplastic disease required histological confirmation for 
definitive diagnosis and subsequent planning of treatment. A sample of tissue 
was obtained by biopsy either in the outpatient clinic or at the time of 
colonoscopy. If the presence of malignancy was confirmed, by the 
histopathologist, the patient would undergo staging of their disease. This 
involved a CT scan of their chest, abdomen and pelvis to identify any distant 
metastases that may be present. If the patient had malignancy involving the 
rectum they would also receive a magnetic resonance imaging (MRI) scan of 
the anorectum and pelvis. The purpose of the MRI scan was to identify any 
lymph node involvement in the mesorectum and/or involvement of the 
circumferential resection margin. If involvement was identified a patient 
underwent pre-operative chemo-radiotherapy to down-stage the disease. 
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In a few patients clarification of the presence of liver metastases was required 
with either an ultrasound or MRI of the liver. If the presence of other distant 
metastases was felt to be equivocal a positron emission tomography (PET) 
scan was obtained for clarification.  
 
All patients with malignant disease had their cases discussed at a weekly multi-
disciplinary meeting (MDT) consisting of colorectal surgeons, oncologists, 
radiologists and histopathologists. A consensus opinion would be formed on the 
most appropriate treatment plan for an individual patient. 
 
Patients with benign disease appropriate for resection were counseled in the 
outpatient clinic regarding the potential benefits and risks of an operation. A 
mutual decision regarding surgery and treatment was then reached. 
 
All patients planned for laparoscopic colorectal resection were considered for 
entry into the trial if they met with the inclusion and exclusion criteria listed 
below. The trial was registered with www.clinicaltrials.gov; NCT 01128088. 
 
2.1.2 Inclusion Criteria 
Patients with benign or malignant colorectal disease who were planned to 
undergo resection by laparoscopic surgery without the formation of a stoma. 
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2.1.3 Exclusion criteria  
If any of the following events occurred or were present patients were not eligible 
for inclusion in the study: 
• Stoma formation 
• Conversion to an open procedure 
• Contraindication to spinal anaesthesia: abnormal clotting, skin infection over 
or near the back, presence of neurological disorders or anatomical 
abnormalities of the vertebral column. 
• Contraindication to the use of an oesophageal Doppler probe: oesophageal 
disease, recent oesophageal surgery or upper airway surgery, moderate to 
severe aortic valve disease or a bleeding diathesis. 
• Diagnosis of diabetes mellitus requiring treatment with insulin 
• Treatment with exogenous steroids in the preceding three months. 
• If an oral bowel preparation was to be used. 
 
2.1.4 Patient recruitment 
Following the MDT, patients would attend the clinic for their diagnosis and the 
recommended treatment plan would be outlined to them. If patients fulfilled the 
inclusion or exclusion criteria they were also invited to participate in the trial by 
the chief investigator or clinical supervisor. 
 
At this time the concept of enhanced recovery was explained, i.e: typical length 
of stay, ability to eat normally the night before surgery, active postoperative 
mobilization and early re-introduction of food after the operation. Also the 
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current analgesic modalities (spinal and patient-controlled analgesia (PCA)) in 
use were explained. The patient was informed that the most appropriate 
analgesic regime and intravenous fluid to be used in laparoscopic colorectal 
surgery were currently unclear. In addition the stress response in the period 
immediately after the operation was explained and how it might be modified by 
different analgesic methods and the enhanced recovery programme was still to 
be confirmed. Hence the reason for the trial was introduced.   
 
Patients were informed that they would be randomized into one of four groups 
to receive either spinal analgesia/Volulyte® fluid, spinal analgesia/Hartmann's 
fluid, PCA/Volulyte® fluid or PCA/Hartmann's fluid. The planned postoperative 
measurements were explained in detail. Patients were provided with a trial 
information leaflet that had been approved by the local ethics committee (see 
appendix A) and they had the opportunity to ask any questions.  
 
If a patient was interested in participating in the trial they were given a phone 
number and e-mail address to contact the chief investigator regarding any 
further questions. All patients were assessed at a preoperative clinic and if any 
concerns were identified, they were reviewed by a consultant anaesthetist.  
 
2.1.5 Consent 
Patients were admitted on the evening prior to surgery or on the day of surgery 
depending on patient choice and bed availability. The trial was re-addressed 
with the patient prior to surgery by discussing each point in the information 
leaflet with them. They were asked to express any concerns or further questions 
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they may have to the researcher. If they were satisfied with all aspects of the 
study and agreed to enter the trial they were asked to initial each point of the 
consent form and sign it (see appendix B). The time between recruitment and 
consent was usually a number of days. 
 
2.1.6 Pre-operative preparation 
Patients were allowed to eat and drink normally during the course of the 
evening prior to their surgery. The elements of the enhanced recovery 
programme were reiterated to the patients by the ward nursing staff and the 
colorectal nurse specialist in the case of malignant disease. Patients received 
100 g of carbohydrate drink (preload®) mixed in 800 ml of water at 21:00 the 
night before surgery and a further 50 g mixed in 400 ml of water at 
approximately 06:00 on the morning of surgery. Patients undergoing a left-sided 
resection received a phosphate enema (a rectal purgative) at 07:00 on the 
morning of the surgery. No patients received any form of oral mechanical bowel 
preparation. 
 
After signing the consent form and recording the initial measurements (see 
below) the randomisation code was opened. The randomisation sequence had 
been pre-prepared by a University of Surrey statistician and were stored in 
opaque envelopes kept in an off-site building. The sequentially numbered 
envelopes were opened in the pre-determined numerical order. Patients were 
randomised to one of four groups: Spinal/Volulyte®, Spinal/Hartmann’s, 
PCA/Volulyte®, PCA/Hartmann’s. The patient was informed of the mode of 
post-operative analgesia and the type of intravenous fluid they were to receive 
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and the randomisation sheet was fixed to the front of the notes. The 
anaesthetist in charge of the case, as well as the operating theatre staff and the 
chief investigator were informed as to the mode of analgesia/intravenous fluid to 
be used for each case.  
 
2.1.7 Pre-operative measurements 
After they had signed their consent form the past medical history and drug 
history for the patient were recorded onto the data collection sheet (see 
appendix C). Patient weight (kg) was measured on a set of digital scales (the 
same scales used for all measurements) and height (cm), obtained from the 
pre-admission paperwork, was recorded. This allowed correlation with the 
correct normogram for accurate use of the oesophageal Doppler probe. The 
abdominal circumference of the patient was measured at the height of the 
anterior superior iliac spines.  
 
At this stage the pain scoring system was explained to the patient. A visual 
analogue score with zero representing no pain and ten representing the worst 
pain imaginable was used. This was recorded at rest and with 
coughing/movement. 
 
The pre-operative blood results were recorded to allow calculation of the 
Physiological and Operative Severity Score (POSSUM). Confirmation that the 
patient had received the correct amount of preload drink and had been given 
their phosphate enema, as appropriate, was obtained. 
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At approximately 07:00 to 08:00 on the day of surgery and after the preload 
drink had been given 10 ml of venous blood was drawn from an antecubital vein 
and placed into Vacuette® tubes for subsequent analysis of the stress 
response compounds. The aim was to draw all control samples at this time in 
order to standardise the insulin and cortisol readings. A few patients had blood 
drawn later in the day as they were not admitted early on the day of surgery. 
Venous blood was divided into Vacuette® serum, glucose and heparin tubes. 
Serum and glucose tubes were sent immediately to the hospital biochemistry 
laboratory with a completed request form specific to each time period and 
patient (see appendix D). The glucose tube was immediately analysed and the 
serum tube was spun, separated and frozen at -200C for later analysis. The 
heparin tube was transferred immediately to the postgraduate medical school 
oncology laboratory and placed on a rocking stand to be processed and 
subsequently stored, see section 2.7.1.  
 
2.2 Peri-operative methodology 
2.2.1 Anaesthetic Protocol 
On arrival at theatre patients were checked in by the theatre team and then 
brought to the anaesthetic room. Anaesthesia was induced using propofol (2-3 
mg/kg), alfentanil (10 µg/kg) and rocuronium (0.6 mg/kg). No pre-medications 
were given. The patient was intubated and mechanically ventilated in the 
standard fashion. A nasogastric tube was not routinely used unless 
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decompression of the stomach was needed. If this was the case the 
nasogastric tube was removed at the end of the procedure.  
 
The oesophageal Doppler probe (Deltex®) was lubricated and inserted straight 
after intubation and baseline readings were recorded. The patient then 
underwent fluid optimisation with the appropriate randomly determined 
intravenous fluid as guided by the stroke volume (see section 2.2.4). Patients 
were fluid-optimised before the operation commenced. A 250 ml bolus of fluid 
was given and if the stroke volume increased by more than 10% a further bolus 
was given, until there was no longer a 10% rise in stroke volume. The volume of 
fluid given in the anaesthetic room was recorded. 
 
Anaesthesia was maintained with sevoflurane at a mean alveolar concentration 
(MAC) of 1.0-1.4, oxygen enriched air and a remifentanil infusion (40 µg/ml) 
titrated to the depth of anaesthesia. All patients had a 16 gauge peripheral line 
and 20 gauge arterial line inserted. A 4-lumen right internal jugular central 
venous line was inserted under ultrasound guidance. A bear-hugger and a 
urinary catheter were used in all cases. All patients received 1.5 g of cefuroxime 
and 500 mg of metronidazole at induction. If phenylephrine was used in the 
anaesthetic room the amount given was recorded. 
 
Patients received one of the following methods of post-operative analgesia as 
determined by the randomisation procedure: 
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1. Spinal anaesthesia:  The spinal anaesthetic was given prior to induction. 
It required the insertion of a spinal needle through the L2-3 or L3-4 
interspace with the patient sitting, and injection of 2.5 ml of 0.5% 
hyperbaric bupivacaine with 0.25 mg of diamorphine. 
2. Patient-controlled analgesia (PCA): Patients were given 10 mg of 
morphine intra-operatively and then attached to a pump in the post-
operative anaesthetic unit (100 mg of morphine in 50 ml of saline) with a 
1 mg bolus and 5 minute lockout, with a maximum dose of 20 mg in 4 
hours. 
 
At the end of surgery any residual neuromuscular blockade was reversed with 
neostigmine, 2.5 mg, and glycopyrolate, 0.5 mg. All patients were given 4 mg of 
ondansetron and 1 g of paracetamol. Patients in the PCA group also received 
20 ml of levobupivicaine, 5 mg/ml, infiltrated into the wounds. 
 
2.2.2 Set-up for laparoscopic colorectal surgery 
Once the patient was anaesthetized they were brought into the operating 
theatre and transferred onto the operating table in a supine position. The draw-
sheet was removed so that the bare skin of the patient was in direct contact 
with the gel mat on the operating table. For left-sided resections (anterior 
resection, left hemicolectomy and sigmoid colectomy) the patient was placed in 
the Lloyd-Davis position with their legs secured in supports with pneumatic calf 
compression attached. Once secured, the bottom half of the table was removed 
to allow access to the perineum for examination and formation of the 
anastomosis.  
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For right-sided resections (right hemicolectomy, extended right hemicolectomy 
and ileo-caecal resections) the legs were left flat and secured with a strap to the 
table. A mixture of shoulder and side supports were used to ensure the patient 
was safely secured to the table as steep head-down and lateral tilt positions 
would be adopted during the procedure. Careful attention was placed to all 
patient pressure points.  
 
A Bair-Hugger® thermal blanket was placed over the upper torso for the length 
of the procedure to maintain normothermia during the operation. The central 
and arterial line were attached to the monitor and calibrated. The oesophageal 
Doppler was once again connected to the monitor and the strongest signal was 
obtained by manipulation of the probe in the oesophagus. At this point baseline 
Doppler readings were recorded onto the patient data collection sheet (see 
appendix C). The readings collected were heart rate (HR), cardiac output (CO), 
stroke volume (SV), cardiac index (CI), flow time corrected for heart rate (FTc) 
and peak velocity.  
 
The Doppler monitor was used to calculate the oxygen delivery (DO2), using the 
pre-operative haemoglobin measurement and oxygen saturation measurement 
obtained from the pulse oximeter, and systemic vascular resistance (SVR) and 
these were also indexed to the body surface area (DO2i, SVRi). 
 
The DO2i was calculated by entering the values as prompted by the monitor, 
which used the formula below to make the calculation: 
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DO2i%(ml/min/m2)%=%(Hb%(g/l)%x%CO%(l/min)%x%(oxygen%saturation/100)%x%1.34)%/%SA%(m2)%
 
The SVRi was also calculated by entering the values as prompted by the 
monitor, which used the following formula: 
 
SVRi%(dyn.s/cm5)=%(MAP%(mmHg)%–%CVP%(mmHg)%/%CO%(l/min))%/%SA%(m2)%
%
Other readings that were recorded from the anaesthetic monitor were the mean 
arterial pressure (MAP), central venous pressure (CVP), oxygen saturations, 
peak ventilation pressure and peak end expiratory pressure (PEEP). 
 
2.2.3 Surgical Technique 
Entry to the abdominal cavity was achieved at the umbilicus by using the 
Hasson technique. A pneumoperitoneum was than created by insufflation of the 
abdominal cavity with carbon dioxide to achieve a pressure of 14 cmH2O. Right-
sided colectomies were performed in a medial-to-lateral dissection plane with 
early ligation of the vessels using either a laparoscopic stapler or the 
Harmonic® scalpel. The resection and anastomosis were performed extra-
corporeally through a short midline incision. 
 
Left-sided resections employed medial-to-lateral dissection along tissue planes 
with early division of the inferior mesenteric artery with a laparoscopic stapler. 
The splenic flexure was mobilized as appropriate for left-sided resections in 
order to achieve a tension-free anastomosis. The bowel was divided intra-
corporeally by a laparoscopic stapler, and the specimen extracted through a 
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Pfannenstiel incision protected by a wound protector. The anastomosis was 
performed with a circular stapling gun introduced to the rectal stump through 
the anus. Drains were not used routinely. 
 
2.2.4 Doppler Probe Usage 
The oesophageal Doppler probe was used to guide the administration of 
intravenous fluids during the operation based on changes in the SV. The 
baseline SV, used to determine if any further fluid was to be administered, was 
taken as the reading obtained after optimisation in the anaesthetic room and the 
patient had been positioned but before surgery commenced. If the stroke 
volume decreased by more than 10% from this baseline the protocol below was 
followed.  
 
Readings were recorded from the Doppler probe and the anaesthetic monitor at 
five minute intervals until the end of the operation. A note was made of the time 
that surgery started, the pneumoperitoneum was applied, the head down 
position was adopted and the abdomen was opened for specimen extraction. 
The need for any vasoconstrictor support was defined by hypotension with a 
mean arterial pressure of less than 60 mmHg. Treatment was with 
phenylepherine, titrated to response. Fluids were administered as per the 
modified Wakeling protocol, figure 2.1. 
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Figure 2.1: The modified Wakeling protocol to optimise stroke volume. 
 
At twenty-five minutes after the start of surgery a central venous blood sample 
was taken to measure the central venous oxygen saturations (cvO2%) using a 
blood gas analyzer. The haemoglobin (Hb) level was noted from this sample as 
Measure 
Stroke 
Volume 
10% fall in 
stroke 
volume 
250 mls of 
Volulyte/ 
Hartmann’s 
over 2 min 
Yes 
Wait 5 
mins Yes No 
Measure 
stroke 
volume every 
5 min 
Increase in stroke 
volume is greater 
than 10% 
No 
  109 
haemodilution may have occurred due to the fluid therapy so far. This new Hb 
level was used for any subsequent DO2i calculations. 
 
At the end of surgery final readings of DO2i, SVRi, HR, CO, SV, CI, FTc, peak 
velocity, CVP and MAP were recorded. The total volume of fluid and any 
phenylepherine given was noted. 
 
2.3 Post-operative management  
2.3.1 Post-operative prescribing 
Post-operative fluids were prescribed as one litre of Hartmann’s solution to run 
over eight hours, followed by a further one litre bag over 12 hours. Intravenous 
fluids were then discontinued unless there was a clinical indication to continue. 
In addition cefuroxime, 750 mg IV, and metronidazole, 500 mg IV, were 
prescribed at eight and 16 hours post-operatively. 
 
For additional pain-relief, patients were started on regular paracetamol one g 
IV/PO quarter die sumendus (QDS) and voltarol 50 g PO ter die sumendum 
(TDS). If contraindicated, patients were prescribed tramadol 50 mg QDS 
instead of voltarol. To provide gastric protection for voltarol, patients were 
prescribed omeprazole, 20 mg omni in die (OD) PO. For rescue analgesia they 
received tramadol 50-100 mg IV/PO/IM and morphine 5-10 mg IV/PO/IM on a 
pro re nata (PRN) basis. The spinal patients did not receive a PCA but had 
morphine available as PRN if required. Anti-emetics available were cyclzine 50 
mg IV/PO TDS and ondansetron four mg IV/PO QDS. Patients were also 
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prescribed lactulose 10 ml bis in die (BD) PO, fortisips 200 ml TDS PO and 
enoxaparin 40 mg OD S/C.  
 
2.3.2 Day of surgery 
After the completion of surgery the patient was extubated and transferred to the 
recovery ward. The patient was seen at three hours following the start of 
surgery and their pain scores were assessed on the visual analogue scale. 
Patients were only deemed able to give an appropriate response if they could 
maintain a conversation and recognize the chief investigator. A further 10 ml of 
blood was drawn from the central line for the stress response analysis and 
divided as described earlier. A central venous blood sample was also taken and 
the oxygen saturation measured on a calibrated blood gas analyser. 
 
When deemed appropriate by the recovery and anaesthetic teams the patient 
was returned to the ward. Patients were encouraged to drink and eat freely as 
tolerated. If the operation had been performed earlier in the day they would be 
expected to sit out for a couple of hours and walk on the spot for a few minutes 
later that evening. This was sometimes impracticable for patients at the end of 
the operating list.  
 
The patient was visited again at six and 12 hours following the start of surgery 
and the importance of mobilization and early diet reiterated. The pain scores at 
rest and during movement were recorded at these time intervals. Venous blood 
(10 ml) was also drawn for the stress response analysis. At the six hour time 
interval a sample of central venous blood was analysed and the oxygen 
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saturation recorded. If the saturations were between 60%-65% the patient was 
encouraged to drink more water. If the saturations were less than 60% a 500 ml 
bolus of randomized specific fluid (Volulyte® or Hartmann’s) was administered 
over two hours. Following this, a repeat central venous sample was analysed to 
note any change in oxygen saturation. 
 
2.3.3 24 hour Intervals 
Patients were visited at 24-hour intervals from the start of surgery. Daily 
measurements of the patients’ abdominal circumference, pain scores, weight, 
presence or absence of bowel sounds, number of vomits, core temperature, 
blood pressure, heart rate and oxygen saturations (using a pulse oximeter) 
were all recorded. The time until the patient was able to tolerate a normal diet 
and when they first opened their bowels and passed flatus were recorded. A 
patient was deemed tolerant of diet if they had not vomited since their last full 
meal, as determined by the patient. The volumes of fluid (intravenous and oral) 
given were noted for any given 24-hour period. 
 
At 24 hours following the start of surgery 10 ml of venous blood was drawn for 
the central line for the stress response analysis. A further central venous 
sample was drawn to obtain the oxygen saturation and if the measurement was 
less than 60% a fluid bolus was given as described above. After this the central 
line was removed. The catheter was either removed at midnight on the day of 
surgery or on day one, unless there was a clinical indication to leave it in.  
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At 48 hours following the start of surgery 10 ml of venous blood was drawn by 
venepuncture from an antecubital vein for stress response analysis. Table 2.1 
shows a Gantt chart for the timing of interventions to patients. 
 
Table 2.1: Gantt chart to show timings of interventions. 
 Pre-op Peri-op 
3hrs 
post-
op 
6hrs 
post-
op 
12hrs 
post-
op 
24hrs 
post-
op 
48hrs 
post-
op 
Oral 
carbohydrate 
load 
       
Phosphate 
enema as 
appropriate 
       
Weight        
Abdominal 
circumference        
Pain score         
Bowel sounds        
Blood sample        
Spinal as per 
randomisation        
GDFT        
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2.3.4 Discharge Criteria 
Patients were deemed appropriate for discharge if they fulfilled the following 
criteria: 
• Clinical observations normal 
• Patient comfortable with oral analgesia 
• Passed urine following removal of urinary catheter 
• Tolerated a normal diet 
• Patient was happy for discharge 
• Fully mobile 
 
The total amount of intravenous fluid, regular analgesia, breakthrough 
analgesia and anti-emetic administered to the patients during their stay was 
recorded. The time in hours to when the patient was deemed medically fit for 
discharge and when the patient actually left the hospital was recorded. The time 
to the first passage of stool and flatus, tolerating diet and presence of bowel 
sounds was calculated from the end of surgery. If the patients had not passed 
stool or flatus prior to discharge they were given a sheet to fill in and return to 
the chief investigator in a stamped-addressed envelope, with the events when 
they happened.  
 
All patients were reviewed in the outpatient clinic at two weeks post-operatively 
for cancer resections and six weeks post-operatively for benign resections. The 
histopathology of cancer resection specimens was reviewed in the MDT and 
any further treatment decided upon in this forum. 
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2.3.5 Study Protocol 
1. Preoperative education 
2. Eat and drink normally the day before surgery 
3. Avoidance of oral bowel preparation, left sided resections received a 
phosphate enema at 07:00 on the day of surgery 
4. Preoperative carbohydrate drink: 100 g of preload® mixed in 800 ml of 
water at approximately 21:00 the night before surgery and 50 g of preload® 
in 400 ml of water 06:00 the morning of surgery. 
5. Avoidance of preoperative sedatives 
6. Pre-operative measurements. 
7. Patient randomized to analgesia/fluid group 
8. Blood taken for stress response analysis. 
9. Spinal anaesthesia (as per randomization) before skin incision 
10. Target driven, oesophageal Doppler probe directed fluid therapy 
11. Upper body air heating cover 
12. Avoidance of abdominal drains 
13. Avoidance of nasogastric tube 
14. Oral fluid in recovery or on arrival back to the ward 
15. 10 ml of blood drawn from central line at three hours from the start of 
surgery. 
16. Sit out of bed on the afternoon or evening of surgery 
17. Normal diet from dinner 
18. Mobilisation on evening of surgery, with walking on the spot for three-five 
minutes 
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19. Measurement of central venous oxygen saturations and 10 ml of venous 
blood drawn for stress response analysis at six hours post-operatively. 
20. Removal of indwelling urinary catheter at midnight on the day of operation if 
clinically appropriate.  
21. 10 ml of blood drawn from central line for stress response analysis at 12 
hours from the start of surgery. 
22. Termination of intravenous fluids at 18-20 hours post-operatively 
23. 10 ml of blood drawn for stress response analysis at 24 hours from the start 
of surgery and measurement of central venous saturations prior to removal 
of the central line. 
24. Daily measurement of weight, abdominal circumference, temperature, 
oxygen saturations, heart rate, blood pressure and bowel function. 
25. Aperient given (lactulose 10 ml BD) 
26. Fortisips 200 ml PO TDS 
27. Further 10 ml of venous blood drawn by venepuncture at 48 hours for stress 
response analysis. 
28. Discharged home if tolerating breakfast, passing urine and comfortable 
29. Follow-up in outpatient clinic following discharge. 
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2.4 Outcome measures 
2.4.1 Primary Outcome 
• The change in plasma interleukin-6 level following surgery for the four 
groups. 
 
2.4.2 Secondary Outcomes 
• The change in plasma cortisol level following surgery for the four groups 
• The change in plasma glucose level following surgery for the four groups 
• The change in plasma insulin level following surgery for the four groups 
• The change in  plasma IL-2, IL-4, IL-8, IL-10, IL-12, Interferon-γ, TNF-α and 
VEGF level for the four groups 
• The volume of fluid given intraoperatively 
• The amount of vasopressor support required (total dose in µg/kg) to 
maintain a MAP >60mmHg 
• The time until bowel sounds returned 
• The time until diet was tolerated 
• The time until flatus was passed 
• The time until bowels first opened 
• The quality of post-operative analgesia measured at rest and on movement, 
scored on a visual analogue scale ranging from zero to ten 
• The length of stay in hospital 
• The incidence of readmissions  
• The incidence of post-operative complications 
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2.5 Sample Size Calculation 
In order to determine if there was a difference between the four groups 
(Spinal/Volulyte®, Spinal/Hartmann’s, PCA/Volulyte® and PCA/Hartmann’s) 
over a six hour period from zero to six hours by a value of 200 pg/ml for 
interleukin-6, the number of patients in each group was calculated, with a power 
of 80% and significance of 5%, using a 2 sided test. This was based on the 
level of variation (standard deviation of 269.4) previously determined in a pilot 
study undertaken at the MATTU and was calculated by the formula shown in 
figure 2.2.  
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Figure 2.2: Power calculation formula 
 
Using the formula in figure 2.2, 30 patients were required in each group. 
However to allow for patient drop out due to conversion to open (rate of 5.6%, 
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obtained from a prospectively kept database for the colorectal unit) 32 patients 
were required for each treatment group. With these group sizes we were also 
able to detect a difference of 100 pmol/l for insulin between zero and six hours 
and a difference of 300 nmol/l for cortisol between zero and six hours. 
 
2.6 Statistical Analysis 
Statistical analysis was performed using SPSS version 19. Data were assessed 
with a Kolmogorov-Smirnov test to see if they were normally distributed. The 
majority of the data were asymmetrically distributed and as such all data is 
presented as medians and interquartile ranges for continuity.  
 
Asymmetrical data, when more than two groups were compared, were analysed 
with an independent-samples Kruskal-Wallis test to determine any statistical 
difference within the four group medians. If a difference was detected a Mann-
Whitney test was used in a pairwise fashion to identify the groups that were 
statistically significant. Asymmetrical data from two groups were analysed with 
an independent-samples Mann-Whitney U test.  
 
Asymmetrical data was presented as box and whisker plots demonstrating the 
median, interquartile range and minimum and maximum values excluding 
outlying values. Outliers are defined as points greater or less than one and half 
times the interquartile range from the edges of the box. 
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A related samples Wilcoxon Signed rank test was used to analyse medians 
within a group. Spearman’s correlation coefficient was used to analyse the 
association between two variables. 
 
Categorical variables were compared using a Pearson chi-squared test.  
 
Analysis of survival curves was performed using the Kaplan-Meier function with 
a log-rank test to assess significance between the survival curves. 
 
2.7 Laboratory methods 
2.7.1 Isolation of peripheral blood mononuclear cells (PBMC) 
from Blood 
The collected blood tubes were spun in a centrifuge at 2000 rpm for 10 mins 
with the brake set on low. The plasma was then drawn off and placed into a 15 
ml Falcon tube and this tube was then placed in the centrifuge at 2000 rpm for 
10 mins. Following this the plasma was aliquoted evenly into three labeled 
cryovials and placed into the freezer at -80 degrees centigrade for later 
analysis. 
 
The rest of the blood in the 15ml Falcon tube containing the PBMC was diluted 
in a ratio of 1:1 with RPMI-1640 (Sigma-Aldrich, Poole, UK). This was then 
layered onto 4ml of Histopaque 1077 (a medium, with a density of 1.077 g/ml, 
that facilitates the recovery of large numbers of viable mononuclear cells 
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manufactured by Sigma-Aldrich, Poole, UK) in another 15ml Falcon tube. This 
tube is then placed in the centrifuge (Beckman Coulter Allegra X-12R) at 690 x 
g for 25 mins with no deceleration brake. 
 
The PBMC’s (the cloudy middle layer) were removed using a disposable plastic 
Pasteur pipette and placed into a 15 ml Falcon tube containing 2 ml of RPMI-
1640. This Falcon tube was then placed in the same centrifuge and spun at 700 
x g for 10 mins and a deceleration brake was applied at the end of the spin. The 
PBMC were then re-suspended in 5 ml of red blood cell lysis buffer (containing 
ammonium chloride) and left at room temperature for 10 mins with intermittent 
mixing. 
 
The Falcon tube containing the PBMC suspended in red blood cell lysis buffer 
was filled with RPMI-1640 and placed in the centrifuge and spun at 700 x g for 
5 mins with a deceleration brake. The fluid was tipped off and the PBMC pellet 
was re-suspended in 1ml of RPMI-1640. 10 µl of the PBMC suspension was 
then mixed with 90 µl of Trypan blue solution in a 96 well U-bottomed plate. 
This solution was then placed on a haemocytometer slide and the number of 
viable cells were counted in a 4 x 4 block. The total number of cells in the 1 ml 
suspension equaled the cell count x 10 (diluted 1:10 in Trypan blue) x 10000 
(for the cell number per ml) x 1 (the total volume of suspension used). 
 
The remainder of the PBMC suspension was placed in the centrifuge and spun 
at 700 x g for 5 mins. The PBMC’s were then re-suspended in a freezing 
medium composed of 70% RPMI-1640, 20% foetal calf serum and 10% 
  121 
dimethylsulphoxide at approximately 5 x 106 cells / ml. This suspension was 
then placed into labeled cryovials at approximately 1 ml per vial. The cryovials 
were then frozen in freezing containers (Nalgene, Rochester, US) where the 
rate of cooling was -1 degree centigrade/min. The samples were left overnight 
at -80 degrees centigrade and transferred the following day to liquid nitrogen for 
storage and potential analysis at a later date. 
 
2.7.2 Bio-Plex Pro Human Cytokine Assay 
The cytokine analysis was carried out using a Bio-Plex Human cytokine assay 
reagent kit supplied by Bio-Rad Laboratories, Hemel Hempstead, UK. A 96-well 
plate was used and the layout was as follows. A total of 8 standards occupied 
the wells A1-H1 with duplicates in wells A2-H2. A blank was placed into wells 
A3 and A4. That left enough space for 39 samples in duplicate to be measured 
per plate, laid out in B3 and B4 through to H11 and H12. 
 
The lyophilized standard was then reconstituted by tapping the vial to ensure 
the pellet is at the bottom and then 500 µl of standard diluent was added. The 
reconstituted standard was gently vortexed for 1-3 secs and then placed on ice 
for 30 mins. While the standard was incubating on ice the plasma samples to be 
analysed were prepared. 
 
The selected plasma samples were thawed overnight in the fridge at 4 degrees 
centigrade and then allowed to come to room temperature prior to preparation. 
The plasma samples were diluted to a ratio of 1:4 by adding 50 µl of plasma 
sample to 150 µl of sample diluent in 1.5 ml polypropylene tubes and vortexed. 
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The coupled beads supplied with the reagent kit were prepared next. The 10x 
stock of coupled beads were vortexed for 30 secs and then 575 µl was carefully 
removed and added to a 15 ml polypropylene tube containing 5175 µl of assay 
buffer in order to dilute to a 1x concentration. This mixture was then vortexed. 
The prepared beads were then protected from the light by wrapping the tube in 
aluminum foil and allowed to equilibrate at room temperature for 20 mins prior 
to use. 
 
Once the lyophilized standard had incubated the standard dilution series was 
prepared. 11 1.5 ml polypropylene tubes were labeled S1 through to S10 and 
one as Blank. Tube S1 had 72 µl of standard diluent added and tubes S2 
through to S10 and Blank had 150 µl of standard diluent added. Next 128 µl of 
the reconstituted lyophilized standard was added to tube S1 and vortexed. 
Using a fresh pipette tip 50 µl was removed from tube S1 and added to tube S2 
and then vortexed. This 1:4 serial dilution was continued through to tube S10 
using a fresh pipette tip for each transfer and the tubes were vortexed after 
each addition. Tubes S3-S10 were used to create the standard curve. The 
standard dilution series was kept on ice until it was added to the 96-well plate. 
 
The next stage was to prepare the 96-well plate in order to run the assay. The 
filter plate was prewet with 100 µl of assay buffer and the liquid was removed by 
vacuum filtration using a vacuum manifold. The bottom of the plate was dried 
thoroughly on a clean paper towel. The prepared diluted coupled beads were 
vortexed for 30 secs and then 50 µl were added to each well of the plate. Each 
well of the plate was then washed with 100 µl of wash buffer and this liquid was 
  123 
removed by vacuum filtration. This was repeated with a further 100 µl of wash 
buffer. 
 
The diluted standards, blank and diluted plasma samples were gently vortexed 
for 1-3 secs and then 50 µl of diluted standard S3-S10, blank and diluted 
sample were added to the corresponding wells as laid out earlier in this section. 
A separate pipette tip was used for each volume transfer. The wells were then 
secured with sealing tape and covered in aluminum foil and placed on a shaker 
at room temperature for 30 mins at 800 rpm.  
 
The detection antibodies were prepared next by adding 2700 µl of detection 
antibody diluent to a 15 ml polypropylene tube. The 10x stock of detection 
antibodies were vortexed for 15-20 secs and 300 µl was then removed and 
added to the tube containing 2700 µl of detection antibody diluent and vortexed. 
This process was performed 10-15 mins prior to use. At this point the Bio-Plex®  
system computer was started up and the plate reader allowed to warm up. The 
waste bottle was emptied and the sheath fluid bottle was filled up. 
 
Once the system had warmed up a calibration was performed using the Bop-
Plex CAL 1 and CAL 2 solutions supplied with the machine using the 
manufacturers recommended low RP1 target value. Following incubation of the 
samples in the plate the sealing tape was carefully removed and all the wells 
were washed with 100 µl of wash buffer and this was removed using vacuum 
filtration. This was performed a further two times. 
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The diluted detection antibodies were vortexed for 1-3 secs and 25 µl was 
added to each well of the plate. The plate was then covered with a new sheet of 
sealing tape and wrapped in aluminum foil and placed on a shaker at room 
temperature at 800 rpm to incubate for a further 30 mins. During this phase the 
correct volume of streptavidin-phycoerythrin (SA-PE) was prepared. 
 
In order to prepare the SA-PE 5940 µl of assay buffer was added to a 15 ml 
tube. The SA-PE stock tube was vortexed for 15-20 secs and then 60 µl was 
removed and added to the tube containing 5940 µl of assay buffer in order to 
produce a 1x concentration. The prepared concentration of SA-PE was 
wrapped in aluminum foil as it is sensitive to light degradation and was only 
prepared 10 mins prior to use. 
 
Following the 30 mins period of incubation with the added detection antibodies 
the sealing tape was removed from the plate and the wells were washed with 
100 µl of wash buffer, which was removed by vacuum filtration. This was 
repeated a further two times. The prepared SA-PE concentration was vortexed 
for 3-5 secs and then 50 µl was added to each well. The plate was again sealed 
with sealing tape and wrapped in aluminum foil and then placed on a shaker at 
room temperature at 800 rpm for 10 mins. 
 
Following the 10 mins SA-PE incubation period the sealing tape was removed 
and the wells washed with 100 µl of wash buffer, which was removed by 
vacuum filtration. This was repeated a further two times. 125 µl of assay buffer 
was then added to each well and the plate sealed with sealing tape and the 
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plate placed on a shaker at room temperature at 1100 rpm for 30 secs. 
Following incubation the sealing tape was removed and the plate was now 
reader to be placed on the plate reader and the Bio-Plex system activated to 
run the protocol.  
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3 Results 
 
One hundred and forty three patients were approached to participate in this 
randomized controlled trial (NCT01128088). One hundred and thirty three 
patients were recruited and randomized. One hundred and twenty patients 
completed the trial. Figure 3.1 shows the recruitment and reason for exclusion 
from the trial. 
 
The PCA/Volulyte group had three exclusions. One patient was converted to 
laparotomy in order to control immediate post-operative bleeding. Two patients 
had no colonic resection, one had endometriosis and required no resection and 
the other had Crohn’s disease affecting the small bowel necessitating only a 
small bowel resection. 
 
The PCA/Hartmann’s group had three exclusions. One patient had no colonic 
resection as the polyp was resected with a transanal approach. One patient had 
a laparotomy to control bleeding. One patient underwent a conversion 
secondary to a large diverticular mass, which required a laparotomy incision to 
complete dissection and remove the mass. 
 
The spinal/Volulyte group had three exclusions. One patient had a total 
mesorectal excision for rectal cancer and given his male gender and obesity a 
defunctioning ileostomy was fashioned. One male patient who had had 
preoperative chemoradiotherapy and cryotherapy required a total mesorectal 
excision, this was converted due to difficulty with dissection and he was also 
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defunctioned. One patient had a laparotomy to control immediate post-operative 
bleeding. 
 
The spinal/Hartmann’s group had four exclusions. One patient had 
endometriosis that required downstaging with Zoladex prior to resection and 
another patient with Crohn’s disease only required a small bowel resection and 
no colonic resection. One patient required a conversion owing to the size of the 
tumour and the other patient also had a conversion and then no subsequent 
resection. 
 
Other than the exclusions listed above the data were analysed on an intention-
to-treat basis. 
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Figure 3.1: CONSORT flow diagram showing patient randomization and 
exclusion. Conversion was defined as any procedure that required an 
incision bigger than that required for specimen extraction. 
143 patients 
approached 
133 patients 
randomised 
7 patients declined 
3 patients not eligible 
PCA/Volulyte 
33 patients 
PCA/Hartmann’s 
33 patients 
Spinal/Volulyte 
33 patients 
Spinal/Hartmann’s 
34 patients 
PCA/Volulyte 
30 patients 
PCA/Hartmann’s 
30 patients 
Spinal/Volulyte 
30 patients 
Spinal/Hartmann’s 
30 patients 
  Conversion =1 
  No colonic 
  resection =2 
  Conversion =2 
  No colonic 
  resection =1 
  Conversion =2 
  Defunctioned =1 
  Conversion =2 
  No colonic 
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Table 3.1a and shows the patient characteristics for the four groups and Table 
3.1b shows the patient characteristics dependent on the type of analgesia or 
fluid used. There were no significant differences between the four groups in 
table 3.1a except the distribution of gender in the spinal groups and whether the 
patient was admitted on the day of surgery. The uneven gender difference 
remained in the two fluid groups regardless of the analgesia used (Table 3.1b).  
 
Table 3.1a: Patient characteristics for the four groups. Median values with 
interquartile range, *Pearson chi-squared test: 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Patients completing 
trial 30 30 30 30  
Age, years 65 (47-72) 
64 
(54-77) 
62 
(52-73) 
71 
(43-79) 0.623 
Gender 
M:F 10 : 20 22 : 8 14 : 16 13 : 17 0.015* 
Weight, kg 74 (63-87) 
75 
(66-86) 
75 
(63-87) 
77 
(61-83) 0.922 
BMI 27 (24-30) 
25 
(23-28) 
26 
(24-28) 
25 
(23-28) 0.302 
P-POSSUM score 26 (23-29) 
24 
(23-28) 
25 
(24-29) 
27 
(23-31) 0.435 
Blood loss  
<100ml 26 26 25 29 
0.225 
Blood loss  
101-500ml 2 4 4 1 
Blood loss 
501-999ml 2 0 0 0 
Blood loss  
>1000ml 0 0 1 0 
ASA 1 10 15 13 8 
0.336 ASA 2 20 14 17 22 
ASA 3 0 1 0 0 
Day of surgery 
admission Y:N 20 : 10 16 : 14 20 : 10 10 : 20 0.029* 
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Table 3.1b: Patient characteristics: Groups were compared on the basis of 
analgesia used regardless of fluid used (columns 2-4) or on the basis of 
fluid infused regardless of analgesia used (columns 5-7). Median values 
with interquartile range, * Pearson chi-squared test. 
 Spinal PCA p-value Volulyte Hartmann’s 
p-
value 
Patients 
completing 
trial 
60 60  60 60  
Age, years 65 (51-73) 
66 
(48-77) 0.672 
64 
(49-72) 
68 
(51-78) 0.241 
Gender 
M:F 32 : 28 27 : 33 0.361 24 : 36 35 : 25 0.045* 
Weight, kg 74 (64-86) 
75 
(62-85) 0.555 
74 
(63-86) 
75 
(65-84) 0.908 
BMI 26 (23-29) 
26 
(24-28) 0.507 
26 
(24-29) 
25 
(23-28) 0.095 
P-POSSUM 
score 
24 
(23-29) 
26 
(23-30) 0.241 
26 
(23-29) 
26 
(23-29) 0.784 
Blood loss 
<100ml 52 54 
0.372 
51 55 
0.356 
Blood loss 
101-500ml 6 5 6 5 
Blood loss 
501-999ml 2 0 2 0 
Blood loss 
>1000ml 0 1 1 0 
ASA 1 25 21 
0.429 
23 23 
0.602 ASA 2 34 39 37 36 
ASA 3 1 0 0 1 
Day of 
surgery 
admission 
Y:N 
36 : 24 30 : 30 0.271 40 : 20 26 : 34 0.10 
 
 
Table 3.2a and 3.2b shows the surgical characteristics of the patients divided 
into the four study groups (Table 3.2a) or into the larger groups comparing 
either analgesia used or fluid infused (Table 3.2b), as with Table 3.1a and 3.1b. 
There were no significant differences between any groups. 
 
  131 
Table 3.2a: Surgical characteristics of patients in the four groups: Data for 
operation time, incision length and number of ports are median values 
with interquartile ranges. 
 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Cancer 20 15 17 13 
 
Diverticular Disease 4 6 2 7 
Endometriosis 2 3 3 3 
TVA 0 4 4 4 
Crohn’s 3 0 0 2 
FAP 0 0 1 1 
Carcinoid 1 0 3 0 
Sigmoid Volvulus 0 2 0 0 
Cancer 20 15 17 13 
0.309 
Non-cancer 10 15 13 17 
Right Hemicolectomy 10 8 13 10 
 
Left Hemicolectomy 2 2 2 3 
Sigmoid Colectomy 1 4 0 4 
Anterior Resection (not 
full TME) 
14 15 10 10 
Anterior Resection (full 
TME) 
1 1 1 1 
Other 2 0 4 2 
Right sided resection 12 8 14 11 
0.446 
Left sided resection 18 22 16 19 
Operative time, mins  
93 
(70-120) 
115 
(74-131) 
90 
(65-136) 
95 
(79-131) 
0.678 
Incision length, cm 
5.3 
(4.9-7) 
6 
(4.8-7) 
6 
(5-7) 
6 
(5-7) 
0.899 
Total number of ports 
4 
(4-4) 
4 
(4-5) 
4 
(4-4) 
4 
(4-4) 
0.663 
Prof Rockall 26 25 28 27 
0.655 
Mr Jourdan 4 5 2 3 
Periumbilical incision 17 14 17 14 
0.688 Pfannensteil incision 12 16 12 15 
Other incision 1 0 1 1 
Splenic flexure mobilized 
Y : N 
6 : 12 6 : 16 3 : 13 6 : 13 0.787 
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Table 3.2b: Surgical characteristics:  Groups were compared on the basis 
of analgesia used regardless of fluid used (columns 2-4) or on the basis of 
fluid infused regardless of analgesia used (columns 5-7). Data for 
operation time, incision length and number of ports are median values 
with interquartile ranges. 
 
 Spinal PCA p-value Volulyte Hartmann’s 
p-
value 
Cancer 35 30 
 
37 28 
 
Diverticular Disease 10 9 6 13 
Endometriosis 5 6 5 6 
TVA 4 8 4 8 
Crohn’s 3 2 3 2 
FAP 0 2 1 1 
Carcinoid 1 3 4 0 
Sigmoid Volvulus 2 0 0 2 
Cancer 35 30 
0.360 
37 28 
0.099 
Non-cancer 25 30 23 32 
Right Hemicolectomy 19 25 
 
26 19 
 
Left Hemicolectomy 4 5 4 5 
Sigmoid Colectomy 5 4 1 8 
Anterior Resection (not 
full TME) 
29 21 25 25 
Anterior Resection (full 
TME) 
2 3 3 2 
Other 1 2 1 1 
Right sided resection 20 25 
0.346 
26 19 
0.187 
Left sided resection 40 35 34 41 
Operative time, mins 
102 
(70-
122) 
95 
(71-
134) 
0.777 
93 
(70-120) 
102 
(75-130) 
0.266 
Incision length, cm 
6 
(5-7) 
6 
(5-7) 
0.832 
5.5 
(5-7) 
6 
(5-7) 
0.465 
Total number of ports 
4 
(4-4) 
4 
(4-4) 
0.860 
4 
(4-4) 
4 
(4-4) 
0.548 
Prof Rockall 51 55 
0.255 
54 52 
0.570 
Mr Jourdan 9 5 6 8 
Periumbilical incision 31 31 
0.797 
34 28 
0.480 Pfannensteil incision 28 27 24 31 
Other incision 1 2 2 1 
Splenic flexure 
mobilized 
Y : N 
12 : 28 9 : 26 0.680 9 : 25 12 : 29 0.788 
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3.1 Primary end points 
Interleukin 6 (IL-6) 
There were no significant differences in the median IL-6 levels for the four 
groups or the combined analgesia and fluid groups, see Tables 3.3 and 3.4. To 
adjust for any preoperative variability in values between the groups the 
percentage changes at each time interval compared with the preoperative value 
were calculated (Tables 3.5 and 3.6). The only significant difference was a 
reduced median percentage change at 3 hours in the combined Hartmann’s 
group compared to the combined Volulyte group, see Table 3.6. There were no 
other significant differences in the percentage change between the four groups 
or the combined analgesia or fluid groups, see Tables 3.5 and 3.6.  
 
Figures 3.2 and 3.3 plot the median IL-6 levels for the four groups and the 
combined analgesia groups respectively. Figures 3.2a and 3.3a plot the 
medians without the error bars to exemplify the IL-6 levels postoperatively in the 
four groups (Figure 3.2a) and combined analgesia groups (Figure 3.3a). 
Postoperatively there was a significant rise in measured IL-6 levels at all time 
intervals in comparison with preoperative levels in each of the four groups. The 
IL-6 levels in the combined spinal group were significantly higher at all 
postoperative time intervals with a peak at 6 hours and then levels returned 
towards the preoperative level, see Figure 3.3a. The IL-6 levels in the combined 
PCA group were significantly higher at all time intervals reaching a plateau 
rather than a peak between 6 and 24 hours before returning towards 
preoperative levels, see Figure 3.3a. 
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Table 3.3: IL-6 levels in the preoperative and postoperative periods for the 
four groups. Median values with interquartile ranges. 
IL-6 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Preoperative 
3.9 
(2.2-8.5) 
3.7 
(2-15) 
3.3 
(1.7-6.6) 
6.0 
(3.3-12.8) 
0.230 
3 hours 
31.9 
(21.9-46.1) 
21.5 
(14.6-45.1) 
25.7 
(11.7-38.3) 
27.5 
(17.6-43.7) 
0.352 
6 hours 
104 
(44-165.9) 
73.2 
(34.1-130.9) 
61.4 
(26.9-149.6) 
52.7 
(31.1-123.7) 
0.527 
12 hours 
52.8 
(30.9-126.6) 
48.4 
(24.6-123.3) 
67.1 
(23.3-109.9) 
53.9 
(34.9-124.5) 
0.995 
24 hours 
46.2 
(26.6-104.3) 
39.3 
(22.3-102.6) 
67.4 
(20.7-115.3) 
49.5 
(22.5-124.6) 
0.919 
48 hours 
27.1 
(16.8-38.3) 
34 
(16-76.8) 
24.3 
(10.5-54.4) 
24 
(13.8-49.5) 
0.818 
At 48 hours n=23 (spi/Vol), n=22 (spi/Hart), n=28 (PCA/Vol), n=28 (PCA/Hart) 
 
Table 3.4: IL-6 levels for the combined analgesia and fluid groups in the 
preoperative and postoperative periods. Median values with interquartile 
ranges. 
IL-6 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Pre-
operative 
3.8 
(2.2-10) 
4.7 
(2.4-7.7) 
0.648 
3.8 
(2-6.7) 
5.5 
(2.4-14.1) 
0.073 
3 hours 
28.3 
(18.1-45.6) 
26.9 
(13.5-40.6) 
0.482 
29 
(14.9-42.3) 
26.9 
(16.8-43.9) 
0.654 
6 hours 
82.8 
(34.3-136.9) 
54.9 
(29.8-
123.8) 
0.221 
86.5 
(32.2-
157.5) 
54.2 
(33.4-127.9) 
0.467 
12 hours 
51.1 
(28.4-122.9) 
58 
(27.7-
115.8) 
0.873 
60.1 
(28.4-
117.4) 
53 
(27.9-123.1) 
0.987 
24 hours 
43.7 
(24.8-97.9) 
56.7 
(22.5-113) 
0.589 
52.1 
(23.9-112) 
47.5 
(22.7-109.1) 
0.737 
48 hours 
28 
(16.3-59.2) 
24 
(12-52.5) 
0.452 
27.1 
(11.8-49) 
25.4 
(14.7-57.9) 
0.573 
At 48 hours n=45 (spinal), n=56 (PCA) 
At 48 hours n= 51 (Volulyte), n=50 (Hartmann’s) 
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Table 3.5: Percentage change of postoperative IL-6 levels from the 
preoperative level for the four groups. Median values with interquartile 
ranges. 
Postoperation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
3 hours 
6.6 
(2.9-16.1) 
4.6 
(1.4-10.6) 
4.4 
(2.8-11) 
3.7 
(1.5-7) 
0.128 
6 hours 
14.6 
(8.5-41.9) 
20.4 
(4-37.8) 
17 
(6.3-33.2) 
9.8 
(3.5-18.9) 
0.198 
12 hours 
12 
(5.6-24.1) 
14.2 
(5.2-22.6) 
16.2 
(6.3-28.2) 
8.6 
(1.9-21) 
0.502 
24 hours 
11.4 
(4.9-24.5) 
9.8 
(4.5-19.1) 
10.1 
(5-31.3) 
7 
(1.9-18.7) 
0.385 
48 hours 
5 
(1.9-11.7) 
8.2 
(2.9-16.4) 
5 
(1.4-10.1) 
3 
(1.1-8.6) 
0.218 
 
 
Table 3.6: Percentage change of postoperative IL-6 levels from the 
preoperative level for the combined analgesia and fluid groups. Median 
values with interquartile ranges. 
Postoperation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
5.7 
(1.7-13.1) 
4 
(2-7.3) 
0.202 
5.5 
(2.9-
15.7) 
3.8 
(1.5-8.1) 
0.044 
6 hours 
17.6 
(5.4-39.7) 
13.2 
(5.9-
28.9) 
0.146 
15 
(7.7-36) 
13.2 
(4.2-25.2) 
0.129 
12 hours 
12.3 
(5.5-23.7) 
12.2 
(4.9-
21.4) 
0.698 
14 
(6-24.3) 
9.9 
(4.8-21.4) 
0.280 
24 hours 
10.4 
(4.9-22) 
7.8 
(3.2-
26.7) 
0.725 
11.1 
(5.3-
27.6) 
7.8 
(2.8-18.3) 
0.118 
48 hours 
7.1 
(1.9-13.1) 
3.9 
(1.4-9.4) 
0.107 
5 
(1.5-
11.6) 
4.4 
(1.7-12.5) 
0.844 
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Figure 3.2: Median IL-6 levels for the four groups, with interquartile ranges 
and minimum and maximum values. Data compared with independent 
samples Kruskal-Wallis test. 
 
 
 
 
Figure 3.2a: Median IL-6 levels, without error bars, for the four groups. 
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Figure 3.3: Median IL-6 levels for the combined analgesia groups with 
interquartile ranges and minimum and maximum values. Data compared 
with a Mann-Whitney U test. 
 
 
Figure 3.3a: Median IL-6 levels, without error bars, for the combined 
analgesia groups. 
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3.2 Secondary end points 
3.2.1 Fluid related outcomes 
3.2.1.1 Volume of fluid to achieve stroke volume optimisation 
Table 3.7 shows the median volumes of fluid and range required to optimise the 
stroke volume prior to the pneumoperitoneum. A siginificantly greater median 
volume of fluid was required in the Hartmann’s groups. The minimum and 
maximum volumes required in the groups is also listed, identifying a wide range 
of requirement. 
  
Table 3.7: Total volume of fluid to optimise stroke volume before 
pneumoperitoneum. Data for volume are median values with interquartile 
ranges. The sub-table shows comparison between groups. 
Volume 
(ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Volume 
500  
(500-
750) 
750 
(500-1000) 
500  
(500-
500) 
750  
(500-750) <0.0005 
Min volume 250 250 250 250 
 
Max volume 1000 1250 1000 1000 
Multiple comparisons for median total volume, ml: 
  p 
Spi/Vol 
Spi/Hart 0.010 
PCA/Vol 1 
PCA/Hart 0.287 
Spi/Hart 
PCA/Vol <0.0005 
PCA/Hart 1 
PCA/Vol PCA/Hart 0.012 
 
 
Table 3.8 shows the volume required by weight to achieve stroke volume 
optimization when normalized to patient weight. Similar conclusions were 
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reached as in Table 3.7 when volumes were not normalized for weight. 
 
Table 3.8: Volume of fluid to optimize stroke volume before 
pneumoperitoneum normalized by patient weight. Data for volume are 
median values with interquartile ranges. The sub-table shows comparison 
between groups. 
ml/kg Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Volume 7.13 
(5.55-9.84) 
9.92 
(7.06-14.6) 
6.46 
(4.68-
8.04) 
8.56 
(6.74-12.04) 
0.001 
Min volume 3.32 4.3 3.28 3.39 
 
Max volume 16.29 16.8 17.92 20.08 
Multiple comparisons for median volume by weight, ml/kg: 
  p 
Spi/Vol 
Spi/Hart 0.055 
PCA/Vol 1 
PCA/Hart 0.214 
Spi/Hart 
PCA/Vol 0.002 
PCA/Hart 1 
PCA/Vol PCA/Hart 0.013 
 
 
Table 3.9 shows the median volume required as millilitres (ml) or normalized to 
weight (ml/kg) required to optimise stroke volume for the combined fluid groups, 
the minimum and maximum of the normalized volumes are also shown. Similar 
conclusions were reached as in Table 3.7 and 3.8, i.e: the Hartmann’s group 
received a significantly greater volume of fluid. When comparing analgesia type 
there was no significant difference in the median volume (ml)(p=0.73) or volume 
normalized by weight (ml/kg)(p=0.318) between those patients receiving either 
type of analgesia.  
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Table 3.9: Volume of fluid to optimise stroke volume by infused fluid. 
Median values with interquartile ranges. 
 Volulyte n=60 
Hartmann’s 
n=60 p-value 
Total volume, ml  500 
(500-688) 
750 
(500-1000) 
<0.0005 
Volume by weight, 
ml/kg 
6.71 
(5.3-8.2) 
8.99 
(7-12.9) <0.0005 
Min volume by 
weight, ml/kg 3.28 3.39 
 
Max volume by 
weight, ml/kg 17.92 20.08 
 
 
Figures 3.4 shows the median volume of fluid normalized by weight (ml/kg) for 
the four groups and Figure 3.5 when the two analgesia groups are combined to 
compare the two fluids. Figure 3.6 is a scatterplot showing the distribution of 
volume of fluid (ml/kg) administered by BMI for all patients. There is a 
significantly negative association with a Spearman correlation coefficient of  
r = -0.467 (p<0.005), such that patients with a higher BMI received less fluid. 
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Figure 3.4: Median volume of fluid to optimise stroke volume prior to 
pneumoperitoneum for the four groups. *signify a significant difference 
(p=0.002) in median volume between spinal/Hartmann’s and PCA/Volulyte 
groups, ^signify a significant difference (p=0.013) in median volume 
between PCA/Volulyte and PCA/Hartmann’s groups. *^ Mann Whitney U 
test. 
 
 
  * 
    * ^ 
  ^ 
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Figure 3.5: Median volume of fluid to optimise stroke volume prior to 
pneumoperitoneum when analgesic groups are combined. * signify a 
significant difference (p<0.0005) in median volume between fluid types, 
Mann-Whitney U test. 
  
Figure 3.6: Fluid volume administered to optimise stroke volume as a 
function of BMI, Spearman’s correlation coefficient. 
* 
 * 
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3.2.1.2: Total volume of fluid administered 
Table 3.10 shows the total volume of fluid administered by goal-directed fluid 
therapy (GDFT) from induction to completion of surgery for the four groups, 
values are shown as medians with the minimum and maximum volumes also 
shown. There was a significantly greater volume of fluid administered using 
Hartmann’s compared with Volulyte for the two analgesic groups. The same 
difference was seen for total volume normalized to body weight, see Table 3.11. 
Figures 3.7 and 3.8 show the median volume of fluid administered by GDFT for 
the four groups as ml and ml/kg respectively. There was a wide distribution of 
fluid required by volume and volume normalized by weight for the study group, 
see Figure 3.9. 
 
Table 3.10: Fluid volume administered with GDFT. Data for total volume 
are median values with interquartile ranges. The sub-table shows 
comparison between groups. 
Volume 
(ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Total 
volume 
1000 
(750-1250) 
1500 
(1250-2000) 
1000 
(1000-1313) 
1500 
(1188-1750) <0.0005 
Min 
volume 500 750 250 750 
 
Max 
volume 2750 3000 1750 2500 
Multiple comparisons of median total volume, ml: 
  p 
Spi/Vol 
Spi/Hart <0.0005 
PCA/Vol 1 
PCA/Hart 0.002 
Spi/Hart 
PCA/Vol <0.0005 
PCA/Hart 1 
PCA/Vol PCA/Hart 0.003 
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Figure 3.7: Median volume of fluid administered by GDFT for the four 
groups. * signify a significant difference (p<0.0005) in median volume 
between spinal/Volulyte and spinal/Hartmann’s groups. ^ signify a 
significant difference (p=0.002) in median volume between spinal/Volulyte 
and PCA/Hartmann’s groups. α signify a significant difference (p=0.003) in 
median volume between PCA/Volulyte and PCA/Hartmann’s groups. δ 
signify a significant difference (p<0.0005) in median volume between 
spinal/Hartmann’s and PCA/Volulyte. *^ α δ Mann-Whitney U test. 
 
 
 
 
 
* δ 
δ"α 
^ α 
* ^ 
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Table 3.11: Total volume of fluid normalized by weight administered with 
GDFT. Data for total volume are median values with interquartile ranges. 
The sub-table shows comparison between groups. 
Volume 
(ml/kg) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Total 
volume 
14.16 
(11.7-17.9) 
21.2 
(17.7-27.4) 
13.95 
(11.7-18.6) 
20.74 
(13.7-25.6) 
<0.0005 
Min 
volume 
8.33 10.74 3.28 10.89 
 
Max 
volume 
24.43 41.54 26.88 40.70 
Multiple comparisons of median volume by weight with GDFT, ml/kg: 
  p 
Spi/Vol 
Spi/Hart <0.0005 
PCA/Vol 1 
PCA/Hart 0.003 
Spi/Hart 
PCA/Vol <0.0005 
PCA/Hart 1 
PCA/Vol PCA/Hart 0.004 
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Figure 3.8: Median volume normalized by weight administered by GDFT 
for the four groups. . * signify a significant difference (p<0.0005) in median 
volume between spinal/Volulyte and spinal/Hartmann’s groups. ^ signify a 
significant difference (p=0.003) in median volume between spinal/Volulyte 
and PCA/Hartmann’s groups. α signify a significant difference (p=0.004) in 
median volume between PCA/Volulyte and PCA/Hartmann’s groups. δ 
signify a significant difference (p<0.0005) in median volume between 
spinal/Hartmann’s and PCA/Volulyte. *^ α δ Mann-Whitney U test. 
* ^ 
 * δ 
"δ"α 
^ α 
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Figure 3.9: Distribution of the number of patients by the fluid volume 
required to maintain stroke volume optimization for the study group, 
dependent on the type of fluid infused.  
 
Table 3.12 shows the total volume of fluid normalized by weight and operative 
time administered by GDFT for the four groups. There was a significantly 
greater median volume administered in the Hartmann’s groups. The pairwise 
comparisons only identified a significantly greater median volume (ml/kg/hr) in 
the spinal/Hartmann’s group compared with the PCA/Volulyte group. Figure 
3.10 shows the median volume normalised by weight and operative time of fluid 
administered with GDFT for the four groups. Normalising for weight and 
operative time has reduced the level of significance identified between groups 
in comparison to normalizing for weight alone, see Figure 3.8. 
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Table 3.12: Total volume of fluid normalized by weight and operative time 
administered by GDFT. Data for total volume are median values with 
interquartile ranges. The sub-table shows comparison between groups. 
Volume 
(ml/kg/hr) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Total volume 9.81 (7.1-12.6) 
12.36 
(8.5-17.5) 
7.85 
(5.6-14.2) 
11.07 
(8.6-18.4) 0.008 
Min volume 4.43 4 2.81 5.24 
 
Max volume 21.84 27.69 40.32 28.73 
Multiple comparisons of median volume normalized by weight and operative 
time with GDFT, ml/kg/hr: 
  p 
Spi/Vol 
Spi/Hart 0.162 
PCA/Vol 1 
PCA/Hart 0.372 
Spi/Hart 
PCA/Vol 0.024 
PCA/Hart 1 
PCA/Vol PCA/Hart 0.068 
 
 
Figure 3.10: Median volume normalized by weight and operative time 
administered by GDFT. * signify a significant difference (p=0.024) in 
median volume between spinal/Hartmann’s and PCA/Volulyte groups, 
Mann-Whitney U test. 
* 
* 
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Table 3.13 shows that a significantly greater median volume of fluid 
administered by GDFT was given in the combined Hartmann’s groups as 
volume alone (ml), or normalized to body weight (ml/kg) and also to operative 
time (ml/kg/hr). There was no significant difference between the spinal and PCA 
groups when the respective fluid groups were combined for a volume variable 
(volume or normalized volume). Figures 3.11 and 3.12 show the median 
normalized fluid volumes administered by GDFT (ml/kg or ml/kg/hr) for the two 
fluid groups, irrespective of analgesia.  
 
Table 3.13: Total volume of fluid administered by GDFT for the groups to 
compare either the fluid or the analgesia used. Data for volume or 
normalised volume are median values with interquartile ranges. 
 Volulyte n=60 
Hartmann’s 
n=60 p-value 
Spinal 
n=60 
PCA 
n=60 
p-
value 
Total volume, ml 
1000 
(1000-
1250) 
1500 
(1250-2000) <0.0005 
1250 
(1000-
1688) 
1250 
(1000-
1500) 
0.389 
Total volume 
normalized by 
weight, ml/kg 
13.95 
(11.76-
18.1) 
20.98 
(16.68-
25.73) 
<0.0005 
17.77 
(13.52-
22.06) 
16.59 
(13.08-
22.3) 
0.578 
Min volume by 
weight, ml/kg 3.28 10.74 
 
8.33 3.28 
 
Max volume by 
weight, ml/kg 26.88 41.54 41.54 40.70 
Total volume 
normalized by 
weight/operative 
time, ml/kg/hr 
8.89 
(6.04-
12.83) 
11.93 
(8.59-17.9) 0.001 
11.22 
(8.29-
14.25) 
9.31 
(6.73-
16.58) 
0.475 
Min volume by 
weight/operative 
time, ml/kg/hr 
2.81 4 
 
4 2.81 
 
Max volume by 
weight/operative 
time, ml/kg/hr 
40.32 28.73 27.69 40.32 
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Figure 3.11: Median volume normalised by weight administered by GDFT 
for the combined analgesic groups for each fluid. * signify a significant 
difference (p<0.0005) in median volume between fluid groups, Mann-
Whitney U test. 
 
Figure 3.12: Median volume normalised by weight and operative time 
administered by GDFT for the combined analgesic groups for each fluid.   
* signify a significant difference (p=0.001) in median volume between fluid 
groups, Mann-Whitney U test. 
* 
* 
* 
* 
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Figures 3.13 and 3.14 are scatterplots showing the distribution of total volume 
of fluid normalized by weight (ml/kg) and by operative time (ml/kg/hr) 
administered by GDFT as a function of BMI for all patients. There was a 
significantly negative association with a Spearman correlation coefficient of     
r= -0.360 (p=<0.0005) for ml/kg and r= -0.418 (p=<0.0005) for ml/kg/hr. Patients 
with a higher BMI received less fluid when normalized by weight (ml/kg) or 
operative time (ml/kg/hr).  
 
  
 
 
 
Figure 3.13: Total fluid volume normalised by weight administered by 
GDFT as a function of BMI, Spearman’s correlation coefficient. 
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Figure 3.14: Total fluid volume normalised by weight and operative time 
administered by GDFT as a function of BMI, Spearman’s correlation 
coefficient. 
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3.2.1.3: Oxygen delivery (DO2i) 
 
There was no significant difference detected between the four groups or the 
combined analgesia and fluid groups in median maximum DO2i, see Tables 
3.14 and 3.15. 
 
Table 3.14: Maximum DO2i readings for the four groups. Median values 
with interquartile ranges. 
ml/min/m2 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Max pre-pneumo DO2i 
recorded 
656 
(548-817) 
581 
(495-680) 
542 
(470-
719) 
631 
(501-711) 
0.489 
Max peri-pneumo DO2i 
recorded 
524 
(445-651) 
547 
(448-620) 
516 
(421-
642) 
502 
(408-637) 
0.946 
Max post-pneumo 
DO2i recorded 
602 
(491-817) 
526 
(454-645) 
461 
(405-
655) 
503 
(432-578) 
0.109 
Max DO2i recorded 
515 
(423-591) 
480 
(418-587) 
472 
(392-
600) 
465 
(424-631) 
0.936 
 
Table 3.15: Maximum DO2i readings for the combined analgesia and fluid 
groups. Median values with interquartile ranges. 
ml/min/m2 Spinal PCA p-value Volulyte Hartmann’s 
p-
value 
Max pre-pneumo 
DO2i recorded 
607 
(513-725) 
582 
(473-
715) 
0.414 
596 
(505-739) 
587 
(498-690) 
0.343 
Max peri-pneumo 
DO2i recorded 
527 
(450-629) 
513 
(415-
638) 
0.792 
521 
(426-645) 
517 
(434-624) 
0.60 
Max post-pneumo 
DO2i recorded 
546 
(461-708) 
498 
(422-
623) 
0.076 
546 
(442-721) 
505 
(438-609) 
0.154 
Max DO2i 
recorded 
488 
(421-589) 
472 
(395-
613) 
0.915 
488 
(396-590) 
473 
(422-630) 
0.630 
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3.2.1.4: Amount of vasoconstrictor used 
 
There was a significantly greater number of patients receiving phenylephrine to 
maintain a mean arterial blood pressure of greater than 60 mmHg in the spinal 
groups compared with the PCA groups, see Table 3.16 and 3.17. This was 
predominately administered intra-operatively. If phenylephrine was 
administered there was a significantly greater amount given in the spinal groups 
when combined compared with the PCA groups, see table 3.18. Pairwise 
comparisons identified a significant difference only between spinal/Volulyte and 
PCA/Volulyte groups and spinal/Hartmann’s and PCA/Volulyte groups.  
 
There was no significant difference between the combined fluid groups for 
median amount of phenylephrine administered, p=0.677. Figure 3.15 and 3.16 
show the median amount of phenylephrine administered by group and 
combined analgesia group respectively. 
 
Table 3.16: The first occasion phenylephrine was administered to maintain 
MAP >60 mmHg for the four groups. 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
Anaesthetic 
room 2 2 5 6 
Intraoperative 21 24 10 12 
Not given 7 4 15 12 
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Table 3.17: The first occasion phenylephrine was administered to maintain 
MAP >60 mmHg for the combined analgesia groups 
 Spinal n=60 
PCA 
n=60 p-value 
Anaesthetic room 4 11 
<0.0005 Intraoperative 45 22 
Not given 11 27 
 
Table 3.18: Amount of phenylephrine administered. Median values with 
interquartile ranges. The sub-table shows comparisons between the 
groups. 
 Spinal PCA  
 Volulyte n=23 
Hartmann’s 
n=26 
Volulyte 
n=15 
Hartmann’s 
n=18 p-value 
Total amount 
(mg) 
900 
(250-2050) 
850 
(300-1525) 
200 
(185-575) 
300 
(275-525)  
900 (300-1600) 300 (200-500) 0.001 
Pairwise comparisons of median amount, mg: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 0.035 
PCA/Hart 0.271 
Spi/Hart 
PCA/Vol 0.035 
PCA/Hart 0.294 
PCA/Vol PCA/Hart 1 
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Figure 3.15: Median amount of phenylephrine administered for the four 
groups. * signify a significant difference (p=0.035) between spinal/Volulyte 
and PCA/Volulyte groups. ^ signify a significant difference (p=0.035) 
between spinal/Hartmann’s and PCA/Volulyte groups. *^ Mann-Whitney U 
test. 
 
 
Figure 3.16: Median amount of phenylephrine administered for the 
combined analgesia groups. * signify a significant difference (p=0.001) 
between analgesia groups, Mann-Whitney U test. 
* 
^ 
* 
* 
* ^ 
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3.2.1.5: Central venous oxygen saturation measurements 
There was no significant difference in the median central venous oxygen 
saturation measurement between the four groups at 25 mins, 3 hrs, 6 hrs and 
24 hrs from the start of surgery, see Table 3.19. There was a significantly 
greater value in the combined PCA group compared with the spinal group at 6 
hours, see Table 3.20. Figure 3.17 shows the central venous oxygen 
saturations for the four groups at various time intervals. There was a reduction 
in the saturation measurements as a function of time but no difference was 
detected between the groups. 
 
Table 3.21 shows the distribution of patients with central venous oxygen 
saturations below 60% at various time intervals. There was no difference 
between the groups for the number of patients requiring 500 ml of rescue fluid 
or in the median change of saturation after the bolus was given. 
 
One patient (spinal/Hartmann’s) had a failed insertion of the CVP line therefore 
no measurements were possible. One patient’s (spinal/Hartmann’s) CVP line 
was mal-positioned in the right subclavian vein, therefore the inaccurate 
readings were not used. The number of patients who required two boluses of 
fluid at 6 and 24 hours were six patients. 11 patients did not have a 24 hour 
central venous oxygen saturation recorded because the line had already been 
removed.  Three patients had a reduction in the repeat central venous oxygen 
saturation reading following 500 ml of rescue fluid at 6 hours. Ten patients had 
a reduction in the repeat central venous oxygen saturation reading after 500 ml 
of rescue fluid at 24 hours, two of these had the same effect at 6 hours as well.  
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Table 3.19: Central venous oxygen saturation measurements at 
postoperative time intervals. Median values with interquartile ranges. p-
value determined by an Independent-samples Kruskal-Wallis test for 
multiple groups. 
 
        % Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
25 mins 85.2 (79.2-89.1) 
81.4 
(78.7-84.2) 
80 
(76-86.1) 
85.9 
(81.6-88.3) 0.089 
3 hours 77.9 (70.5-83.8) 
70 
(62.9-82.5) 
75.2 
(71.6-83) 
78.4 
(71.6-82.5) 0.422 
6 hours 70.2 (66.2-75.7) 
70.7 
(63.4-77.9) 
75.5 
(70-80) 
73.5 
(69.3-80.4) 0.145 
24 hours 62.4 (61.4-68.7) 
67 
(59.4-70.2) 
66 
(60-74.7) 
66.1 
(60-68.1) 0.821 
 
Table 3.20: Central venous oxygen saturation measurements at 
postoperative time intervals for the combined analgesic and fluid groups. 
Median values with interquartile ranges. 
% Volulyte Hartmann’s 
p-
value 
Spinal PCA 
p-
value 
25 mins 
82.4 
(77.4-
86.5) 
82.9 
(79.5-86.6) 0.443 
82.1 
(79-86) 
83.7 
(77.4-88) 0.314 
3 hours 
77.4 
(71.6-
83.8) 
74.9 
(67.4-82.5) 0.571 
75.6 
(66.1-
82.8) 
77.7 
(71.6-
82.6) 
0.245 
6 hours 
73.5 
(67.5-
79.1) 
73 
(66.3-79.2) 0.848 
70.2 
(64.7-
77.1) 
74 
(70-80) 0.021 
24 
hours 
62.7 
(61-71.2) 
66.1 
(59.9-69.3) 0.830 
64.9 
(60.1-
69.7) 
66 
(60-69.3) 0.896 
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Figure 3.17: Median central venous oxygen saturations for the four groups 
at different postoperative time intervals. 
 
Table 3.21: The distribution of patients with central venous oxygen 
saturation measurements below 60%. p-value determined by an 
Independent-samples Kruskal-Wallis test for multiple groups. 
 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Number of patients with 
SVcvc <60% at 3 hours 
3 3 2 3  
Number of patients with 
SVcvc <60% at 6 hours 
3 3 2 0  
Number of patients with 
SVcvc <60% at 24 hours 
5 7 6 7  
Number of patients 
requiring 500 ml of rescue 
fluid 
8 (27%) 7 (23%) 6 (20%) 7 (23%) 0.946 
Median (IQR) change in 
SVcvc after bolus 
9.6 
(-4.7-19) 
2.7 
(-2.4-7) 
-2.25 
(-7.9-
8.5) 
-1 
(-3.2-7.6) 
0.664 
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3.2.1.6: Maximum weight gain prior to discharge 
There were no data recorded for two patients from the spinal/Hartmann’s group 
as they were too uncomfortable to stand, one patient from the spinal/Volulyte 
group due to inability to stand secondary to discomfort and two patients from 
the PCA/Volulyte group as one patient was too uncomfortable to stand and one 
patient was too drowsy after a return to theatre for bleeding. There was a 
postoperative weight gain for all groups but no significant difference was seen 
between the groups, see Table 3.22. 
 
Table 3.22: Maximum weight gain prior to discharge. Median values with 
interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=29 
Hartmann’s 
n=28 
Volulyte 
n=28 
Hartmann’s 
n=30 p-value 
Maximum 
weight gain 
(kg) 
2 
(1.6-3.5) 
2.1 
(0.5-3) 
1.5 
(0.9-3.2) 
2.5 
(0.7-3.5) 0.493 
2 
(1.1-3.2) 
1.8 
(0.9-3.4) 0.640 
Volulyte Hartmann’s  
1.8 
(1.1-3.4) 
2.2 
(0.6-3.2) 0.843 
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3.2.1.7: Volume of intravenous fluid administered during the post-
operative period 
There were no significant differences in the total volume of intravenous fluid 
administered during the postoperative period between the four groups, see 
Table 3.23. When the amount of intraoperative and postoperative intravenous 
fluid administered was combined there was only a significantly greater volume 
given in the combined Hartmann’s group, see Table 3.24. 
 
Table 3.23: Volume of postoperative fluid. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 p-value 
Volume of 
intravenous 
fluid given post-
operatively 
(litres) 
2 
(2-3) 
2 
(2-3.5) 
2.5 
(2-3.6) 
2 
(2-3) 0.497 
2 (2-3) 2.5 (2-3) 0.369 
Volulyte Hartmann’s  
2.25 (2-3) 2 (2-3) 0.449 
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Table 3.24: Total volume of intra- and post-operative fluid. Median values 
with interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 p-value 
Volume of 
intravenous 
fluid given 
Intra- and post-
operatively 
(litres) 
3.25 
(3-4.3) 
4 
(3.5-5.1) 
3.6 
(3-5.3) 
3.9 
(3.3-4.6) 0.072 
3.6 (3.3-4.5) 3.8 (3.3-4.9) 0.860 
Volulyte Hartmann’s  
3.5 (3-4.4) 4 (3.5-4.9) 0.017 
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3.2.1.8: Creatinine measurements 
There were no significant differences seen in creatinine levels pre and 
postoperatively between the four groups (Table 3.25) or the combined 
analgesia and fluid groups (Table 3.26). 
 
Table 3.25: Creatinine levels in the preoperative and postoperative period 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Creatinine 
(µmol/l) 
Spinal/ 
Volulyte 
n=29 
Spinal/ 
Hartmann’s 
n=28 
PCA/ 
Volulyte 
n=28 
PCA/ 
Hartmann’s 
n=29 
p-value 
Pre-
operative 
72 
(57-83) 
76 
(63-86) 
68 
(60-78) 
66 
(57-97) 
0.717 
Post-
operative 
day 1 
66 
(55-81) 
76 
(66-83) 
68 
(57-78) 
65 
(55-100) 0.292 
 
 
Table 3.26: Creatinine levels in the preoperative and postoperative period 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Creatinine 
(µmol/l) 
Spinal 
n=57 
PCA 
n=57 
p-
value 
Volulyte 
n=57 
Hartmann’s 
n=57 p-value 
Pre-
operative 
74 
(60-83) 
66 
(58-86) 0.603 
72 
(60-82) 
74 
(58-93) 0.300 
Post-
operative 
day 1 
69 
(59-81) 
66 
(56-82) 0.360 
67 
(55-80) 
69 
(59-88) 0.206 
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3.2.1.9: Haematocrit measurements 
There were no significant differences seen in the haematocrit pre- and post-
operatively between the four groups (Table 3.27), or the combined analgesia 
and fluid groups. 
 
Table 3.27: Haematocrit in the pre- and post-operative period for the four 
groups. Data for preop and postop haematocrit are median values with 
interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
Haematocrit (%) Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Number of patients 
pre-operative 30 30 30 30  
Pre-operative 
haematocrit (%) 
0.40 
(0.37-
0.42) 
0.41 
(0.39-0.42) 
0.40 
(0.36-
0.44) 
0.40 
(0.37-0.43) 0.82 
Number of patients 
day 1 29 28 27 29  
Day 1 post-
operative 
haematocrit (%) 
0.35 
(0.31-
0.39) 
0.36 
(0.34-0.38) 
0.36 
(0.3-
0.38) 
0.36 
(0.33-0.39) 0.797 
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3.2.2: Pain and analgesia related outcomes 
3.2.2.1: Pain scores at three hours 
There were no pain scores recorded at three hours for three patients in the 
spinal/Volulyte group, four patients in the spinal/Hartmann’s group, five patients 
in the PCA/Volulyte group and four patients in the PCA/Hartmann’s group. This 
is because the patient was either still on the operating table or in the process of 
being extubated. The number of patients that were too drowsy to record their 
pain scores at three hours were significantly greater in the PCA groups, see 
Table 3.28. There were significantly higher pain scores in the PCA groups 
compared with the spinal groups at three hours at rest and with movement, see 
table 3.29. 
 
Table 3.28: The distribution of patients too drowsy to record their pain 
scores at three hours. 
 
Spinal PCA  
Volulyte Hartmann’s Volulyte Hartmann’s p-value 
Number of 
patients too 
drowsy to record 
pain scores at 3 
hours 
6 6 11 16  
12 27 0.003 
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Table 3.29: Pain scores at three hours. Median values with interquartile 
ranges. The sub-tables shows comparisons between the groups. p-value 
for multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
 
Spinal PCA  
Volulyte 
n=21 
Hartmann’s 
n=20 
Volulyte 
n=13 
Hartmann’s 
n=10 p-value 
3 hours at rest 
4 
(2-5.25) 
3.5 
(2-5) 
5 
(4.5-8.5) 
8 
(5.75-8.25) 0.001 
4 (2-5) 8 (5-8) <0.0005 
3 hours with 
movement 
7 
(3-9.5) 
6 
(2.25-8) 
7 
(5-10) 
10 
(8-10) 0.005 
6 (2.5-8) 10 (6-10) 0.004 
Pairwise comparisons at rest at three hours: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 0.343 
PCA/Hart 0.01 
Spi/Hart 
PCA/Vol 0.119 
PCA/Hart 0.003 
PCA/Vol PCA/Hart 1 
Pairwise comparisons with movement at three hours: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 1 
PCA/Hart 0.039 
Spi/Hart 
PCA/Vol 0.7 
PCA/Hart 0.003 
PCA/Vol PCA/Hart 0.368 
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3.2.2.2: Pain scores at six hours 
There were no data recorded for five patients from the spinal/Volulyte group, 
five patients from the spinal/Hartmann’s group, three patients from the 
PCA/Volulyte group and six patients from the PCA/Hartmann’s group. These 
patients were asleep and therefore not woken to record the pain scores. There 
were significantly higher pain scores recorded in the PCA groups compared 
with the spinal groups at rest and with movement, see Table 3.30.  
 
Table 3.30: Pain scores at six hours. Median values with interquartile 
ranges. The sub-table shows comparisons between the groups. p-value 
for multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
 
Spinal PCA  
Volulyte 
n=25 
Hartmann’s 
n=25 
Volulyte 
n=27 
Hartmann’s 
n=24 
p-
value 
6 hours at rest 
3 
(2-5) 
3 
(0.5-4.5) 
5 
(3-6) 
5 
(4-6.9) 0.006 
3 (1-5) 5 (3-6.5) 0.001 
6 hours with 
movement 
6 
(3.5-9) 
5 
(2.5-8.5) 
8 
(5-10) 
7.5 
(6-8.75) 0.09 
6 (3-8.25) 8 (5-10) 0.017 
Pairwise comparisons at rest at six hours: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 0.607 
PCA/Hart 0.160 
Spi/Hart 
PCA/Vol 0.058 
PCA/Hart 0.01 
PCA/Vol PCA/Hart 1 
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3.2.2.3: Pain scores at 12 hours 
There were no data recorded for 19 patients from the spinal/Volulyte group, 12 
patients from the spinal/Hartmann’s group, 15 patients from the PCA/Volulyte 
group and 13 patients from the PCA/Hartmann’s group. These patients were 
asleep and not woken to record the pain scores. There were significantly higher 
pain scores recorded in the PCA groups compared with the spinal groups at 
rest and with movement at 12 hours, see Table 3.31. 
 
Table 3.31: Pain scores at 12 hours. Median values with interquartile 
ranges. The sub-table shows comparisons between the groups. p-value 
for multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
 
Spinal PCA  
Volulyte 
n=11 
Hartmann’s 
n=18 
Volulyte 
n=15 
Hartmann’s 
n=17 
p-
value 
12 hours at rest 
3 
(1-4) 
1.5 
(0.75-3) 
4 
(1-5) 
3 
(2-6) 0.046 
2 (1-3) 3.5 (2-5) 0.008 
12 hours with 
movement 
6 
(3-7) 
3.5 
(1.75-8) 
6 
(4-8) 
7 
(5-9.5) 0.098 
5 (2.5-7.5) 7 (5-9) 0.039 
Pairwise comparisons at rest at 12 hours: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 1 
PCA/Hart 0.826 
Spi/Hart 
PCA/Vol 0.302 
PCA/Hart 0.047 
PCA/Vol PCA/Hart 1 
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3.2.2.4: Pain scores at 24 hours 
No data were recorded from one patient in the PCA/Volulyte group. This patient 
had returned to theatre overnight for bleeding and was too drowsy to assess the 
pain score appropriately. A significantly higher pain score was only seen in the 
PCA combined group at rest at 24 hours, see Table 3.32. 
 
Table 3.32: Pain scores at 24 hours. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=29 
Hartmann’s 
n=30 
p-
value 
Pain score at rest at 
24 hours 
2 
(0.75-5) 
2 
(0.38-4) 
3 
(2-4) 
4 
(2-5) 0.083 
2 (0.63-4) 3 (2-5) 0.027 
Pain score with 
movement at 24 
hours 
6 
(4-8) 
6 
(1.75-8) 
6 
(4-8) 
6 
(5-9) 
0.296 
6 (3-8) 6 (4-8) 0.183 
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3.2.2.5: Pain scores at 48 hours 
There were no data recorded on two patients from the spinal/Volulyte group, 
seven patients from the spinal/Hartmann’s group and one patient from the 
PCA/Volulyte group. These patients were discharged before 48 hours. There 
were significantly higher pain scores at rest but not movement for the PCA 
groups compared with the spinal groups at 48 hours, see Table 3.33. 
 
Table 3.33: Pain scores at 48 hours. Median values with interquartile 
ranges. The sub-table shows comparisons between the groups. p-value 
for multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
 
Spinal PCA  
Volulyte 
n=28 
Hartmann’s 
n=23 
Volulyte 
n=29 
Hartmann’s 
n=30 
p-
value 
Pain score at rest at 
48 hours 
1 
(0-2) 
0 
(0-2) 
1 
(0-3) 
2 
(0-3) 0.029 
1 (0-2) 1.5 (0-3) 0.045 
Pain score with 
movement at 48 
hours 
4 
(1.25-
6.5) 
3  
(0.5-5) 
4 
(1.5-6) 
3.5 
(1-5.25) 0.283 
3 (1-5) 4 (1-6) 0.327 
Pairwise comparisons at rest at 48 hours: 
  p 
Spi/Vol 
Spi/Hart 0.154 
PCA/Vol 1 
PCA/Hart 1 
Spi/Hart 
PCA/Vol 0.066 
PCA/Hart 0.043 
PCA/Vol PCA/Hart 1 
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Figures 3.18-3.21 show the pain scores over time for the four groups and the 
combined analgesia groups at rest and with movement. There was a reduction 
in median pain score over time in all groups. The spinal groups had significantly 
reduced pain scores at rest at all time intervals and for the first 12 hours with 
movement but not thereafter. 
 
Figure 3.18: Median pain scores at rest for the four groups. *signify a 
significant difference (p=0.01) between spinal/volulyte and 
PCA/Hartmann’s groupsat 3 hours. ^signify a significant difference 
(p=0.003) between the spinal/Hartmann’s and PCA/Hartmann’s groups at 3 
hours. α signify a significant difference (p=0.047) between the 
spinal/Hartmann’s and PCA/Hartmann’s groups at 12 hours. δ signify a 
significant difference (p=0.01) between the spinal/Hartmann’s and 
PCA/Hartmann’s groups at 6 hours. λ signify a significant difference 
(p=0.043) between the spinal/Hartmann’s and PCA/Hartmann’s groups at 
48 hours. *^αδλ Mann-Whitney U test. 
* 
 * ^ 
^ δ 
δ 
α 
λ 
λ 
α 
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Figure 3.19: Median pain scores at rest for the combined analgesia 
groups. The following signify a significant difference * 3hours (p<0.0005), 
^ 6hours (p=0.001), δ 12 hours (p=0.008), α 24 hours (p=0.027) and λ 48 
hours (p=0.045). *^αδλ Mann-Whitney U test. 
 
Figure 3.20: Median pain scores with movement for the four groups. * 
signify a significant difference (p=0.039) between spinal/Volulyte and 
PCA/Hartmann’s at 3 hours. ^ signify a significant difference (p=0.003) 
between spinal/Hartmann’s and PCA/Hartmann’s at 3 hours. *^ Mann-
Whitney U test. 
* * ^ ^ 
δ 
δ α α 
λ 
λ 
* *"^ ^ 
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Figure 3.21: Median pain scores with movement for the combined 
analgesia groups. The following signify a significant difference between 
analgesia groups at * 3hours (p=0.004), ^ 6 hours (p=0.017) and δ 12 hours 
(p=0.039). *^δ Mann-Whitney U test. 
 
 
 
 
 
 
 
 
 
 
* * ^ ^ δ δ 
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3.2.2.6: Amount of paracetamol used postoperatively 
There was no significant difference in the amount of paracetamol used between 
the groups, see Table 3.34. 
 
Table 3.34: Amount of paracetamol used postoperatively. Median values 
with interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 p-value 
Paracetamol 
dose (g) 
8.5 
(6.8-12) 
8 
(6.8-12.8) 
10 
(7-14) 
8 
(7-14) 0.877 
8 (7-12) 9.5 (7-14) 0.473 
 
 
3.2.2.7: Amount of voltarol used postoperatively 
There was no significant difference in the amount of voltarol used between the 
groups, see Table 3.35 
 
Table 3.35: Amount of voltarol used postoperatively. Median values with 
interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=26 
Hartmann’s 
n=27 
Volulyte 
n=28 
Hartmann’s 
n=23 p-value 
Voltarol dose 
(mg) 
250 
(150-363) 
250 
(200-350) 
250 
(200-388) 
250 
(150-400) 0.996 
250 (200-350) 250 (150-400) 0.893 
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3.2.2.8: Amount of tramadol used postoperatively 
There was no significant difference in the amount of tramadol used regularly or 
for breakthrough pain relief between the groups, see Table 3.36 and 3.37 
respectively. 
 
Table 3.36: Amount of tramadol used regularly postoperatively. Median 
values with interquartile ranges. p-value for multiple groups determined 
by an Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=4 
Hartmann’s 
n=3 
Volulyte 
n=2 
Hartmann’s 
n=5 p-value 
Regular 
tramadol dose 
(mg) 
350 
(100-600) 
250 
(75-250) 
300 
(150-300) 
300 
(225-400) 0.882 
250 (75-450) 300 (200-450) 0.805 
 
 
Table 3.37: Amount of tramadol used as breakthrough analgesia 
postoperatively. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
 
Spinal PCA  
Volulyte 
n=17 
Hartmann’s 
n=19 
Volulyte 
n=20 
Hartmann’s 
n=16 p-value 
Breakthrough 
tramadol dose 
(mg) 
100 
(50-200) 
100 
(50-200) 
100 
(50-238) 
125 
(50-238) 0.989 
100 (50-200) 100 (50-238) 0.796 
 
 
  176 
3.2.2.9: Amount of codeine phosphate used postoperatively 
A small number of patients received codeine phosphate postoperatively (Table 
3.38). No analysis has been performed due to the small numbers involved. 
 
Table 3.38: Amount of codeine phosphate used postoperatively. Median 
values. 
 
Spinal PCA 
Volulyte 
n=1 
Hartmann’s 
n=3 
Volulyte 
n=1 
Hartmann’s 
n=1 
Codeine dose 
(mg) 
420 60 360 120 
90 240 
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3.2.2.10: Morphine administered 
There was no significant difference in the median amount of morphine 
administered in recovery (Post-anaesthesia care unit (PACU)) between the four 
groups, see Table 3.39. There was no significant difference in the median 
amount of morphine administered by PCA in the two PCA groups, see Table 
3.40. There was a significantly greater amount of morphine administered in the 
PCA groups compared with the spinal groups, see Table 3.41 and Figure 3.22.  
 
Three patients who were randomized to spinal analgesia (two spinal/Volulyte 
and one spinal/Hartmann’s) required an additional PCA to control their pain 
postoperatively. These patients have been analysed on an intention-to-treat 
basis. In calculating the total amount of morphine administered postoperatively 
this includes the on table morphine the PCA groups got prior to extubation as 
per study protocol. 
 
Table 3.39: Amount of morphine administered in recovery. Median values 
with interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 p-value 
Amount of 
morphine 
administered 
in PACU (mg) 
10 
(0-12.5) 
10 
(0-11) 
10 
(0-10) 
10 
(2.8-13.5) 0.665 
10 (0-11.9) 10 (1.25-10) 0.994 
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Table 3.40: Amount of morphine administered via a PCA in the 
postoperative period for the two groups randomized to receive PCA. 
Median values with interquartile ranges. 
 PCA/Volulyte PCA/Hartmann’s p-value 
Amount of 
morphine 
administered via 
PCA (mg) 
26.5 (16.3-39) 27 (16.5-36.8) 0.976 
 
 
Table 3.41: Total amount of morphine administered postoperatively. 
Median values with interquartile ranges. p-value for multiple groups 
determined by an Independent-samples Kruskal-Wallis test. The sub-table 
shows comparisons between the groups. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 p-value 
Total amount 
of morphine 
administered 
postoperatively 
(mg) 
10 
(3-16.5) 
10 
(2.3-15.3) 
47.5 
(31-74.3) 
44 
(36.3-58.3) <0.0005 
10 (3.3-15.8) 45.5 (34-60.5) <0.0005 
Pairwise comparisons for total amount of morphine: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol <0.0005 
PCA/Hart <0.0005 
Spi/Hart 
PCA/Vol <0.0005 
PCA/Hart <0.0005 
PCA/Vol PCA/Hart 1 
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Figure 3.22: Median total amount of morphine administered 
postoperatively per analgesia group. * signify a significant difference 
(p<0.0005) between the two analgesia groups, Mann-Whitney U test. 
 
 
 
 
 
 
 
 
 
* 
* 
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3.2.2.11: Total amount of anti-emetic given postoperatively 
There was no significant difference in the amount of cyclizine or ondansetron 
used postoperatively between the groups, see Table 3.42. A few patients 
received metoclopramide in addition to the protocolled anti-emetics but there 
was no significant difference between the groups, see Table 3.43. 
 
Table 3.42: Total amount of cyclizine and ondansetron administered 
postoperatively. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
 
Spinal PCA 
p-value Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 
Cyclizine dose 
(mg) 
50 
(0-112.5) 
12.5 
(0-50) 
50 
(0-100) 
50 
(0-100) 
0.381 
50 (0-93.8) 50 (0-100) 0.561 
Ondansetron 
dose (mg) 
4 
(0-8) 
2 
(0-4) 
4 
(0-8) 
4 
(0-8) 0.842 
4 (0-4) 4 (0-8) 0.765 
 
Table 3.43: Total amount of metoclopramide administered postoperatively. 
Median values with interquartile ranges. p-value for multiple groups 
determined by an Independent-samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=1 
Hartmann’s 
n=1 
Volulyte 
n=4 
Hartmann’s 
n=6 
Total amount of 
metoclopramide 
administered 
(mg) 
20 10 35 (10-82.5) 
10 
(10-15) 0.413 
15 (10-15) 10 (10-37.5) 0.909 
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3.2.2.12: Chlorpheniramine administration 
Only five patients required chlorpheniramine for itching, see Table 3.44. 
 
Table 3.44: Chlorpheniramine administered. Data for dose are median 
values with interquartile ranges. 
 Spinal PCA 
Number of 
patients 1 4 
Dose (mg) 8 9 (4-57.5) 
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3.2.3: Other outcome variables 
3.2.3.1: Maximum increase in abdominal circumference prior to discharge 
There were no data recorded for two patients from the spinal/Hartmann’s group 
as they were too uncomfortable to stand and two patients from the 
PCA/Volulyte group as one patient was too uncomfortable to stand and one 
patient was too drowsy after a return to theatre for bleeding. There was an 
increase in abdominal circumference in the postoperative period across all 
groups. There was no significant difference detected between the groups, see 
Table 3.45. 
 
Table 3.45: Maximum increase in abdominal circumference prior to 
discharge. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
 
Spinal PCA  
Volulyte 
n=30 
Hartmann’s 
n=28 
Volulyte 
n=28 
Hartmann’s 
n=30 p-value 
Maximum 
increase in 
abdominal 
circumference 
(cm) 
5.3 
(3.8-8) 
5 
(1.3-7.8) 
7 
(3-10.5) 
4.8 
(2.8-7.3) 0.539 
5 
(2-8) 
5 
(3-8.3) 
0.580 
Volulyte Hartmann’s  
6 
(3-8) 
5 
(2-7.3) 0.180 
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3.2.3.2: Number of patients requiring a postoperative blood transfusion 
There was no significant difference in the number of patients receiving a 
postoperative blood transfusion between the four groups, see Table 3.46. There 
were a total of six (5%) patients requiring transfusion. Of those transfused, five 
received a transfusion subsequent to the 48 hour blood sample and one patient 
(PCA/Volulyte group) received a transfusion following the 12 hour sample. 
 
Table 3.46: Number of patients requiring a postoperative blood 
transfusion. 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Patients 
requiring  
post-op blood 
transfusion 
1 (3%) 2 (7%) 2 (7%) 1 (3%) 0.873 
 
3.2.3.3: Number of patients vomiting postoperatively 
There was no significant difference in the number of patients who vomited in the 
postoperative period between the groups, see Table 3.47. Although there is an 
increased number of patients in the PCA groups who experienced 
postoperative vomiting. 
 
Table 3.47: Number of patients vomiting postoperatively 
 Spinal PCA  Volulyte Hartmann’s Volulyte Hartmann’s p-value 
Number of 
patients 
vomiting 
postoperatively 
8 7 12 12 0.369 
15 (25%) 24 (40%) 0.079 
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3.2.4: Length of stay 
There was no significant difference in the time to patients achieving the 
discharge criteria and the time to actual discharge between the groups, see 
Tables 3.48 and 3.49 and Figures 3.23 and 3.24 respectively. When comparing 
the post-operative day of discharge there was a significant difference in the 
distribution between the groups, with a greater proportion of spinal patients 
being discharged earlier, see Figure 3.25. 
 
Table 3.48: Time to achieving discharge criteria. Median values with 
interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 
Time to fit for 
discharge 
(days) 
1.94 
(1.71-2.88) 
1.92 
(1.71-3.15) 
2.27 
(1.79-3.13) 
2.48 
(1.86-2.93) 
0.538 
1.92 (1.71-2.88) 2.46 (1.8-2.96) 0.150 
Volulyte Hartmann’s  
1.96 (1.79-2.92) 1.92 (1.8-2.92) 0.842 
 
 
 
 
 
 
  185 
Table 3.49: Time to actual discharge. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 
Time to 
discharge 
(days) 
2.52 
(1.91-3.27) 
2.19 
(1.89-3.34) 
2.85 
(2.11-4.32) 
3.08 
(2.03-3.78) 
0.299 
2.25 (1.89-3.13) 2.9 (2.09-3.93) 0.059 
Volulyte Hartmann’s  
2.75 (2.08-3.6) 2.29 (2.01-3.59) 0.807 
 
 
 
Figure 3.23: Median time to discharge for the four groups. 
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Figure 3.24: Median time to discharge per analgesia group. 
 
 
Figure 3.25: Patient distribution for postoperative day of discharge per 
analgesia used. 
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3.2.5: Time to return of bowel function 
The median time to the first bowel action was significantly shorter in the 
combined Hartmann’s group compared with the combined Volulyte group. 
Otherwise there were no significant differences detected for time to first bowel 
action (Table 3.50), time to first passing flatus (Table 3.51), time to first time 
bowel sounds being heard (Table 3.52) and the time to first tolerating a diet 
(Table 3.53) between all four groups. One patient in the spinal/Hartmann’s 
group died and one patient in the PCA/Volulyte group underwent a further 
operation due to an anastomotic leak before their bowels opened. No bowel 
sounds were detected in six patients (one from spinal/Volulyte, one from 
spinal/Hartmann’s and four from PCA/Hartmann’s groups) prior to discharge. 
 
Table 3.50: Time to bowels first open. Median values with interquartile 
ranges; no data were recorded for two patients. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=30 
Hartmann’s 
n=29 
Volulyte 
n=29 
Hartmann’s 
n=30 
Time to 
bowels first 
open (days) 
2.23 
(1.95-2.81) 
1.88 
(1.08-2.92) 
2.63 
(1.77-3.79) 
1.98 
(1.59-2.98) 
0.084 
2.08 (1.54-2.88) 2.13 (1.75-3.58) 0.345 
Volulyte Hartmann’s  
2.38 (1.83-3.58) 1.96 (1.38-2.88) 0.017 
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Table 3.51: Time to first passing flatus. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 
Time to first 
passing flatus 
(days) 
1.19 
(0.66-1.89) 
1.19 
(0.85-1.64) 
1.46 
(0.86-1.71) 
1.23 
(0.91-1.8) 
0.830 
1.19 (0.72-1.82) 1.35 (0.89-1.71) 0.349 
Volulyte Hartmann’s  
1.25 (0.73-1.8) 1.23 (0.89-1.76) 0.964 
 
 
Table 3.52: Time to bowel sounds first heard. Median values with 
interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=29 
Hartmann’s 
n=29 
Volulyte 
n=30 
Hartmann’s 
n=26 
Time to bowel 
sounds first 
heard (days) 
0.96 
(0.88-1.73) 
0.92 
(0.88-0.96) 
0.96 
(0.92-1.74) 
0.96 
(0.88-1.81) 
0.149 
0.92 (0.88-1.05) 0.96 (0.92-1.78) 0.093 
Volulyte Hartmann’s  
0.96 (0.88-1.71) 0.92 (0.88-1.08) 0.195 
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Table 3.53: Time to first tolerating diet. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
 
Spinal PCA 
p-value Volulyte 
n=30 
Hartmann’s 
n=30 
Volulyte 
n=30 
Hartmann’s 
n=30 
Time to first 
tolerating diet 
(days) 
0.85 
(0.66-1.64) 
0.88 
(0.66-1.64) 
1.08 
(0.7-2.45) 
1.04 
(0.88-1.79) 
0.382 
0.88 (0.67-1.63) 1.06 (0.79-2.02) 0.081 
Volulyte Hartmann’s  
0.94 (0.68-1.95) 0.92 (0.77-1.76) 0.916 
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3.2.6: Complications 
Thirty-two patients experienced a complication before or after discharge, some 
had more than one. There was one out of hospital death on day four 
postoperatively, this gave a mortality rate of 0.8% for the whole trial. There were 
no significant differences in the distribution of complications before or after 
discharge between the four groups, see Tables 3.54 and 3.55 respectively. 
There were no significant differences comparing the complication distribution for 
the combined analgesia (p=0.255) and combined fluid (p=0.308) groups. Ten 
patients were readmitted within 30 days of surgery; nine of these with 
complications. One further patient developed a post-dural tap headache and 
two others developed incisional hernias after 30 days. 
 
There were significantly more complications in the combined PCA group 
compared with the combined spinal group, see Table 3.56. This is a reflection 
of the greater number of patients experiencing a post-operative ileus in the PCA 
groups (11 patients) compared with the spinal groups (two patients). There 
were no significant differences in the number of readmissions between the four 
groups, see Table 3.57. There was an 8.3% readmission rate for the whole trial. 
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Table 3.54: Distribution of complications before discharge. 
 
Spinal/ 
Volulyte 
n=3 
Spinal/ 
Hartmann’s 
n=4 
PCA/ 
Volulyte 
n=8 
PCA/ 
Hartmann’s 
n=8 
p-value 
Intraoperative 
bleed 1 1 0 0 
0.402 
Anastomotic 
bleed 1 0 1 1 
Myocardial 
infarction 0 1 0 0 
Postoperative 
bleed 1 0 1 0 
Ureteric 
injury 0 0 1 0 
UTI 0 0 0 1 
Atrial 
fibrillation 0 1 0 2 
Ileus 0 1 5 4 
Wound 
infection 0 0 0 1 
Acute urinary 
retention 0 1 0 0 
Neuropraxia 0 0 1 0 
Total 3 5 9 9  
 
 
 
 
 
 
 
 
 
 
 
  192 
Table 3.55: Distribution of complications after discharge:  
 
Spinal/ 
Volulyte 
n=3 
Spinal/ 
Hartmann’s 
n=2 
PCA/ 
Volulyte 
n=4 
PCA/ 
Hartmann’s 
n=3 
p-value 
Ileus 1 0 1 1 
0.439 
Dural tap 
headache 1 0 0 0 
Abdominal 
wall 
haematoma 
0 1 0 0 
Anastomotic 
leak 0 0 1 0 
AF 0 0 1 0 
Death 0 1 0 0 
Bladder 
Abscess 0 0 0 1 
Incisional 
hernia 1 0 1 1 
Total 3 2 4 3  
 
 
Table 3.56: Total number of complications 
  Spinal PCA Volulyte Hartmann’s 
Complication 
occurred 
Yes 10 22 16 16 
No 50 38 44 44 
p-value 0.013 1 
 
 
Table 3.57: Number of readmissions 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Number of 
patients 
readmitted 
within 30 
days 
1 3 3 3 0.727 
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3.2.7: Pathology of resected specimens 
There were 64 patients with adenocarcinoma of the colon or rectum. There 
were no positive resection margins. There were no significant differences in the 
staging of the disease between the four groups, see Table 3.58. 
 
Table 3.58: Pathology data for the adenocarcinoma specimens. Data for 
number of resected and positive lymph nodes are median values with 
interquartile ranges. 
 
Spinal/ 
Volulyte 
n=20 
Spinal/ 
Hartmann’s 
n=14 
PCA/ 
Volulyte 
n=17 
PCA/ 
Hartmann’s 
n=13 
p-value 
Dukes A 4 4 5 4 
0.946 
Dukes B 9 6 6 4 
Dukes C 5 4 5 3 
Dukes D 2 0 1 2 
T0 0 0 1 0 
0.410 
T1 2 1 5 3 
T2 2 3 0 1 
T3 15 8 8 7 
T4 1 2 3 2 
N0 14 10 12 7 
0.737 N1 5 3 2 4 
N2 1 2 3 2 
M0 18 14 16 11 
0.486 
M1 2 0 1 2 
G1 0 0 0 0 
0.106 G2 16 12 8 7 
G3 4 2 7 6 
L0 13 11 12 6 
0.332 
L1 7 3 5 7 
V0 16 13 13 7 
0.177 V1 3 1 4 6 
V2 1 0 0 0 
Number of 
lymph nodes 
resected 
25 
(16-37) 
28 
(20-43) 
28 
(18-39) 
19 
(17-30) 
0.474 
Number of 
positive lymph 
nodes 
1.5 
(1-3) 
2.5 
(1-5) 
9 
(2-13) 
3 
(2-8) 
0.103 
 
  194 
3.2.8: Adherence to the elements of ERAS 
There was an extremely high adherence to all the elements of the ERAS 
programme, see Table 3.59. The majority of patients had their urinary catheters 
removed the day following surgery, there were no differences between the 
groups. 
 
Table 3.59: Adherence to ERAS elements 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
Overall 
Compliance 
Provision of 
preop  
information 
100% 100% 100% 100% 100% 
Avoidance of 
preop bowel 
preparation 
100% 100% 100% 100% 100% 
Preload given 97% 100% 100% 93% 98% 
Antibiotic 
prophylaxis 100% 100% 100% 100% 100% 
Thrombo-
embolic 
prophylaxis 
100% 100% 100% 100% 100% 
Avoidance of 
nasogastric 
tube postop 
100% 100% 100% 100% 100% 
Use of body 
warmer 100% 100% 100% 100% 100% 
Use of 
Doppler 
guided fluid 
administration 
100% 100% 100% 100% 100% 
TWOC day 1 25 23 23 22 
p=0.77 
TWOC day 2 3 5 4 6 
TWOC day 3 1 0 2 0 
Home with 
IDC 1 2 1 2 
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3.2.9: Blood outcome variables 
3.2.9.1: Glucose measurements 
Median glucose levels were significantly different three hours after the start of 
surgery. Pairwise comparisons identified a significantly greater level in the 
PCA/Hartmann’s group compared with the spinal/Hartmann’s group, see Table 
3.60. A greater level was also seen in the combined spinal group compared 
with the combined PCA group at three hours, see Table 3.61. Otherwise there 
were no other significant differences seen between the groups. Tables E.1 and 
E.2 (appendix E) shows the percentage change at various time points 
compared with the preoperative level for the four groups and the combined 
groups. No significant differences were seen between all four groups, or the 
combined analgesia and fluid groups at the measured time points. Figures 3.26 
and 3.27 show the median glucose levels over time for the four groups and the 
combined analgesia groups respectively.  
 
There were no data recorded on 18 patients 48 hours after the start of surgery 
(seven each from the spinal/Volulyte and the spinal/Hartmann’s groups and two 
each from the PCA/Volulyte and the PCA/Hartmann’s groups) as they had 
already been discharged. 
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Table 3.60: Glucose levels in the preoperative and postoperative period. 
Median values with interquartile ranges. p-value for multiple groups 
determined by an Independent-samples Kruskal-Wallis test. The sub-table 
shows comparisons between the groups. 
Glucose 
(mmol/l) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Preoperative 
5.5 
(4.7-7.8) 
5.6 
(4.7-8.1) 
5.6 
(4.9-6.3) 
6.3 
(4.7-9.1) 
0.785 
3 hours 
6.3 
(5.9-7.6) 
6.1 
(5.2-7.2) 
6.7 
(5.8-7.4) 
7.4 
(6.5-7.8) 
0.014* 
6 hours 
6.7 
(5.5-7.6) 
6 
(5.1-6.7) 
6.7 
(5.5-7.3) 
6.8 
(6-7.2) 
0.098 
12 hours 
7.1 
(6-7.4) 
6.6 
(5.9-8) 
6.7 
(6.1-7.5) 
7.3 
(6.3-7.9) 
0.745 
24 hours 
6.8 
(6-8.8) 
6.5 
(5.9-9.6) 
6.6 
(5.8-7.7) 
6.8 
(6.1-9) 
0.899 
48 hours 
7 
(5.8-7.7) 
7.4 
(6.4-8.3) 
6.9 
(5.7-7.5) 
7.1 
(6.1-8.2) 
0.529 
*Pairwise comparisons for median glucose at 3 hours: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 1 
PCA/Hart 0.173 
Spi/Hart 
PCA/Vol 1 
PCA/Hart 0.009 
PCA/Vol PCA/Hart 0.407 
 
Table 3.61: Glucose levels in the pre- and post-operative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
Glucose Spinal PCA p-value Volulyte Hartmann’s p-value 
Preoperative 
5.6 
(4.7-7.8) 
5.7 
(4.7-7.7) 
0.992 
5.6 
(4.7-6.7) 
5.8 
(4.7-8.9) 
0.446 
3 hours 
6.1 
(5.4-7.5) 
7 
(6-7.7) 
0.012 6.5 
(5.8-7.5) 
6.8 
(5.8-7.7) 
0.560 
6 hours 
6.2 
(5.4-7.4) 
6.7 
(5.8-7.3) 
0.115 
6.7 
(5.5-7.5) 
6.4 
(5.6-7.1) 
0.369 
12 hours 
6.8 
(5.9-7.5) 
6.9 
(6.1-7.6) 
0.699 
6.8 
(6.1-7.5) 
6.9 
(6-7.9) 
0.646 
24 hours 
6.6 
(5.9-8.9) 
6.7 
(5.9-8.4) 
0.801 
6.6 
(5.9-8.5) 
6.7 
(5.9-9) 
0.763 
48 hours 
7.3 
(6.3-7.8) 
6.9 
(6-7.7) 
0.521 
7 
(5.8-7.5) 
7.3 
(6.4-8.3) 
0.184 
At 48 hours n=46 (spinal), n=56 (PCA) and n=51 (Volulyte and Hartmann’s).  
  197 
 
Figure 3.26: Median postoperative glucose levels for the four groups. * 
signify a significant difference (p=0.009) between spinal/Hartmann’s and 
PCA/Hartmann’s groups at 3 hours, Mann-Whitney U test. 
 
Figure 3.27: Median postoperative glucose levels for the combined 
analgesia groups. * signify a significant difference (p=0.012) between 
analgesia groups at 3 hours, Mann-Whitney U test. 
* * 
* * 
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3.2.9.2: Cortisol measurements 
Median cortisol levels were significantly different three hours from the start of 
surgery. Pairwise comparison identified a significantly higher cortisol level in the 
PCA/Hartmann’s groups compared with the spinal/Volulyte and 
spinal/Hartmann’s groups, see Table 3.62. A significantly greater cortisol level 
was also measured in the PCA combined group compared with the combined 
spinal group at three hours, see Table 3.63. The combined Hartmann’s group 
had a significantly higher preoperative cortisol level compared with the 
combined Volulyte group, see Table 3.63.  
 
Table 3.64 shows the median percentage change in cortisol levels at the 
various time points compared with the preoperative cortisol level. No significant 
difference can be seen between the four groups. Table 3.65 shows the median 
percentage change in cortisol levels for the combined analgesia and fluid 
groups. The percentage change at three hours from the preoperative level was 
significantly less in the spinal group compared with the PCA group. In addition 
the percentage change was significantly reduced at six and 12 hours to the 
preoperative level in the Hartmann’s group compared to the Volulyte group. 
Figures 3.28 and 3.29 show the median cortisol levels over time for the four 
groups and the combined analgesia groups respectively.  
 
Those patients who received a PCA had a peak in cortisol levels between three 
to six hours, which then returned to below preoperative levels by 12 hours. Only 
cortisol levels at three (p<0.0005) and six (p<0.0005) hours, in patients with a 
PCA, were significantly different from preoperative levels, see figures 3.28a and 
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3.29a. By comparison, cortisol levels in patients who received a spinal peaked 
at six hours and then returned to preoperative levels. Cortisol levels were 
significantly greater at six hours (p=0.039) and significantly less at 48 hours 
(p=0.002), in comparison to preoperative levels in those patients who received 
a spinal, see Figures 3.28a and 3.29a. 
 
There were no data recorded on 18 patients at 48 hours (seven each from the 
spinal/Volulyte and spinal/Hartmann’s groups and two each from the 
PCA/Volulyte and PCA/Hartmann’s groups) as they had already been 
discharged. There is missing data from one patient in the PCA/Hartmann’s 
group at 24 hours. 
 
Table 3.62: Cortisol levels in the preoperative and postoperative period. 
Median values with interquartile ranges. p-value for multiple groups 
determined by an Independent-samples Kruskal-Wallis test. The sub-table 
shows comparisons between the groups. 
Cortisol 
(nmol/l) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Pre-operative 362 (266-561) 
415 
(309-544) 
343 
(245-490) 
446 
(365-553) 0.184 
3 hours 494 (319-689) 
444 
(322-671) 
584 
(314-804) 
714 
(539-840) 0.007* 
6 hours 547 (274-769) 
434 
(224-780) 
630 
(388-875) 
556 
(458-713) 0.362 
12 hours 391 (242-537) 
401 
(210-593) 
390 
(239-554) 
321 
(235-413) 0.489 
24 hours 403 (286-524) 
417 
(235-536) 
332 
(236-435) 
395 
(266-509) 0.417 
48 hours 285 (183-465) 
331 
(260-456) 
381 
(279-613) 
370 
(245-442) 0.524 
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*Pairwise comparisons for median cortisol at three hours: 
  p 
Spi/Vol 
Spi/Hart 1 
PCA/Vol 1 
PCA/Hart 0.011 
Spi/Hart 
PCA/Vol 1 
PCA/Hart 0.022 
PCA/Vol PCA/Hart 0.307 
 
 
Table 3.63: Cortisol levels in the preoperative and postoperative period for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
Cortisol 
(nmol/l) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Pre-
operative 
407 
(298-
556) 
406 
(297-
531) 
0.960 
349 
(258-
538) 
439 
(328-548) 0.045 
3 hours 
468 
(329-
678) 
701 
(429-
820) 
0.004 
510 
(316-
726) 
602 
(383-813) 0.127 
6 hours 
509 
(243-
770) 
575 
(425-
772) 
0.101 
588 
(291-
827) 
517 
(373-740) 0.548 
12 hours 
397 
(237-
576) 
347 
(238-
466) 
0.414 
391 
(243-
548) 
357 
(233-497) 0.591 
24 hours 
407 
(240-
532) 
339 
(256-
480) 
0.184 
360 
(262-
495) 
406 
(237-531) 0.531 
48 hours 
318 
(191-
458) 
371 
(267-
533) 
0.245 
356 
(191-
497) 
367 
(260-453) 0.797 
At 24 hours n=59 (PCA and Hartmann’s), n=60 (spinal and Volulyte) 
At 48 hours n=56 (PCA), n=46 (spinal), n=48 (Hartmann’s), n=51 (Volulyte) 
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Table 3.64: Percentage change of cortisol levels from the preoperative 
level for the four groups. Median values with interquartile ranges. p-value 
for multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
0.04 
(-0.26-1.1) 
0.03 
(-0.22-0.58) 
0.48 
(-0.08-
1.49) 
0.67 
(0.12-1.23) 
0.063 
6 hours 
0.52 
(-0.13-
0.52) 
-0.05 
(-0.43-0.79) 
0.51 
(0.03-1.71) 
0.13 
(0.01-0.73) 
0.064 
12 hours 
-0.03 
(-0.27-
0.56) 
-0.15 
(-0.53-0.59) 
0.1 
(-0.36-
0.64) 
-0.25 
(-0.47-0.05) 
0.118 
24 hours 
0.12 
(-0.28-
0.53) 
-0.14 
(-0.44-0.19) 
-0.08 
(-0.48-
0.55) 
-0.19 
(-0.47-0.02) 
0.219 
48 hours 
-0.27 
(-0.47-
0.35) 
-0.26 
(-0.42- -
0.03) 
0.09 
(-0.31-
0.58) 
-0.24 
(-0.42- -
0.42) 
0.103 
 
Table 3.65: Percentage change of cortisol levels from the preoperative 
level for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
0.04 
(-0.24-
0.78) 
0.52 
(-0.04-
1.36) 
0.009 0.29 
(-0.18-1.3) 
0.36 
(-0.09-0.94) 
0.871 
6 hours 
0.28 
(-0.41-1) 
0.35 
(0.02-
1.31) 
0.115 
0.51 
(0.02-
1.17) 
0.08 
(-0.18-0.74) 
0.031 
12 hours 
-0.05 
(-0.51-
0.56) 
-0.12 
(-0.43-
0.26) 
0.622 
0.02 
(-0.32-
0.59) 
-0.23 
(-0.49-0.17) 
0.032 
24 hours 
-0.01 
(-0.37-
0.34) 
-0.18 
(-0.47-
0.29) 
0.154 
0.03 
(-0.33-
0.52) 
-0.17 
(-0.44-0.12) 
0.150 
48 hours 
-0.27 
(-0.45-
0.02) 
-0.15 
(-0.39-
0.34) 
0.226 
-0.1 
(-0.41-
0.53) 
-0.25 
(-0.42- -
0.04) 
0.06 
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Figure 3.28: Median cortisol levels for the four groups. * signify a 
significant difference (p=0.011) between spinal/Volulyte and 
PCA/Hartmann’s groups at 3 hours. ^ signify a significant difference (p= 
0.022) between spinal/Hartmann’s and PCA/Hartmann’s groups at 3 hours. 
*^ Mann-Whitney U test. 
 
Figure 3.28a: Median cortisol levels, without error bars, for the four 
groups. 
* 
"*""^ ^ 
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Figure 3.29: Median cortisol levels for the combined analgesia groups. * 
signify a significant difference (p=0.004) between analgesia groups at 3 
hours, Mann-Whitney U test. 
 
Figure 3.29a: Median cortisol levels, without error bars, for the combined 
analgesia groups. 
* * 
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3.2.9.3: Insulin measurements 
There were no significant differences seen in the median insulin levels for the 
four groups or the combined analgesia and fluid groups, see Tables 3.66 and 
3.67. There were no significant differences in the percentage changes of insulin 
levels between the four groups and the combined analgesia and fluid groups, 
see Tables E.3 and E.4 (appendix E).  
 
During the postoperative period there was a reduction in levels between three 
and 12 hours with all groups, but there was a subsequent increase to levels 
measured pre-operatively after 24 and 48 hours, see Figures 3.30 and 3.31. 
Significantly greater median insulin levels were measured at 24 hours 
compared with pre-operative levels in the combined spinal group (p=0.022). No 
significant difference was measured at 48 hours (p=0.217) in the combined 
spinal group or at 24 hours (p=0.287) and 48 hours (p=0.209) in the combined 
PCA group. 
 
There were no data from 18 patients at 48 hours (seven each from the 
spinal/Volulyte and spinal/Hartmann’s groups and two each from the 
PCA/Volulyte and PCA/Hartmann’s groups) as they had already been 
discharged. There were also missing data from the PCA/Hartmann’s group in 
one patient at 12 hours and one patient at 24 hours. 
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Table 3.66: Insulin levels in the preoperative and postoperative period for 
the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Insulin 
(pmol/l) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Preoperative 119 (42-238) 
98 
(63-274) 
69 
(33-211) 
175 
(48-410) 0.380 
3 hours 40 (31-79) 
47 
(20-73) 
58 
(28-95) 
59 
(36-106) 0.206 
6 hours 36 (21-53) 
24 
(16-59) 
34 
(20-65) 
39 
(30-82) 0.188 
12 hours 52 (20-92) 
46 
(29-96) 
39 
(25-95) 
55 
(30-133) 0.780 
24 hours 223 (67-386) 
124 
(48-298) 
192 
(71-428) 
160 
(65-470) 0.821 
48 hours 169 (94-244) 
202 
(74-344) 
190 
(70-423) 
188 
(120-338) 0.812 
 
Table 3.67: Insulin levels in the preoperative and postoperative period for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
Insulin 
(pmol/l) Spinal PCA p-value Volulyte Hartmann’s p-value 
Preoperative 109 (52-245) 
130 
(43-366) 
0.777 
95 
(35-226) 
131 
(54-355) 
0.172 
3 hours 41 (25-76) 
59 
(34-98) 
0.051 
44 
(29-82) 
50 
(28-92) 
0.832 
6 hours 33 (18-58) 
36 
(25-75) 
0.106 
36 
(20-59) 
35 
(20-65) 
0.840 
12 hours 50 (24-92) 
49 
(28-101) 
0.629 
46 
(23-93) 
50 
(30-108) 
0.419 
24 hours 162 (57-334) 
181 
(69-424) 
0.606 
206 
(69-409) 
136 
(56-350) 
0.657 
48 hours 172 (75-302) 
189 
(103-386) 
0.476 
174 
(70-330) 
202 
(99-344) 
0.547 
At 12 and 24 hours n=60 (spinal), n=59 (PCA), n=60 (Volulyte), n=59 (Hartmann’s) 
At 48 hours n=46 (spinal), n=56 (PCA), n=51 (Volulyte), n=51 (Hartmann’s) 
 
  206 
 
Figure 3.30: Median insulin levels for the four groups. 
 
Figure 3.31: Median insulin levels for the combined analgesia groups. 
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3.2.9.4: HOMA- Insulin resistance 
There were no significant differences detected between the four groups or the 
combined fluid groups in the homeostatic model assessment (HOMA) of insulin 
resistance (IR) at any of the time intervals, see Table 3.68 and 3.69. In the 
combined analgesia groups HOMA-IR was significantly lower in the spinal 
group compared to the PCA group at three hours only, see Table 3.69. 
 
Table 3.68: HOMA-IR in the preoperative and postoperative period for the 
four groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
HOMA-IR ratio Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Preoperative 3.7 (1.1-13) 
3 
(2.1-14.4) 
2.4 
(1.1-7.4) 
8.4 
(1.5-25.6) 0.401 
3 hours 1.7 (1.3-2.5) 
1.7 
(0.8-3.5) 
2.3 
(1.1-4.7) 
2.6 
(1.5-5.5) 0.084 
6 hours 1.4 (0.9-2.4) 
1 
(0.6-2.4) 
1.3 
(0.8-3) 
1.7 
(1.3-3.3) 0.126 
12 hours 2.1 (0.8-4.4) 
1.9 
(1-5.7) 
1.7 
(1.1-4.2) 
2 
(1.4-6.1) 0.7 
24 hours 10.9 (2.6-19.3) 
5.8 
(1.8-17.3) 
7.7 
(2.7-20.1) 
6 
(3.2-30.2) 0.899 
48 hours 6.8 (3.4-11.5) 
8 
(3.4-21.1) 
8.5 
(2.6-22.8) 
8.7 
(4.7-18.3) 0.808 
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Table 3.69: HOMA-IR in the preoperative and postoperative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
HOMA-IR ratio Spinal PCA p-value Volulyte Hartmann’s p-value 
Preoperative 
3.6 
(1.3-14) 
4.7 
(1.2-19.2) 
0.769 
3.6 
(1.1-10.2) 
5.1 
(1.7-16.6) 
0.178 
3 hours 
1.7 
(1-2.8) 
2.4 
(1.3-4.8) 
0.023 1.8 
(1.2-3.9) 
1.9 
(1.1-4.3) 
0.779 
6 hours 
1.2 
(0.7-2.3) 
1.6 
(0.9-3.3) 
0.077 
1.3 
(0.9-2.6) 
1.5 
(0.7-3.1) 
0.946 
12 hours 
1.9 
(1-4.7) 
1.9 
(1.1-5.5) 
0.636 
1.9 
(1-4.2) 
1.9 
(1.2-5.9) 
0.363 
24 hours 
6.6 
(2.1-18.5) 
7.3 
(2.8-21.9) 
0.734 
9.4 
(2.8-19.3) 
6 
(1.9-19) 
0.702 
48 hours 
7 
(3.4-17.5) 
8.7 
(4.1-19.2) 
0.558 
7.8 
(2.8-16.2) 
8.6 
(4-19.3) 
0.443 
At 12 and 24 hours n=60 (spinal), n=59 (PCA), n=60 (Volulyte), n=59 (Hartmann’s) 
At 48 hours n=46 (spinal), n=56 (PCA), n=51 (Volulyte), n=51 (Hartmann’s) 
 
 
 
Figure 3.32: Median HOMA-IR for the four groups 
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Figure 3.33: Median HOMA-IR for the combined analgesia groups. * signify 
a significant difference (p=0.023) between analgesia groups at 3 hours, 
Mann-Whitney U test. 
 
 
 
 
 
 
 
 
 
* * 
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3.2.9.5: White cell and lymphocyte count measurements 
There were no significant differences detected between the four groups in white 
cell or lymphocyte count, see Table 3.70. In addition there were also no 
significant differences between the combined analgesia and fluid groups. 
 
Table 3.70: White cell and lymphocyte counts in the preoperative and 
postoperative period for the four groups. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
 Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
Pre-operation white 
cell count (109/l) 
7.1 
(5.5-8) 
6.3 
(5.3-7.7) 
6.2 
(5-7.3) 
7.6 
(5.9-8.5) 0.12 
Day 1 post-
operation 
10.5 
(8.6-13) 
9.3 
(7.6-11.4) 
9.5 
(7.4-
11.3) 
11 
(8.2-12.3) 0.247 
Pre-operation 
lymphocyte count 
(109/l) 
1.7 
(1.4-1.9) 
1.7 
(1.5-2.2) 
1.5 
(1.3-2.1) 
1.5 
(1.2-2.4) 0.744 
Day 1 post-
operation  
1.2 
(1-1.6) 
1.3 
(0.9-1.6) 
1 
(0.8-1.6) 
1.1 
(0.8-1.5) 0.646 
At day one for WCC and lymphocyte n=29 (spi/Vol), n=28 (spi/Hart), n=27 (PCA/Vol), n=29 
(PCA/Hart) 
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3.2.9.6: C-reactive protein (CRP) measurements 
There were no significant differences in the median level of CRP on day one 
and two postoperatively between the four groups, see Table 3.71. There were 
also no significant differences in the combined analgesia and fluid groups. 
 
Table 3.71: CRP levels in the preoperative and postoperative period for 
the four groups. Data for day one and two CRP levels are median values 
with interquartile ranges. p-value for multiple groups determined by an 
Independent-samples Kruskal-Wallis test. 
CRP Spinal/ Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
Number of 
patients, 
day 1 
18 20 24 17  
Day 1 
postop CRP 
level (mg/l) 
78.5 
(35-94) 
43 
(26-79) 
46 
(26-103) 
75 
(39-107) 0.349 
Number of 
patients, 
day 2 
7 10 14 10  
Day 2 
postop CRP 
level (mg/l) 
134 
(97-160) 
100 
(56-150) 
133 
(68-188) 
104 
(48-154) 0.620 
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3.2.9.9: Interleukin 2 (IL-2) 
There were no significant differences seen in median IL-2 levels between the 
four groups or the combined analgesia or fluid groups, see Tables 3.72 and 
3.73. Due to the sensitivity of IL-2 in the assay the percentage changes were 
not calculated.  
 
Table 3.72: IL-2 levels in the pre- and post-operative period for the four 
groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
IL-2 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 4 9 6 11  
Preoperative  1.7 (0.1-4.2) 
1.9 
(0.6-5.6) 
0.5 
(0.3-522.6) 
4 
(1.1-16.9) 0.268 
n 5 6 5 10  
3 hours 1.9 (0.4-3.1) 
1.8 
(1.1-3.6) 
0.5 
(0.3-1063.1) 
5.6 
(0.9-27.4) 0.568 
n 8 8 7 11  
6 hours 1.4 (0.8-3.2) 
2 
(1.2-2.7) 
0.8 
(0.3-1.9) 
4.5 
(0.6-20.4) 0.433 
n 4 9 6 11  
12 hours 3.7 (0.9-4.3) 
2.1 
(0.2-4.6) 
0.8 
(0.6-606.4) 
4.8 
(0.6-9.8) 0.783 
n 7 8 3 15  
24 hours 2.4 (0.1-3) 
1.3 
(0.6-2.6) 
1.2 
(1.1-) 
2.7 
(0.7-8.8) 0.517 
n 5 3 4 9  
48 hours 0.7 (0.3-1.2) 
0.8 
(0.2-) 
2 
(0.9-1380.2) 
0.8 
(0.4-34.3) 0.396 
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Table 3.73: IL-2 levels in the preoperative and postoperative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
IL-2 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Preoperative 
1.9 
(0.3-
4.4) 
1.8 
(0.5-
13.9) 
0.509 0.5 
(0.2-3.5) 
2.6 
(0.8-8.4) 
0.1 
3 hours 
1.9 
(0.6-
2.8) 
3.8 
(0.4-
11.4) 
0.305 1.2 (0.3-5.6) 
3 
(1.1-7.5) 0.336 
6 hours 
1.8 
(0.9-
2.7) 
1.8 
(0.3-
13.3) 
0.670 1.1 (0.4-2.5) 
2.6 
(1.1-6.8) 0.147 
12 hours 
2.2 
(0.2-
4.2) 
1.7 
(0.6-9) 0.563 
1.5 
(0.6-4.1) 
2.1 
(0.4-8.2) 0.713 
24 hours 
1.3 
(0.3-
2.9) 
2.6 
(0.8-
10.1) 
0.135 1.8 (0.3-3.8) 
1.8 
(0.7-4.7) 0.630 
48 hours 
0.8 
(0.3-
1.2) 
1.3 
(0.6-
34.3) 
0.210 1.1 (0.6-2) 
0.8 
(0.3-5.1) 0.808 
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3.2.9.10: Interleukin 4 (IL-4) 
IL-4 levels were not significantly changed from the preoperative levels in all 
groups. There were no significant differences in the median IL-4 levels between 
the four groups or the combined analgesia and fluid groups, see Tables 3.74 
and 3.75. In addition, there were no significant differences in the median 
percentage change for the four groups or combined groups, see Tables E.5 and 
E.6 (appendix E). Figures 3.34 and 3.35 show the median IL-4 level for the four 
groups and the combined analgesia group. 
 
Table 3.74: IL-4 levels in the preoperative and postoperative period for the 
four groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
IL-4 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 25 28 27 29  
Preoperative 
0.4 
(0.1-0.8) 
0.5 
(0.3-1) 
0.5 
(0.2-0.7) 
0.3 
(0.2-0.6) 0.357 
n 23 26 28 24  
3 hours 0.2 (0.1-0.5) 
0.3 
(0.1-0.7) 
0.3 
(0.1-0.4) 
0.4 
(0.2-0.4) 0.766 
n 27 26 29 27  
6 hours 0.2 (0.1-0.6) 
0.4 
(0.1-1.2) 
0.4 
(0.2-0.8) 
0.3 
(0.1-0.5) 0.469 
n 28 28 29 28  
12 hours 0.3 (0.1-0.5) 
0.4 
(0.3-0.9) 
0.4 
(0.2-0.8) 
0.5 
(0.2-0.7) 0.486 
n 27 28 29 28  
24 hours 0.3 (0.1-0.7) 
0.4 
(0.2-0.6) 
0.3 
(0.2-0.7) 
0.4 
(0.2-0.6) 0.537 
n 16 14 21 190  
48 hours 0.3 (0.1-0.6) 
0.3 
(0.2-0.8) 
0.2 
(0.1-0.9) 
0.3 
(0.1-0.6) 0.756 
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Table 3.75: IL-4 levels in the preoperative and postoperative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
IL-4 
(pg/ml) Spinal PCA p-value Volulyte Hartmann’s p-value 
Preoperative  0.4 (0.2-0.8) 
0.4 
(0.2-0.6) 0.698 
0.5 
(0.2-0.8) 
0.4 
(0.2-0.7) 0.925 
3 hours 0.3 (0.1-0.6) 
0.3 
(0.1-0.4) 0.767 
0.2 
(0.1-0.4) 
0.3 
(0.2-0.4) 0.363 
6 hours 0.3 (0.1-0.7) 
0.3 
(0.2-0.6) 0.790 
0.3 
(0.2-0.7) 
0.3 
(0.1-0.6) 0.993 
12 hours 0.4 (0.2-0.6) 
0.4 
(0.2-0.7) 0.528 
0.4 
(0.2-0.6) 
0.4 
(0.2-0.7) 0.189 
24 hours 0.3 (0.2-0.6) 
0.4 
(0.2-0.6) 0.652 
0.3 
(0.1-0.7) 
0.4 
(0.2-0.6) 0.235 
48 hours 0.3 (0.2-0.6) 
0.3 
(0.1-0.8) 0.573 
0.3 
(0.1-0.8) 
0.3 
(0.2-0.7) 0.437 
 
 
 
Figure 3.34: Median IL-4 levels for the four groups 
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Figure 3.35: Median IL-4 levels for the combined analgesia groups 
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3.2.9.11: Interleukin 8 (IL-8) 
IL-8 levels were significantly reduced in all groups in the postoperative, 
compared to preoperative periods, apart from at 12 hours in the PCA/Volulyte 
group and at 24 hours in the Spinal/Volulyte, PCA/Volulyte and 
PCA/Hartmann’s groups. There were no significant differences seen in the 
median IL-8 levels between the four groups, or the combined analgesia and 
fluid groups, see Tables 3.76 and 3.77. There were also no significant 
differences seen in the median percentage changes from the preoperative level 
for the four groups or the combined analgesia group, see Tables E.7 and E.8 
(appendix E).  
 
Figures 3.36 and 3.37 show the median IL-8 levels for the four groups and the 
combined analgesia groups. Median percentage changes from preoperative 
levels were significantly greater at 24 and 48 hours in the combined Hartmann’s 
group compared to the combined Volulyte group, see Table E.8. Figure 3.38 
shows the median IL-8 levels for the combined fluid groups. 
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Table 3.76: IL-8 levels in the pre- and post-operative period for the four 
groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
IL-8 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 30 30 30 30  
Preoperative 
69.4 
(32-243.4) 
137.6 
(40.9-581.4) 
80.2 
(28.4-237.5) 
129.4 
(35.4-296.9) 
0.485 
n 30 30 29 30  
3 hours 
25.6 
(8.1-76.1) 
24.7 
(12.6-121.3) 
28.7 
(10.4-75.2) 
26.3 
(17.3-97.3) 
0.768 
n 30 30 30 30  
6 hours 
31.4 
(17.4-106) 
28.1 
(16.9-92.1) 
30.1 
(17.1-60.5) 
37.1 
(18.3-91) 
0.951 
n 30 30 30 30  
12 hours 
41 
(21.8-65) 
35.6 
(20.1-114.5) 
40.4 
(21.1-177.2) 
42.2 
(20.1-140.8) 
0.790 
n 30 30 30 30  
24 hours 
55.2 
(27.6-187.6) 
31.8 
(13.1-74.1) 
67.5 
(26.7-273.8) 
56.4 
(25.7-199.6) 
0.161 
n 23 22 27 28  
48 hours 
28.3 
(13.7-83.9) 
22.8 
(13.3-34) 
26.4 
(10.9-71.7) 
20.8 
(13.9-41) 
0.609 
 
Table 3.77: IL-8 levels in the preoperative and postoperative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
IL-8 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Pre-
operative 
106.3 
(36.6-281) 
124.9 
(34.3-283.3) 
0.985 
76.5 
(31.2-237) 
130.5 
(38.8-461.7) 
0.135 
3 hours 
25.5 
(10.1-89.8) 
28.2 
(16.4-76.1) 
0.480 
26.2 
(10.3-74.2) 
25.3 
(15.5-97.7) 
0.538 
6 hours 
29.5 
(17-102.4) 
31.7 
(17.6-81) 
0.896 
30.7 
(17.5-83.1) 
32.2 
(17.1-90.4) 
0.832 
12 hours 
38.7 
(21.5-90) 
41.7 
(20.9-156.7) 
0.384 
41 
(21.7-88) 
38.7 
(20.6-129) 
0.896 
24 hours 
41.9 
(20-133.6) 
65.2 
(26.6-210.7) 
0.189 
61.8 
(27.7-213) 
40.1 
(20.1-135.9) 
0.134 
48 hours 
24.7 
(13.8-64.5) 
20.9 
(13-42.9) 
0.488 
26.7 
(13-73.5) 
20.9 
(14-34.3) 
0.263 
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Figure 3.36: Median IL-8 levels for the four groups 
 
 
Figure 3.37: Median IL-8 levels for the combined analgesia groups 
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Figure 3.38: Median IL-8 levels for the combined fluid groups. 
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3.2.9.12 Interleukin 10 (IL-10) 
There were no significant differences in the median IL-10 levels between the 
four groups or the combined analgesia or fluid groups, see Tables 3.78 and 
3.79. There were no significant differences in the median percentage change of 
IL-10 levels compared to preoperative levels between the four groups, see 
Table E.9 (appendix E).  
 
There was a greater negative median percentage change in the combined 
spinal group at three hours compared to the combined PCA group, see Table 
E.10 (appendix E). There was a greater increase in the median percentage 
change from the preop level in the combined Volulyte group compared to the 
combined Hartmann’s group at 12 and 24 hours, see Table E.10. Otherwise 
there were no additional differences detected. Figures 3.39, 3.40 and 3.41 show 
the median IL-10 levels overtime for the four groups and the combined 
analgesia and fluid groups. 
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Table 3.78: IL-10 levels in the preoperative and postoperative period for 
the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
IL-10 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 30 28 30 30  
Preoperative 
15.1 
(7.2-22.9) 
17.4 
(13.3-25) 
13.3 
(5-24.8) 
18.1 
(9-33.8) 
0.395 
n 29 29 29 30  
3 hours 
10.5 
(4.8-16.9) 
12.5 
(6.5-20.5) 
12 
(4.3-22.8) 
15.9 
(7.4-29.9) 
0.247 
n 29 30 28 30  
6 hours 
15.5 
(9.5-26.9) 
13.4 
(6.2-27.1) 
15.2 
(7.5-33) 
19.7 
(9.9-28.7) 
0.646 
n 30 30 30 30  
12 hours 
20 
(12.3-30.3) 
17.4 
(11.9-27.6) 
21.9 
(7.7-35.8) 
20.5 
(11.9-31.5) 
0.943 
n 30 29 29 30  
24 hours 
17.1 
(10-25.3) 
14.5 
(6.9-19.1) 
18.1 
(9.1-23.8) 
17.9 
(11.1-32.2) 
0.412 
n 21 20 26 28  
48 hours 
9.9 
(3.2-17) 
8.1 
(4.4-17.2) 
10 
(3.6-22.2) 
12.3 
(4.5-18.3) 
0.901 
 
Table 3.79: IL-10 levels in the preoperative and postoperative period for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
IL-10 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Pre-
operative 
15.8 
(9.7-24.3) 
16.1 
(7.5-28.8) 
0.94 
14.3 
(6.2-23.9) 
17.7 
(11.1-29.3) 
0.09 
3 hours 
11.4 
(5.6-19.4) 
13.8 
(6.3-24.8) 
0.159 
11.4 
(4.8-20.7) 
12.9 
(7.5-24.6) 
0.146 
6 hours 
14.7 
(6.9-26.9) 
16.2 
(9.3-29.8) 
0.280 
15.2 
(8.9-27.7) 
15.1 
(8.5-27.5) 
0.959 
12 hours 
18.8 
(12.3-29.4) 
21 
(10.9-31.9) 
0.696 
21 
(11.9-31.7) 
19.6 
(12-28.2) 
0.805 
24 hours 
14.7 
(8.7-23.6) 
18.1 
(10.4-26.8) 
0.240 
18.1 
(9.8-24.9) 
15 
(9.2-26.8) 
0.809 
48 hours 
9.3 
(4-17.1) 
11.3 
(4-20) 
0.452 
9.9 
(3.7-20) 
9.7 
(4.5-17.2) 
0.955 
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Figure 3.39: Median IL-10 levels for the four groups 
 
 
Figure 3.40: Median IL-10 levels for the combined analgesia groups 
  224 
 
Figure 3.41: Median IL-10 levels for the combined fluid groups. 
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3.2.9.13: Interleukin 12 (IL-12) 
There were no significant differences seen of the median IL-12 levels for the 
four groups or the combined analgesia and fluid groups, see Tables 3.80 and 
3.81. There was a significantly greater reduction of median percentage changes 
at 24 hours in the combined Hartmann’s group compared to the Volulyte group, 
see Table E.12 (appendix E). There were no other significant differences in 
median percentage change between the four groups or the other time intervals 
for the combined analgesia or fluid groups, see Tables E.11 and E.12. Figures 
3.42, 3.43 and 3.44 show the median IL-12 level for the four groups and the 
combined analgesia and fluid groups. 
 
Table 3.80: IL-12 levels in the pre- and post-operative period for the four 
groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
IL-12 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 30 30 30 30  
Preoperative  20.7 (10.6-31.8) 
20.9 
(10.9-31) 
18.4 
(9.3-32.5) 
22.2 
(15.1-42.6) 0.628 
n 30 30 30 30  
3 hours 10.8 (4.3-21.4) 
12.9 
(5.8-26.2) 
12.3 
(4.9-23.3) 
15.2 
(7.7-30) 0.507 
n 30 30 29 30  
6 hours 15.5 (7.3-26.8) 
12.6 
(4.4-25.9) 
16.5 
(8.2-34.6) 
17.5 
(8.1-38.3) 0.763 
n 30 30 30 30  
12 hours 24.1 (15.5-38.6) 
21.4 
(11.8-37.2) 
27.2 
(6.3-49.5) 
24.4 
(6.3-49.5) 0.965 
n 30 30 30 30  
24 hours 20.1 (9-26.3) 
10.6 
(5.9-24.6) 
17.2 
(9.1-27.7) 
17.5 
(7.1-35.7) 0.376 
n 23 21 27 28  
48 hours 10.8 (2.7-21.3) 
7.7 
(4-15.7) 
12.1 
(3.5-21.8) 
9.6 
(4.5-23) 0.866 
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Table 3.81: IL-12 levels in the preoperative and postoperative period for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
IL-12 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Pre-
operative  
20.7 
(11.3-31.3) 
20.2 
(11.6-
34.1) 
0.797 
18.5 
(10.3-
31.7) 
22.2 
(11.9-31.5) 
0.320 
3 hours 
11.1 
(4.9-24.8) 
13.3 
(7-27.5) 
0.385 
11.1 
(4.5-22) 
14.5 
(7.3-28.5) 
0.226 
6 hours 
14.2 
(6.1-25.3) 
16.8 
(8.4-35.5) 
0.348 
16.5 
(7.7-33.3) 
15.4 
(7.3-30.4) 
0.994 
12 hours 
22.3 
(14.6-38.1) 
25.3 
(9.9-42) 
0.867 
25 
(14.5-
39.3) 
22.6 
(11-37.6) 
0.627 
24 hours 
14.6 
(6.8-25.7) 
17.3 
(8.9-17.3) 
0.246 
18.5 
(9.2-26.8) 
15.2 
(6.6-28.4) 
0.368 
48 hours 
9.1 
(3.8-19.2) 
9.6 
(3.7-21.8) 
0.561 
11.5 
(3.3-21.4) 
9.5 
(4.5-18) 
0.780 
 
 
 
 
Figure 3.42: Median IL-12 levels for the four groups. 
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Figure 3.43: Median IL-12 levels for the combined analgesia groups 
 
 
Figure 3.44: Median IL-12 levels for the combined fluid groups. 
  228 
3.2.9.14: Interferon gamma (IFN-γ) 
There were no significant differences in the median IFN-γ levels between the 
four groups or the combined analgesia and fluid groups, see Tables 3.82 and 
3.83. In addition, no differences were detected in the median percentage 
change data for IFN-γ, see Tables E.13 and E.14 (appendix E). Figures 3.45 
and 3.46 show the median IFN-γ levels for the four groups and the combined 
analgesia groups. 
 
Table 3.82: IFN-γ levels in the preoperative and postoperative period for 
the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
IFN-γ 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 25 29 28 30  
Preoperative  
16 
(10.3-27.7) 
25.6 
(11-32.9) 
18.5 
(9.8-28.7) 
16.1 
(7.9-27.2) 0.693 
n 24 26 27 29  
3 hours 9.6 (6.1-24.9) 
20.6 
(7.3-27.3) 
11.7 
(5.9-24.6) 
13.8 
(8.3-21.8) 0.714 
n 28 27 27 29  
6 hours 14.9 (6.6-24.9) 
16.7 
(7.8-32.6) 
17.3 
(7.4-29.8) 
13.5 
(7.6-28.5) 0.812 
n 29 29 27 29  
12 hours 15.7 (9.1-27) 
20.2 
(9.4-35.2) 
21.9 
(13.8-36.1) 
14.4 
(6.1-29.5) 0.374 
n 28 27 28 28  
24 hours 13.6 (6.6-24.2) 
16.5 
(10.3-30.1) 
18.4 
(11.1-29) 
15.5 
(8.2-29.9) 0.681 
n 17 19 21 22  
48 hours 9.7 (4.7-25.4) 
9.9 
(4.2-29.4) 
12.4 
(5.5-36.2) 
9 
(4.2-27.8) 0.885 
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Table 3.83: IFN-γ levels in the preoperative and postoperative period for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
IFN-γ 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Preoperative  
17.3 
(10.7-
30.9) 
16.9 
(9.3-
27.2) 
0.547 
16.5 
(10.3-
28.1) 
18 
(9.5-30.5) 
0.677 
3 hours 
12.7 
(6.1-
26.4) 
13.2 
(6.8-
23.2) 
0.761 11.1 (6-24.6) 
14.1 
(8.2-26.1) 0.306 
6 hours 
16.5 
(7.1-
27.1) 
15.4 
(7.6-29) 0.915 
15.4 
(7-25) 
16.6 
(7.9-30.4) 0.429 
12 hours 
16.5 
(9.5-
30.1) 
19.1 
(9.2-
31.8) 
0.608 17.7 (9.6-30.7) 
16.8 
(8.4-32.4) 0.685 
24 hours 
16 
(8.2-
29.4) 
17.5 
(10.8-
29.9) 
0.461 16.7 (9.6-26.2) 
16.5 
(9.6-29.9) 0.811 
48 hours 
9.8 
(4.4-
26.6) 
12.2 
(4.4-
32.6) 
0.679 12 (5-26.7) 
9.9 
(4.2-28) 0.596 
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Figure 3.45: Median IFN-γ levels for the four groups. 
 
 
Figure 3.46: Median IFN-γ levels for the combined analgesia groups 
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3.2.9.15: Tumour necrosis factor alpha (TNF-α) 
There were no significant differences in the median TNF-α levels between the 
four groups or the combined analgesia and fluid groups, see Tables 3.84 and 
3.85. A significant difference was measured in the median percentage change 
between the four groups at six hours compared to preoperative levels, see 
Table E.15 (appendix E). However pairwise comparisons failed to identify a 
significant difference between any of the groups. In addition a significantly 
greater TNF-α median percentage change compared to preoperative levels was 
measured in the combined PCA group compared with the combined spinal 
group, see Table E.16. Figures 3.47 and 3.48 show the median TNF-α levels for 
the four groups and the combined analgesia groups. 
 
Table 3.84: TNF-α levels in the pre- and post-operative period for the four 
groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
TNF-α 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 21 27 25 23  
Preoperative  
3 
(1.8-7.5) 
2.7 
(1.4-7.1) 
1.8 
(1-4.3) 
2.9 
(1.5-5.6) 
0.405 
n 20 23 24 22  
3 hours 
2.7 
(0.9-6.4) 
2.8 
(0.7-4.9) 
1.9 
(0.9-3.7) 
2.8 
(1.4-5.6) 
0.795 
n 27 21 26 24  
6 hours 
2.9 
(1.4-6.9) 
3.3 
(1.5-13.5) 
3.5 
(1.4-6.2) 
3.1 
(1-5.7) 
0.713 
n 28 26 25 27  
12 hours 
3 
(1.5-5.4) 
3.1 
(1.3-10.2) 
2.9 
(1.5-6.9) 
2.8 
(1.8-3.6) 
0.953 
n 26 24 28 26  
24 hours 
3.9 
(1.3-5.6) 
3.6 
(1.2-7.6) 
3.2 
(1.7-7.6) 
3.3 
(1.8-6.4) 
0.928 
n 17 17 18 20  
48 hours 
2.8 
(1.6-5.4) 
2.7 
(1.3-4.4) 
4.1 
(0.9-6) 
1.8 
(0.7-4.2) 
0.541 
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Table 3.85: TNF-α levels in the pre- and post-operative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
TNF-α 
(pg/ml) Spinal PCA p-value Volulyte Hartmann’s p-value 
Preoperative  2.9 (1.5-7) 
2.2 
(1.4-4.7) 0.259 
2.6 
(1.2-5.8) 
2.7 
(1.5-6) 0.538 
3 hours 2.8 (0.8-4.9) 
1.9 
(1.2-4.9) 0.984 
2 
(0.9-4.2) 
2.8 
(1.1-5.2) 0.646 
6 hours 3.1 (1.5-7.5) 
3.3 
(1.3-5.8) 0.604 
3.3 
(1.4-6.7) 
3.3 
(1.4-7.2) 0.708 
12 hours 3 (1.4-7) 
2.8 
(1.5-5.3) 0.788 
2.9 
(1.5-5.6) 
2.8 
(1.4-6.8) 0.872 
24 hours 3.9 (1.3-6.6) 
3.3 
(1.8-7.1) 0.560 
3.4 
(1.4-7) 
3.3 
(1.7-6.9) 0.728 
48 hours 2.7 (1.5-4.3) 
2.3 
(0.9-5.4) 0.800 
3.5 
(1.1-5.8) 
2.4 
(0.9-4.3) 0.237 
 
 
 
Figure 3.47: Median TNF-α levels for the four groups. 
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Figure 3.48: Median TNF-α levels for the combined analgesia groups 
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3.2.9.16: Vascular endothelial growth factor (VEGF) 
There were no significant differences in the median VEGF levels between the 
four groups or the combined analgesia or fluid groups, see Tables 3.86 and 
3.87. A significant difference was measured between the four groups in the 
median percentage change at three hours compared with preoperative levels, 
see Table E.17 (appendix E). Pairwise comparisons identified a significant 
difference between the spinal/Volulyte and spinal/Hartmann’s groups and the 
spinal/Volulyte and PCA/Volulyte groups. A significantly greater reduction was 
measured in the combined Hartmann’s group compared with the combined 
Volulyte group at 48 hours, see Table E.18. There were no further significant 
differences seen. Figures 3.49, 3.50 and 3.51 show the median VEGF levels for 
the four groups and the combined analgesia and fluid groups. 
Table 3.86: VEGF levels in the pre- and post-operative period for the four 
groups. Median values with interquartile ranges. p-value for multiple 
groups determined by an Independent-samples Kruskal-Wallis test. 
VEGF 
(pg/ml) 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s p-value 
n 30 30 30 30  
Preoperative  
119 
(90-196) 
138 
(70-179) 
99 
(65-219) 
146 
(88-234) 
0.715 
n 30 30 30 30  
3 hours 
62 
(40-131) 
81 
(54-162) 
92 
(48-167) 
92 
(58-181) 
0.216 
n 30 30 30 30  
6 hours 
96 
(61-167) 
90 
(50-185) 
104 
(69-224) 
132 
(80-180) 
0.649 
n 30 30 30 30  
12 hours 
148 
(113-223) 
144 
(97-144) 
190 
(78-301) 
171 
(87-243) 
0.687 
n 30 30 30 30  
24 hours 
132 
(81-217) 
83 
(60-155) 
145 
(92-205) 
169 
(73-217) 
0.144 
n 22 22 28 28  
48 hours 
85 
(52-166) 
59 
(39-124) 
84 
(48-171) 
83 
(39-132) 
0.644 
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Table 3.87: VEGF levels in the pre- and post-operative period for the 
combined analgesia and fluid groups. Median values with interquartile 
ranges. 
VEGF 
(pg/ml) Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
Pre-
operative  
129 
(75-179) 
127 
(79-216) 0.602 
116 
(80-200) 
141 
(73-204) 0.676 
3 hours 72 (48-144) 
92 
(55-175) 0.125 
79 
(44-142) 
86 
(56-165) 0.194 
6 hours 94 (58-169) 
113 
(72-206) 0.257 
98 
(62-190) 
112 
(56-179) 0.830 
12 hours 146 (104-213) 
182 
(86-277) 0.702 
170 
(101-
270) 
147 
(90-210) 0.248 
24 hours 111 (65-200) 
147 
(91-212) 0.103 
138 
(91-213) 
124 
(61-201) 0.276 
48 hours 63 (43-145) 
84 
(48-152) 0.588 
84 
(49-166) 
65 
(39-131) 0.293 
 
 
Figure 3.49: Median VEGF levels for the four groups 
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Figure 3.50: Median VEGF levels for the combined analgesia groups. 
 
Figure 3.51: Median VEGF levels for the combined fluid groups 
  237 
3.3 Retrospective analysis of the effect of postoperative 
analgesia on survival in patients after laparoscopic 
resection of colorectal cancer 
The mainstay of treatment for cancer is surgical resection. However surgery 
itself has the potential to promote the development of metastases and reduce 
subsequent survival. Surgery can promote metastatic disease due to 
inappropriate tumour handling leading to seeding, removing inhibition of 
residual disease by removal of the primary tumour, release of growth factors 
such as vascular endothelial growth factor, and, perhaps most importantly, 
immunosuppression (Snyder, & Greenberg 2010). Major surgery suppresses 
cell-mediated immunity, in particular natural killer cells, which are important 
during the peri- and post-operative period to reduce micrometastatic formation  
(Ben-Eliyahu 2003).  
 
There has been recent interest in the effect post-operative analgesia may have 
on disease recurrence and survival following cancer surgery  (Exadaktylos et al 
2006; Biki et al 2008; Christopherson et al 2008; Myles et al 2011; Ahlers et al 
2008; Gupta et al 2011). Post-operative pain relief usually involves a choice of 
either regional analgesia or systemically administered opiates, normally 
morphine. Morphine can produce immunosuppression by inhibiting components 
of the immune system such as a reduction in natural killer cell activity and 
altering cytokine expression (Afsharimani et al 2011). Regional analgesia 
(spinal or epidural) causes a sympathetic blockade, which is thought to 
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attenuate the neuro-endocrine stress response and preserve cellular immunity  
(Kurosawa, & Kato 2008). 
 
Two retrospective studies for breast (Exadaktylos et al 2006) and prostate (Biki 
et al 2008) cancer have identified a potential reduction in disease recurrence 
with the use of regional analgesia. A randomized study for colon cancer has 
also identified an enhanced survival with the use of epidural analgesia but only 
up to 1.46 years post-surgery (Christopherson et al 2008). However two other 
retrospective series have identified no benefit with epidural analgesia for cancer 
recurrence following major abdominal cancer surgery (Myles et al 2011) and 
colorectal cancer surgery (Gottschalk et al 2010). 
 
As the current evidence is limited and conflicting a retrospective analysis of 
patients undergoing laparoscopic colorectal surgery for bowel cancer was 
performed. It was hypothesised that regional analgesia (epidural and spinal) 
would provide a survival advantage in colorectal cancer resection over 
morphine based patient controlled analgesia. 
 
3.3.1 Methods 
A retrospective study of all patients undergoing laparoscopic colorectal 
resections for bowel cancer between October 2003 and December 2010 was 
performed. Necessary data were gathered from a prospectively kept database, 
the patients’ clinical records, electronic patient records and by contacting the 
primary care doctor as appropriate.  
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The treatment plan for patients was decided by consensus opinion at the local 
multi-disciplinary team (MDT) meeting; where appropriate imaging, histology 
and patient history were reviewed. Laparoscopic resections were either 
performed or supervised by two consultant laparoscopic colorectal surgeons in 
one hospital. The dissection was in a standard medial to lateral approach, with 
early division of the vessels. The specimen was extracted through an incision in 
the abdominal wall, protected by a wound protector, just large enough to allow 
specimen extraction. If an incision was made larger than that required for 
specimen extraction this was considered a conversion. If chemotherapy was 
considered appropriate by the MDT, this was administered locally. 
 
The primary post-operative analgesia was determined either by the 
anaesthetist, patient preference or by randomisation if enrolled in a trial. During 
the time period analysed two randomized trials were conducted: NCT 18926278 
and NCT01128088. Ethical approval was given for these trials from the local 
ethics committee. Epidural analgesia involved placement of a catheter between 
T9 and T12, with a bolus of 10 ml 0.2% bupivacaine with 100 µg fentanyl. An 
infusion of 0.15% bupivacaine with 0.0002% fentanyl was then commenced at 
4-8 ml/h as tolerated throughout surgery and for the first 48 hours post-
operatively. Spinal analgesia involved insertion of 2.5 ml 0.5% hyperbaric 
bupivacaine with 0.25 mg diamorphine at the L2-3 or L3-4 interspace with the 
patient sitting before induction. Patients receiving patient-controlled analgesia 
(PCA) were given 10 mg of morphine during surgery and then attached to a 
pump to deliver a 1mg bolus on demand with a maximum of 20 mg every 4 
hours. In addition it is standard practice within the hospital for patients to 
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receive intra-operative goal directed fluid administration with oesophageal 
Doppler monitoring. Patients would also not routinely receive dexamethasone. 
 
Survival and recurrence were calculated from the time of operation to event. 
The data was analysed using PASW Statistics Version 18.0. Categorical 
variables were analysed using a Pearson Chi-Squared test, parametric data 
were analysed using a one-way ANOVA and non-parametric data were 
analysed using an Independent samples Kruskal-Wallis test and an 
independent samples median test. Survival analysis was performed using the 
Kaplan-Meier survival function with a log rank test to assess significance.  The 
Null hypothesis was rejected when p<0.05. 
 
3.3.2 Results 
During the time period analysed there were a total of 457 elective laparoscopic 
colorectal resections performed for colorectal adenocarcinoma. Of these, 33 
were excluded from analysis because they received oral analgesia only (n=6), 
intravenous morphine not via a PCA (n=19) and information was missing  (n=8). 
This left 424 cases suitable for analysis divided as: epidural (107), spinal (144), 
PCA (173), see Figure 3.52. The various analgesia methods were not 
distributed evenly over the time period analysed as shown by Table 3.88. This 
reflects the median follow up times of 37 months for the epidural group, 28 
months for the PCA group and 17 months for the spinal group. 
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Figure 3.52: Consort flow diagram of patient selection: 
 
Table 3.88: Distribution of analgesia methods administered over the time 
period studied: 
Year Epidural Spinal PCA 
2003 2 0 2 
2004 6 0 18 
2005 24 5 22 
2006 21 7 14 
2007 10 15 31 
2008 23 25 21 
2009 16 44 24 
2010 5 48 41 
Assessed for eligibility 
n = 457 
Excluded n = 33 
Oral analgesia only n = 6 
IV morphine not via PCA n= 19 
Missing data n= 8 
Suitable for analysis 
n= 424 
Epidural 
analysed 
n= 107 
Spinal 
analysed 
n= 144 
PCA 
analysed 
n= 173 
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Table 3.89 shows the basic patient characteristics for the three groups. There 
was no significant difference between the groups for age, gender or rate of 
conversion (p=0.229). There was a significant difference in the distribution of 
ASA classification between the groups (p=0.006); the epidural group had a 
greater proportion of ASA category 3 patients. The median length of stay was 
significantly longer in the epidural group at five days compared with the spinal 
and PCA groups at three days (p<0.0005). Table 3.90 shows the distribution of 
operations performed for the three groups. Whilst there was no significant 
difference, the epidural group does have the largest number of abdomino-
perineal resections. If all patients receiving a stoma (defunctioning or end) were 
removed and the length of stay re-analysed, there was still a significantly longer 
length of stay (p=0.0005) in the epidural group (four days) compared with the 
spinal (three days) and PCA (three days) groups. Table 3.91 shows the major 
complications that occurred for the three groups. The percentage of patients 
receiving a post-operative blood transfusion prior to discharge is also shown. 
 
Table 3.89: Patient Characteristics:  
 PCA (n=173) 
Spinal 
(n=144) 
Epidural 
(n= 107) p 
Age 
(mean) 70 70 72  
Male 90 (52%) 70 (49%) 60 (56%) 
 Female 83 74 47 
ASA 1 22 (13%) 22 (15%) 6 (6%) 
0.006 ASA 2 126 (73%) 103 (72%) 75 (70%) 
ASA 3 25 (14%) 19 (13%) 26 (24%) 
Median 
length of 
stay (range) 
3 
(1-43) 
3 
(1-59) 
5 
(2-30) <0.0005 
Conversion 9 (5%) 5 (4%) 9 (8%) 0.229 
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Table 3.90: Distribution of operations performed: 
 PCA (n=173) 
Spinal 
(n=144) 
Epidural 
(n= 107) p 
Anterior Resection (TME) 14 24 14 
0.071 
High Anterior Resection 53 42 18 
Right Hemi 68 53 40 
Left colonic resection 29 22 11 
APER 4 0 18 
Subtotal Colectomy 1 0 1 
Panproctocolectomy 1 1 4 
Hartmann’s 2 0 1 
Right Hemi and Anterior Resection 1 2 0 
 
Table 3.91: Major Complications and Transfusion: 
 PCA Spinal Epidural 
Anastomotic 
Leak 1.7% (3/173) 3.5% (5/144) 3.7% (4/107) 
Bleed 0.6% (1/173) 1.4% (2/144) 0% (0/107) 
Ischaemic 
Stoma 0 0.7% (1/144) 0 
Abscess 0 0 1.9% (2/107) 
PE 1.2% (2/173) 0 1.9% (2/107) 
MI 0 0.7% (1/144) 0.9% (1/107) 
Arrythmias 0 1.4% (2/144) 0.9% (1/107) 
Haemolytic 
Anaemia 0 0.7% (1/144) 0 
Pneumonia 0.6% (1/173) 0 1.9% (2/107) 
Renal 
Failure 0.6% (1/173) 0 0 
Patients 
requiring blood 
transfusion 
(p=0.265) 
9.8% (17/173) 10.4% (15/144) 15.8% (17/107) 
 
Table 3.92 categorises the staging of the resected specimens using the TNM 
(Tumour, Node and Metastasis) classification. There was no significant 
difference between the three groups for T stage (p=0.513), N stage (p=0.081), 
M stage (p=0.450), tumour differentiation (p=0.697), extramural venous 
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invasion (p=0.199) or lymphovascular invasion (p=0.675). There was no 
significant difference between the three groups in the number of lymph nodes 
resected with the specimen (p=0.055) and the mean number of positive lymph 
nodes if N1/N2 (p=0.224), see Table 3.93. 
 
Table 3.92: TNM Staging: 
 PCA (n=173) 
Spinal 
(n=144) 
Epidural 
(n=107) p 
T0 3 (2%) 1 (1%) 3 (3%) 
0.513 
T1 21 (12%) 17 (12%) 11 (10%) 
T2 20 (11%) 18 (12%) 13 (12%) 
T3 95 (55%) 90 (63%) 67 (63%) 
T4 34 (20%) 18 (12%) 13 (12%) 
N0 96 (56%) 96 (67%) 66 (62%) 
0.081 N1 45 (26%) 32 (22%) 27 (25%) 
N2 32 (18%) 16 (11%) 14 (13%) 
M0 154 (89%) 133 (92%) 94 (88%) 
0.450 M1 19 (11%) 11 (8%) 13 (12%) 
Gx 2 (1%) 0 3 (3%) 
0.697 
G1 0 0 3 (3%) 
G2 118 (68%) 101 (70%) 60 (56%) 
G3 53 (31%) 43 (30%) 41 (38%) 
V0 125 (72%) 112 (78%) 87 (81%) 
0.199 
V1 48 (28%) 32 (22%) 20 (19%) 
L0 126 (73%) 107 (74%) 83 (78%) 
0.675 L1 47 (27%) 37 (26%) 24 (22%) 
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Table 3.93: Analysis of lymph node harvest: 
 PCA (n=173) 
Spinal 
(n=144) 
Epidural 
(n=107) p 
Mean LN 
harvest 
(SD) 
25 
(11.7) 
27 
(12) 
24 
(11.3) 0.055 
Mean number of 
positive LN if 
N1/N2 
(SD) 
4.6 
(4) 
3.5 
(3.5) 
3.7 
(3.5) 0.224 
CRM 
involvement in 
rectal cancer 
1 (2.7%) 0 (0%) 1 (2.3%) 0.673 
 
There was no significant difference detected between the three groups in 
overall survival for all patients (p=0.622), see Figure 3.53. The five-year overall 
survival following laparoscopic colorectal resection for epidural, spinal and PCA 
groups was 69.4%, 78.2% and 77.0% respectively. If the extranodal metastatic 
patients are removed and only those with Dukes A, B or C pathology were 
analysed there was still no significant difference between the three groups for 
overall survival (p=0.284). The five-year overall survival following laparoscopic 
colorectal resection for Dukes A, B or C patients for epidural, spinal and PCA 
groups was 75.8%, 78.2% and 82.8% respectively. In addition there was no 
significant difference detected in disease free survival for the three groups 
(p=0.490), see Figure 3.54. The five-year disease-free survival following 
laparoscopic colorectal resection for epidural, spinal and PCA groups was 72%, 
76% and 72% respectively. 
 
To allow for potential confounding effects of various covariates, a cox 
regression analysis was performed, including all statistically significant 
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covariates. The covariates gender, T-stage and ASA classification were not 
significant. The following covariates were significant: N-stage (p<0.0005), M-
stage (<0.0005), transfusion (p=0.017), conversion (p=0.006) and age 
(p=0.008). Using all significant covariates in the cox regression analysis along 
with the three analgesia methods studied, no significant difference in survival 
was found between the three groups (p=0.75). 
 
  
No. at risk 
Spinal 144 74 33 8 2 0 0 
PCA 173 116 78 43 25 5 0 
Epi 107 90 56 38 12 2 0 
 
Figure 3.53: Kaplan-Meier overall survival curves for the spinal, PCA and 
epidural groups, log rank: p=0.622 
 
 
 
 
  247 
 
  
No. at risk 
Spinal 132 59 28 8 1 0 0 
PCA 154 101 70 37 21 5 0 
Epi 94 80 47 34 10 2 0 
 
Figure 3.54: Kaplan-Meier disease-free survival curves for the spinal, PCA 
and epidural groups, log rank: p=0.490 
 
3.3.3 Discussion 
While surgical resection is essential in the treatment of colorectal cancer it has 
potential negative consequences. The immunosuppression that accompanies 
surgery in the peri- and post-operative period may have an effect on disease 
recurrence and subsequent survival. Suppression of cellular immunity and 
reduced natural killer cell numbers and function may allow micrometastatic 
disease to develop (Ben-Eliyahu 2003).  Any action that can attenuate this 
effect would be extremely valuable.  
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Initial research into regional analgesia focused on the short-term benefits that 
could be achieved in open colorectal surgery (Kehlet, & Holte 2001). Epidural 
analgesia reduces the stress response and preserves natural killer cell 
cytotoxicity in open colectomy (Koltun et al 1996). In addition, epidural 
analegesia during surgery as well as in the post-operative period further 
attenuates the immunosupression (Ahlers et al 2008). If regional analgesia 
techniques are not employed then opiate-based analgesia (usually morphine) is 
used. This itself can produce immunosuppression by reducing natural killer cells 
and altering the balance of cytokines (Afsharimani et al 2011). 
  
Experimental work on mice and rats has examined post-operative immune 
function and metastatic formation. A spinal block administered to rats 
undergoing laparotomy attenuated the promotion of lung tumour development 
following inoculation compared to general anaesthesia alone (Bar-Yosef et al 
2001). Interestingly there was no attenuation in the reduction of natural killer 
cells. Wada et al has also shown a greater reduction in the formation of 
metastases following laparotomy in mice when accompanied by a spinal block  
(Wada et al 2007).  
 
Retrospective studies have investigated the effect regional analgesia may have 
on disease recurrence and survival in different cancers. Biki et al (Biki et al 
2008) showed a 57 % lower risk of recurrence (using prostate-specific antigen 
as a marker of biochemical recurrence) with epidural analgesia compared to 
morphine analgesia following open radical prostatectomy surgery. The study 
was not randomized and the epidural group had a greater number of clear 
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margins on the resection package, that just failed to reach significance 
(p=0.06). Exadaktylos et al (Exadaktylos et al 2006) examined patients 
undergoing breast cancer surgery and compared disease recurrence for 
patients given paravertebral analgesia with those given morphine analgesia. 
There was a significant recurrence-free survival of 94% with paravertebral 
analgesia and 77% with morphine analgesia at 3 years (p<0.05). 
 
Two retrospective studies have measured the effect of epidural analgesia 
compared to morphine analgesia on recurrence and survival following colorectal 
cancer surgery. Gottschalk et al (Gottschalk et al 2010) found no decrease in 
cancer recurrence with epidural analgesia, except for a potential benefit in older 
patients. Gupta et al (Gupta et al 2011) identified a significant reduction in all-
cause mortality after rectal cancer resection with epidural usage, but not in 
colonic cancer. Caution must be taken, as the numbers in the rectal group 
receiving morphine PCA (n= 35) were very small in comparison to the epidural 
group (n=260). Our own study with the rectal subgroup found no difference in 
overall survival (p=0.749) between the three groups; epidural (n=44), spinal 
(n=30) and PCA (n=36). 
 
Two further studies have used data from randomised trials using short-term 
outcomes for epidural analgesia (Christopherson et al 2008; Myles et al 2011). 
Christopherson et al identified enhanced survival among patients with non-
metastatic colon cancer receiving epidural analgesia, but only up to 1.46 years; 
thereafter no advantage was seen for long-term survival. Myles et al showed no 
difference in recurrence-free survival with the use of epidural analgesia in 
  250 
patients undergoing major abdominal cancer surgery. Whilst their study 
incorporated a number of different tumour types, there were reasonable 
numbers to allow a subgroup analysis of those patients with colon cancer. They 
still did not identify any advantage with the use of epidural analgesia. 
 
Our retrospective study, with an adequate cohort of patients, identified no 
overall or disease-free survival advantage with the use of regional analgesia 
(spinal or epidural) in patients undergoing laparoscopic colorectal cancer 
resection. Even with the removal of patients with extranodal metastases from 
analysis no survival advantage was seen. There are obviously limitations to this 
study due to its retrospective nature. Patients were not randomized, although 
during the time period reviewed there have been two separate randomized 
controlled trials (NCT 18926278 and NCT01128088) that measured short-term 
outcomes of analgesia in laparoscopic colorectal surgery. These two trials 
accounted for 24% of patients in the analysis. Accurate data on the median 
dose of morphine (0 mg and 40 mg for the spinal and PCA groups respectively) 
administered is available from trial NCT18926278, which provides a fair 
representation of the care of non-trial patients. 
 
The epidural group had a greater number of ASA category 3 patients, which 
may have contributed to the trend in reduced overall survival. As seen from 
Table 3.88, epidural usage has reduced significantly in recent years due to the 
results obtained from a RCT conducted in my unit showing a longer length of 
stay with epidural analgesia compared to spinal or PCA analgesia (Levy et al 
2011). There is evidence that blood transfusion may have an 
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immunosuppressive effect  (Ben-Eliyahu 2003), however our analysis showed 
no significant difference (p=0.265) in the number of patients receiving a blood 
transfusion during the post-operative period. The majority of those patients that 
were transfused were not as a result of blood loss, but instead in an effort to 
optimise oxygen delivery secondary to anaemia resulting from their cancer. It is 
worth noting that the epidural group did have a higher rate of transfusion; 
probably is reflection of the number of co-morbidities that lie within this group. 
 
All studies published so far have investigated patients undergoing open surgery 
and not via a laparoscopic approach. Our study has looked only at those 
receiving laparoscopic colorectal resections. The reason we did not identify a 
survival advantage with the use of regional analgesia may be due to the 
laparoscopic approach. Laparoscopy reduces the immunosuppression that 
occurs during the post-operative period compared to that at open colorectal 
resection (Evans et al 2009). If a significant preservation of immune function is 
occurring with laparoscopic colorectal resection the choice of analgesia used 
may be less important. 
 
Overall, our study has identified no overall or disease-free survival advantage 
with the use of regional analgesia in laparoscopic colorectal surgery versus the 
use of PCA. The results of current RCTs are awaited. 
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4 Discussion 
4.1.1 The stress response  
Enhanced recovery programs in colorectal surgery confer significant benefits 
with respect to patient care and outcome (Varadhan et al 2010). Significant 
reductions of length of stay and post-operative complications are possible with 
the correct implementation of an enhanced recovery pathway (Varadhan et al 
2010). The majority of this research has been conducted on patients 
undergoing open resections rather than laparoscopic surgery. There has only 
been one randomized trail in patients undergoing segmental resection of colon 
cancer that has identified a significant reduction of length of stay for 
laparoscopic surgery in comparison to open surgery within an enhanced 
recovery pathway (Vlug et al 2011b).  
 
The positive benefits of thoracic epidural analgesia in open colorectal surgery is 
evidence based (Kehlet, & Holte 2001; Fotiadis et al 2004; Marret et al 2007). 
One of the proposed benefits of such an analgesic regime is suppression of the 
post-operative stress response (Holte, & Kehlet 2002a), which would be 
reflected by a reduction of post-operative complications and length of stay. 
However, its application to laparoscopic colorectal surgery has not been 
rigorously evaluated. Shorter lengths-of-stay can be achieved with the use of 
spinal analgesia or patient controlled analgesia (PCA) compared to epidurals  
(Levy et al 2011). Certainly at The Royal Surrey County Hospital, where this 
study was conducted, thoracic epidurals for analgesia are no longer used as 
this delays discharge in our cohort of patients. Overall, there are few robust 
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data available on the stress response following laparoscopic colorectal surgery 
within an enhanced recovery program.  
 
We therefore aimed to quantify the stress response in our cohort of patients and 
also identify any variability that may exist between spinal analgesia and 
morphine based PCA. The null hypotheses that the study was designed to test 
were: that the choice of analgesia had no effect on the post-operative stress 
response, length of stay or amount of morphine required post-operatively. In 
addition the study generated data on intravenous fluid administration with the 
oesophageal Doppler monitor. The null hypotheses that the study tested were: 
there would be no effect on the number of complications, length of stay and that 
a predictive narrow volume range and not the ODM is all that was required for 
fluid administration. 
 
Patients were randomised to receive either a morphine PCA or spinal analgesia 
and either Hartmann’s solution or 6% Volulyte as the intravenous fluid 
administered as guided by the ODM. All patients underwent a laparoscopic 
colorectal resection within an established enhanced recovery program. A 
number of physiological and biochemical parameters were measured in order to 
test the hypotheses listed in section 1.10. These data are discussed in the 
following sections so that any conclusions can be easily applied to the clinical 
setting. They focus on the stress response following laparoscopic colorectal 
surgery, the validity of the ODM, the difference between crystalloid and colloid 
and the effect of analgesia on the measured physiological parameters and 
patient outcomes. 
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4.1.2 Primary outcome – IL-6 
The study was powered on IL-6, as data was available from a pilot study using 
only this cytokine. No difference was seen in median IL-6 values between the 
four groups and between the combined analgesia and fluid groups. The post-
operative median values of IL-6 at all the measured time intervals in all the 
groups were significantly greater than the baseline pre-operative values. In this 
study the peak of median IL-6 values was at six hours in patients who received 
spinal analgesia and then the levels returned to near normality by 48 hours. In 
those patients receiving a PCA there was a plateau of median IL-6 values 
between the six and 24 hours time intervals with values being similar to those 
measured in the spinal group at 48 hours. 
 
The actual post-operative rise, however, was relatively small in comparison with 
data that has been previously published following open colorectal surgery  
(Harmon et al 1994), were the IL-6 peak can be higher and the rise last longer  
(Mehigan et al 2001). This probably reflects the reduced abdominal wall trauma 
that is achievable with laparoscopic surgery and possibly the quicker post-
operative recovery time. 
 
The choice of post-operative analgesia had no significant effect on the post-
operative inflammatory response as measured by IL-6 in this study. The null 
hypothesis proposed at the start of the study that the choice of analgesia would 
have no effect on the post-operative stress response is therefore accepted In 
part, as reflected in the inflammatory element of this response. 
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4.1.3 Inflammatory response 
No significant differences were measured in the concentrations of IL-2, -4, -8, -
10, -12, IFN-γ, TNF-α or VEGF over the time periods measured between 
patients receiving spinal analgesia or morphine PCA within an enhanced 
recovery program. Despite this there are some interesting aspects of these 
data.  
 
IL-2 could be measured in only 25% of the patients within our study both in pre-
operative and post-operative samples. Moreover, there was no significant 
difference between the spinal analgesia and PCA groups at any time period. 
This represents a limitation of the assay we used to detect the IL-2 that were 
present in this study. The assay has a limit of detection of <1 pg/ml. 
 
IL-4 has also been shown to increase in the post-operative period after open 
surgery (Ishikawa et al 2009). However, in this study no such significant 
increase or difference was measured in either the spinal analgesia or PCA 
groups. IL-4 is a cytokine that down-regulates the effect of pro-inflammatory 
mediators (Lin et al 2000). As such the lack of any change may reflect a 
reduced pro-inflammatory response, which was also demonstrated by the low 
levels of IL-6 after laparoscopic surgery. 
 
IL-8 is a pro-inflammatory cytokine and has been proposed to rise post-
operatively (Lin et al 2000). However, this study detected a median reduction of 
IL-8 in both the spinal analgesia and PCA groups that persisted up to 48 hours 
after surgery. However, because of the significant variability of the data these 
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differences were not significant. One other study has identified a similar finding 
in laparoscopic colonic surgery (Wu et al 2003). The lack of an increase in the 
post-operative period may again reflect a reduced pro-inflammatory response 
with laparoscopic surgery, but the relevance of any prolonged suppression is 
unclear. There was no significant difference detected between the spinal or the 
PCA groups at any time point.  
 
IL-10 is a recognized modulator of the pro-inflammatory response driven by IL-6 
following surgery (Lin et al 2000). IL-10 median concentrations however did not 
follow the trend of IL-6 results as a transient increase in the early post-operative 
period. Rather there was a small median reduction after 3 hours that failed to 
achieve significance and small median, but still non-significant, increase after 
12 hours. No difference in response was detected between the spinal analgesia 
and PCA groups. Therefore if IL-10 was a reflection of IL-6 changes this was 
not observed here and further supports the relatively small IL-6 changes after 
laparoscopic compared with open surgery.  
 
IL-12 is also a pro-inflammatory cytokine (Lin et al 2000). The levels of 
response were similar to IL-10 with no significant difference between pre- and 
post-operative intervals, albeit with similar median changes.  
 
IFN-γ levels changed very little from the pre-operative control period in all the 
groups, with no difference between the groups. IFN-γ is pro-inflammatory (Lin et 
al 2000) and the lack of change in levels probably reflects the reduced stimulus 
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that laparoscopic surgery has on the inflammatory elements of the stress 
response. 
 
TNF-α is one of the first cytokines to be released and to stimulate any post-
operative inflammatory response (Lin et al 2000). In this study no significant 
changes were observed in the post-operative interval and also there were no 
differences between the spinal analgesia and PCA groups. TNF-α has a very 
short half-life (Lin et al 2000) and so a lack of change at the 3 hours post-
operative time point may result from an immediate release that was degraded 
before the first post-operative collection time point. Alternatively, it may be a 
reflection of the reduced and shortened inflammatory response that occurs with 
laparoscopic surgery. Certainly large and persistent TNF-α rises are associated 
with significant inflammatory processes seen in patients in intensive care units  
(Jawa et al 2011). 
 
VEGF is a growth factor released in response to inflammation (Angelo, & 
Kurzrock 2007). The pattern of response was similar to that of IL-10 and IL-12 – 
small but non-significant changes to median levels 3 hours after operation with 
a small but insignificant median rise at a later time (12 hours post-operative). 
VEGF has an angiogenic action (Angelo, & Kurzrock 2007) and elevated levels 
are associated with subsequent metastatic development and a poorer 
prognosis in cancer (Evans et al 2006) and may have implications in metastatic 
development in colorectal cancer. It could be hypothesised that an attenuated 
rise in VEGF, with laparoscopic colorectal surgery, could have a beneficial 
effect on long-term survival. 
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No significant difference was identified in the post-operative inflammatory 
process following laparoscopic colorectal surgery between either spinal 
analgesia or morphine PCA. This indicates that the use of regional analgesia to 
block the spinal afferents will not alter the inflammatory response generated by 
surgery. An additional benefit of spinal analgesia is to reduce the amount of 
systemic morphine required post-operatively, as recorded in this study. 
Morphine may have immunosuppressive properties (Afsharimani et al 2011) but 
no evidence of this in the amounts used in this study was observed.  
 
The magnitude of the inflammatory response detected in this study was 
reduced in comparison to that shown in available data on open colorectal 
surgery in the current literature (Sammour et al 2010). Our cohort of patients 
exhibited an inflammatory response that was reduced in magnitude and time. 
This is reflected by the short length of stay achieved across the whole study 
with a median length of stay being 2.7 days this is in comparison to a published 
median length-of-stay of 8 days following open surgery (King et al 2006). 
 
Thus, laparoscopic colorectal surgery produces a small and truncated 
inflammatory response post-operatively compared with open surgery, and the 
choice of spinal analgesia or morphine PCA does not affect this response. 
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4.1.4 Endocrine and Metabolic response 
The endocrine/metabolic response following surgery was monitored with 
measurement of the following elements: cortisol, insulin, glucose and insulin 
resistance. The only difference that was detected was a significant attenuation 
of the increase of cortisol and glucose that was measured at three hours from 
the start of surgery in those patients receiving spinal analgesia compared with 
morphine PCA. The rest of the time intervals showed no significant difference 
between the two groups for all variables measured. There were, however, some 
interesting changes overall. 
 
Following surgery hyperglycaemia was an expected finding, occurring in 
patients receiving both spinal analgesia and PCA. This could be due to a 
change in the stress hormones, such as cortisol, generating a predominately 
catabolic phase, with increased gluconeogenesis and reduced glucose uptake 
in the cells. For the study group as a whole, the post-operative glucose levels 
rose significantly from a median pre-operative level of 5.6 mmol/l to 7.1 mmol/l 
at 48 hours from the start of surgery. The degree of hyperglycaemia following 
laparoscopic colorectal surgery is relatively small compared with open surgery  
(Wang et al 2010), which may have a positive effect on recovery and wound 
healing. The increase of glucose at three hours was significantly less in the 
spinal analgesia group compared with the PCA group, but it is unclear if this 
difference is clinically significant. This small rise of post-operative glucose 
concentration, and the difference between the two groups at three hours may 
be reflected in cortisol levels over the same course. 
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Cortisol is known to rise following surgery, due predominately to stimulation of 
the HPA axis via activation of the spinal afferents (O'Connor et al 2000). In this 
study the rise of cortisol peaked at six hours and three hours in the spinal 
analgesia and PCA groups respectively. There was a significant reduction in 
this rise at three hours in patients receiving spinal analgesia compared to 
morphine PCA and the level was also less at six hours but not significantly so. 
By 12 hours from the start of surgery the cortisol levels had returned to the pre-
operative values. It appears that activation of the HPA axis, as represented by 
cortisol release, is minimal and short-lived following laparoscopic colorectal 
surgery. With reduced cortisol secretion comes a reduction in the catabolic 
post-operative phase, which is represented by the small rise in glucose seen in 
this study. The use of spinal analgesia attenuates this further in the immediate 
post-operative period.  
 
Insulin release is suppressed following surgery (Ljungqvist et al 2000) and so 
are its anabolic effects of glucose uptake and glycogen production. The degree 
of insulin suppression and insulin resistance and the resultant hyperglycaemia 
has been shown to be related to the severity of trauma (Thorell et al 1999). In 
this study a median reduction of insulin levels was measured in the post-
operative interval up to 24 hours in both groups of subjects, however, the 
changes were not significantly different. Thereafter, median levels returned to 
the control values. This, once again, may reflect the lesser amount of trauma 
caused by laparoscopic surgery and an earlier reestablishment of an oral diet.  
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Surgery is recognised to cause an increase in insulin resistance which 
compounds the hyperglycaemia generated by the elevated cortisol levels and 
reduced insulin secretion in the post-operative period (Thorell et al 1999). The 
HOMA model was used to calculate insulin resistance, with values above 2.4 
indicating resistance (Wang et al 2010). The HOMA model is a well established 
method for determining insulin resistance but the hyperinsulinaemic 
euglycaemic clamp is generally recognised as the gold standard method  
(Wallace et al 2004), however this technique was impractical in this study. In 
this study we identified a fall of insulin resistance as measured at three hours in 
the whole cohort, with median levels remaining low after six and 12 hours. At 24 
and 48 hours median values increased above the control levels but the wide 
spread of absolute value precluded these increases being different from control. 
This is somewhat contrary to the available evidence, where an increase of 
insulin resistance might be expected immediately in the post-operative phase  
(Ljungqvist et al 2002; Wang et al 2010). At three hours the fall in insulin 
resistance was significantly greater in those patients receiving spinal analgesia 
compared with those receiving morphine PCA. This may reflect the reduced 
hyperglycaemia and cortisol levels that were measured at three hours in the 
spinal group. 
 
The use of spinal analgesia attenuates the endocrine/metabolic response in the 
immediate post-operative period in comparison with a morphine PCA. This is 
secondary to blockade of the spinal afferents and the subsequent stimulation of 
the HPA axis and release of cortisol. That this effect only lasts for the initial few 
hours post-operation is perhaps not unsurprising as 0.5% bupivacaine was 
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used, which will only have an effect for 6-8 hours. So, one could argue that if a 
thoracic epidural was used as recommended by the ERAS group (Lassen et al 
2009) a prolonged attenuation of the cortisol response would be achieved. As 
seen from the data in this study the cortisol response appears to have 
dissipated by 12 hours and there appears little benefit to be gained from leaving 
an epidural in situ for 48 hours, particularly as the majority of patients were 
being discharged on day one or day two. The use of spinal analgesia in the 
study had no effect on median insulin levels in the post-operative period in 
comparison to morphine PCA following laparoscopic colorectal surgery. 
 
Laparoscopic colorectal surgery produces a small and short-lived response in 
altered median insulin and cortisol levels and the resultant hyperglycaemia 
compared with open surgery. By 24 hours from the start of surgery this 
response has returned to baseline. This was demonstrated by nearly half (49%) 
of patients going home by the second post-operative day. The use of spinal 
analgesia did attenuate the immediate change in cortisol and glucose levels but 
this was not reflected in any change in length of stay in this study. 
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4.2.1 Validity of the oesophageal Doppler monitor 
The use of goal-directed fluid therapy to guide the intra-operative administration 
of intravenous fluids during colorectal surgery is highly recommended by the 
ERAS society (Lassen et al 2009), ASGBI and now NICE. The oesophageal 
Doppler monitor (ODM), is a practical and user-friendly method of achieving 
fluid optimisation in colorectal surgery, through achieving maximum 
cardiovascular function. There is, however, an opinion that this field is being 
lead by industry commercial imperatives rather than evidence-based medicine, 
and this is reflected in some of the published literature (Ghosh et al 2011). 
Indeed there have been some publications that have identified no benefit or 
even a detrimental effect in terms of length of stay and the incidence of 
complications with the use of ODM and goal-directed therapy (Brandstrup et al 
2012; Challand et al 2011). Whilst this study was not designed to directly 
measure any benefits from the use of an ODM system, some pertinent 
observations can nevertheless be made. 
 
A traditionalist would suggest that using traditional methods of haemodynamic 
monitoring and a standard volume-by-weight approach to guide fluid 
administration would be a more appropriate approach for peri-operative fluid 
management. In this study it was possible to calculate the amount of fluid used 
to achieve stroke volume optimisation prior to the pneumoperitoneum with units 
of ml per kg body weight (ml/kg). A wide range of normailsed fluid volumes was 
calculated, varying from 3 – 17 ml/kg for 6% Volulyte and 3 – 20 ml/kg for 
Hartmann’s solution. Thus if this standard formula alone was used the wide 
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range of values would indicate that there would be a significant number of 
patients who would be either under-filled or over-filled.  
 
The distribution of normalised fluid volumes required to optimise oxygen 
delivery through measurement of stroke volume (SV) prior to the 
pneumoperitoneum was positively skewed. The majority (80%) of patients 
receiving 6% Volulyte required less than 8 ml/kg, compared with only 50% who 
received Hartmann’s solution. In a 70kg patient this equates to approximately 
500 ml of fluid. It may be possible to propose that a standard 500ml infusion 
given to all patients would optimise SV following induction of anaesthesia. 
However, this would leave a large minority of patients under-filled with fluid: 
20% of patients receiving 6% Volulyte and 50% receiving Hartmann’s solution. 
It would thus be more appropriate to tailor fluid administration on an individual 
patient-specific basis with goal-directed therapy. Patients would then not be 
under-filled or over-filled but get the right amount of fluid at the right time. 
 
It is also important to record the total amount of fluid required to keep a patient 
SV-optimized until the end of surgery. The range of fluid required to maintain 
SV optimisation is large. Patients receiving 6% Volulyte required 3-27 ml/kg, 
and those with Hartmann’s solution required 11-42 ml/kg. The distribution of 
values resembled more of a normal distribution for Hartmann’s solution, but was 
still positively skewed for those receiving 6% Volulyte. The great majority (92%) 
of patients receiving 6% Volulyte required less than 19 ml/kg to maintain SV-
optimization, compared with only 45% of those receiving Hartmann’s solution. 
In a 70 kg patient 19 ml/kg equates to 1330 ml of fluid. Despite there being a 
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wide range of values, overall these are not very large volumes of infusates. 
Thus, a goal-directed approach seems both reasonable and sensible to guide 
fluid administration during laparoscopic colorectal surgery. 
 
One of the criticisms of the ODM approach is that patients who received larger 
volumes of fluid, as directed by the measured parameters, could experience 
fluid overload with the subsequent sequelae. Fluid overload will manifest itself 
as an increase in weight gain as well as bowel wall oedema, which is reflected 
by post-operative ileus. Considering the cohort of patients in this study those 
who received greater or less than 8 ml/kg to optimise SV prior to the 
pneumoperitoneum and those who received greater or less than 19 ml/kg for 
the whole operation showed no difference in maximum weight gain. The rate of 
ileus was also not different.  
 
Thus, it is possible to conclude from this study that a large range of fluid volume 
infusion is required by patients undergoing laparoscopic colorectal surgery. It is 
important to note that our patients were also within an enhanced recovery 
program. They did not, therefore, receive oral bowel preparation, and were all 
given oral carbohydrate loading pre-operatively. They should, therefore, be as 
near to their homeostatic state as possible. It is not possible to predict the 
amount of fluid required by an individual patient and it would therefore be 
recommended that the use of goal-directed fluid therapy to guide intra-operative 
fluid therapy was adopted. In this study, goal-directed fluid therapy was guided 
by use of the ODM. 
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4.2.2 Crystalloid or Colloid for goal-directed fluid 
therapy? 
It seems reasonable to expect that the oesophageal Doppler monitor (ODM) is 
a valid method of delivering goal-directed fluid therapy during colorectal 
surgery. All the trials investigating the validity of the ODM in colorectal surgery, 
as we discussed in section 1.8, used colloid boluses to fluid optimise the 
amount of fluid required to maintain peak cardiovascular function, based on 
measurement of stroke volume or cardiac output. There is, however, no 
evidence to suggest that a colloid solution would be more effective than using a 
crystalloid solution in order to achieve such fluid-optimisation. This study was 
not powered to determine any difference between crystalloid and colloid 
solutions when used in laparoscopic colorectal surgery. However, it was 
possible to randomly assign patients to receive either fluid type. 
 
Patients who received Hartmann’s solution required significantly greater 
volumes of fluid to optimise cardiac output based on measurement of stroke 
volume (SV) and to maintain this optimisation of SV during surgery, compared 
with those patients who received a colloid solution of 6% Volulyte. This is 
consequential to the distribution of fluids among the body compartments on 
delivery to the circulation, as explained in section 1.9. The different volumes of 
crystalloid or colloid solution administered does highlight the fact that the 
Doppler algorithm was sensitive to the cardiovascular changes irrespective of 
the particular fluid. Of interest was that the mean total volumes of fluid 
administered were not judged to be excessive being approximately 1000 ml in 
the 6% Volulyte group and 1600 ml in the Hartmann’s group.  Both of these 
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quantities were much less than the recommended maximum of 3000 ml by the 
ERAS group. 
 
Hartmann’s solution will cross the vascular wall more freely than 6% Volulyte 
leaving only approximately 20% of the infused volume in the intravascular 
compartment. This could in theory lead to greater tissue oedema, which is 
associated with subsequent weight gain and a delay in return of bowel function  
(Lassen et al 2009). Although the volume of Hartmann’s solution administered 
was significantly greater there was no significant difference detected in weight 
gain or increased abdominal circumference between the two groups. There was 
also no difference in the rate of post-operative ileus (12% in the 6% Volulyte 
group and 10% in the Hartmann’s group) or vomiting between the groups. A 
larger volume of infused fluid may also produce greater haemodilution, as 
reflected by a reduced haematocrit. Although there was a reduction of 
haematocrit, there was no significant difference of this magnitude detected 
between the two groups. 
 
Fluid overload is associated with weight gain and bowel wall oedema, which 
delays the return of gut function (Lassen et al 2009). The time to return of bowel 
sounds, first passage of flatus and return to oral diet were used to reflect the 
return of bowel function in the post-operative period. There was no significant 
difference detected in this study between the two groups. However, there was a 
significant difference in the median time to passage of first stool, with the 
Hartmann’s group being earlier at 2 days compared to 2.4 days in the 6% 
Volulyte group. There was also no significant difference in the number of 
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complications that occurred between the groups (see section 4.4). This 
similarity in outcomes was reflected by no significant difference in the median 
length of stay between the two fluid groups.  
 
The rapid distribution of an infused volume of Hartmann’s solution through the 
body compartments may lead to a reduction of oxygen delivery by the 
cardiovascular system. However, this was not seen in this study: there was no 
significant difference in the maximum indexed oxygen delivery with either fluid. 
In addition mixed venous oxygen saturations, which reflects the state of gut 
perfusion, also did not differ between the two groups.  
 
There has been some evidence that hydroxyl-ethyl starch colloids may produce 
a reduction of inflammatory responses following administration (Chen et al 
2013). From data in this study, using 6% Volulyte as the hydroxyl-ethyl starch 
colloid, there was no evidence of this. No significant difference was detected 
between this fluid infusion and that of Hartmann’s solution in any of the 
cytokines that were measured. Yates et al (Yates et al 2014) recent work 
corroborates with our findings for post-operative IL-6 levels. In addition this 
study also identified that there was no difference in outcomes between 6% 
hydroxyethylstarch and Hartmann’s solution when administered by GDFT with 
aid of a LiDCO Rapid monitor. The outcomes that were studied were recovery 
of bowel function, rate of complications and length of stay. The crystalloid group 
did receive a significantly greater volume of fluid as was found in this study. 
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Heavy molecular weight colloids (>200 kDa) may also cause acute kidney injury 
when infused in large volumes (Morris, & Rogerson 2011). However, no 
difference was detected in the post-operative serum creatinine levels between 
the two groups. However, the volumes infused in our study are low and 6% 
Volulyte only has a size of 130 kDa, so any differences might have been difficult 
to identify in this study. 
 
We have identified no difference in the measured outcomes of this study 
between the two fluid groups. While a greater number of patients receiving 
Hartmann’s solution received a greater volume of fluid compared to the 6% 
Volulyte group there was no difference detected in the biochemical or 
physiological parameters measured in this study. The maximum amount of 
Hartmann’s solution given to any one patient in this study was 3000 ml, a 
volume that would still be considered ‘restrictive’. However the median 
operative time for the study was only 98 minutes, a period that is considered to 
be relatively short in laparoscopic colorectal surgery.  
 
With operation times for difficult cases of rectal cancer surgery approaching four 
to six hours, the choice of fluid may become more relevant. Extrapolating from 
the mean total fluid given in our study, a six-hour case in an average body 
weight 70 kg patient may require approximately 4.3 litres with 6% Volulyte 
solution and 5.7 litres with Hartmann’s solution. Whether this difference of fluid 
infusions will produce measureable differences in physiological parameters was 
not possible to determine from this study but would be a useful further 
investigation. 
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It may be concluded that in these cohorts of patients there was no measureable 
difference between the administration of 6% Volulyte or Hartmann’s solution 
with the ODM. It must be emphasised that the study was not powered for this 
particular aspect and larger numbers may be required to determine any 
difference or otherwise. 
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4.3 The effect of analgesia on length of stay and post-
operative recovery 
Thoracic epidural is still widely used as the predominant method of analgesia in 
laparoscopic colorectal surgery, as discussed in section 1.3 of the introduction. 
There is good evidence to show that an epidural can delay discharge and is 
unnecessary in laparoscopic colorectal surgery (Levy et al 2011). Other 
techniques such as single-infusion spinal, PCA, transversus abdominis plane 
blocks, or a combination, are probably more appropriate in this setting. There is 
no definitive evidence to suggest which of these techniques, or combinations 
thereof, are most applicable.  
 
This study randomized patients to receive either a single-infusion spinal or 
morphine PCA as their primary postoperative analgesia. From the data 
gathered in this study it was possible to analyse if there was any advantage or 
disadvantage to a particular analgesic regime in terms of post-operative 
recovery. 
 
In the study cohort of 120 patients there was no significant difference detected 
in the length of hospital stay between the two analgesic methods used. Patients 
receiving spinal analgesia had a median length of stay of 2.25 days compared 
to 2.9 days in the PCA group. However the distribution of the number of 
patients discharged on each postoperative day was significantly different. 
Those patients receiving a spinal analgesia were more likely to be discharged 
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surgery. This has obvious important implications for a health-economical 
evaluation of the surgical procedure, as well as improving patient experience.  
 
The earlier discharge in the spinal group may be secondary to improved 
analgesia in the first two days following surgery. Patients receiving spinal 
analgesia showed significantly reduced pain scores at rest and also with 
movement at three, six and 12 hours following the start of surgery. At 24 and 48 
hours the pain scores were significantly reduced at rest but not during 
movement in the spinal group. This reduced postoperative pain will allow a 
patient to return to normal mobility as soon as possible. Failure to mobilise has 
been identified as a predictor for delayed discharge and deviation from recovery  
(Boulind et al 2011). A further indication of potentially reduced mobility in the 
early postoperative period is reflected by the significantly greater number of 
patients in the PCA group who were too drowsy at three hours to record their 
pain score. There was no significant difference in the median operating time 
between the groups to account for this. 
 
There was a significantly greater number of patients in the PCA group (18%) 
who experienced a postoperative ileus compared to the spinal group (3%), 
p=0.008. The incidence of postoperative vomiting was also greater in the PCA 
group, although not significant (spinal 25% vs PCA 40%). An ileus could 
potentially delay discharge due to failure to establish an oral diet and reduced 
mobility. There was however no significant difference between the two groups 
in return of gastrointestinal function - as measured by time to bowel opening, 
passing flatus, return of bowel sounds or return of diet. In addition, no 
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significant difference was detected in the maximum increase of abdominal 
circumference between the groups. Those patients in the morphine PCA group 
received significantly greater amounts of morphine in the postoperative period 
in comparison with the opiate sparing spinal group. This is likely to have 
contributed to the incidence of postoperative ileus. 
 
A potential issue with the use of spinal analgesia is vasodilation of the 
peripheral vasculature. This can produce reduced afterload and hypotension. 
This may in turn require administration of increased fluid volumes to maintain 
mean arterial pressure within defined limits. There was, however, no significant 
difference in the amount of fluid required to maintain SV-optimisation during the 
operation between the two analgesic methods. Patients receiving spinal 
analgesia were significantly more likely to have phenylephrine administered and 
in larger amounts to maintain mean arterial pressure when SV optimised.  
 
With the use of vasoconstrictors to maintain MAP there is the risk of affecting 
oxygen delivery due to poor microcirculatory flow. No significant difference, 
however, was detected between the analgesia groups in the measured mean 
maximum indexed oxygen delivery. A further concern is reduced gut perfusion 
with spinal analgesia due to distribution of fluid to the peripheral tissues, and a 
failure to recognize this and manage it appropriately. At three and 24 hours 
following the start of surgery there was no difference measured in the mixed 
central venous oxygen saturation (a surrogate indicator of gut perfusion). At six 
hours the spinal group had a significantly reduced saturation compared to the 
PCA group, albeit only by 4%. At this time point the spinal analgesic is still 
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functioning but no oesophageal monitoring was being performed to guide fluid 
administration. 
 
From this study it appears that the use of morphine PCA can significantly 
increase the rate of postoperative ileus, and control pain less well. However, the 
time to return of gut function or the length of postoperative stay does not differ 
when compared with those patients receiving spinal analgesia. Therefore, with 
regards to discharge and postoperative recovery no clear recommendation can 
be made in favour of either spinal or morphine PCA from this study. 
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4.4 Complications 
Thirty-two (27%) out of 120 patients experienced one or more complications 
during the trial. There was no significant difference in the number or distribution 
of complications between the four groups for the whole trial. There was no 
significant difference in the distribution of complications between the analgesia 
groups, but the PCA group had a significantly greater total number of 
complications. This was a reflection of the greater incidence of postoperative 
ileus in the PCA patients.  
 
There was a very low 30-day mortality rate of 0.8% (1/120) for the study. One 
patient experienced an anastomotic leak, and continuity of bowel was 
subsequently restored. The readmission rate was 8.3%, in line with previously 
published data for this unit (Levy et al 2011). There was almost 100% 
adherence to the elements of the ERAS protocol in this study. Two patients 
failed to receive oral carbohydrate loading prior to surgery. 
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4.5 Limitations of the study 
No study is perfect, and this study does have its limitations. This section will 
briefly highlight these and the reader is urged to consider them when analyzing 
this manuscript. 
 
As mentioned the study identified no significant differences between the two 
fluid types used in the biochemical or physiological parameters measured. This 
may be because there was no difference to detect, but the study design was not 
suitably powered to detect any difference so this conclusion cannot be made 
from these data. In addition the two fluids administered in this study were not 
blinded to the primary investigator, and so there is the possibility of observer 
bias in the results that were obtained. 
 
Patients were operated on at different times of the day, which will undoubtedly 
have had an effect on the measured values of the biochemical parameters. 
Ideally all patients would have had their operation at the same time of day, 
however, this is impractical in a busy NHS hospital. This in part may reflect the 
wide error bars that were identified for the biochemical parameters measured. 
The biochemical parameters measured are sensitive to many changes within an 
individual and as such a significantly greater number of patients would probably 
be required than were used in this study. 
 
This study was a single-centre study and as discussed earlier the median 
operating time was just over an hour and a half, which is relatively quick. Ideally 
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the study should be multi-centred which would have made the data more 
applicable to a diverse patient population.  
 
This study has had to make some suppositions regarding the use of a thoracic 
epidural in laparoscopic colorectal surgery. This study has suggested that as 
the stress response following surgery with either a spinal or morphine PCA had 
returned to normal by 24 – 48 hours, using a thoracic epidural in this group of 
patients as indicated by previous work would provide no additional benefit and 
may even have a detrimental effect (Levy et al 2011). However, there was no 
epidural group used within this study under guidance from the local ethics 
committee. So this study can provide no direct evidence to that effect. 
 
The IL-2 levels measured in this study were below the detectable range of the 
assay used in this study. As such no reliable conclusions can be drawn 
regarding IL-2. 
 
The heparin sample containers were collected and plasma was isolated from 
multiple samples at a convenient time later the same day. This will have 
introduced error to the cytokine values measured in this study. Ideally each 
sample would have been prepared for storage as soon as it was collected, 
however, there was simply not the manpower to conduct the study in this way. 
 
This study used 6% Volulyte, a low molecular weight hydroxyl-ethyl starch in a 
balanced solution, which subsequent to cessation of the study has been 
banned from use in the UK. There have been concerns over an increased risk 
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of acute kidney injury and mortality with all starch colloids, particularly in the 
cohort of patients being treated for sepsis. This study identified no such 
evidence to this effect in patients undergoing elective laparoscopic colorectal 
surgery with fluid administered in a goal-directed manner. 
 
In general, the results of this study must be viewed in the context of an overall 
enhanced recovery after surgery programme. Within multi-modal programmes 
of this type single interventions, i.e: one type of analgesia method, are likely to 
have only marginal gains on overall patient outcomes. 
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4.6 Further work 
This study has identified some potential avenues for further research. 
 
As discussed in the introduction of this thesis the method of analgesia used 
may have an effect on the function of the immune system during the post-
operative period. This may have potential implications for the incidence of 
recurrence of colorectal cancer. It would be interesting to measure various 
elements of immune function as was discussed in section 1.4.3 and correlate 
these with the method of analgesia used. Unfortunately this was not possible 
within the financial and time constraints of this study. 
 
Just over half of the patients in this study had surgery for colorectal cancer with 
roughly an even split between the two analgesic modalities. Subsequent 5-year 
survival analysis of this randomised cohort of patients should be conducted to 
identify if any difference exists between the two analgesia types. 
 
Part of this study compared the differing effects of a colloid and a crystalloid on 
measured physiological parameters. An additional biochemical parameter that 
could be measured is copeptin, a stable surrogate marker for vasopressin  
(Szinnai et al 2007). Vasopressin levels, and hence copeptin, will increase with 
raised plasma osmolality levels and a reduction in blood volume (Szinnai et al 
2007). As the effect of these fluids on fluid balance in the post-operative period 
are important, measurement of copeptin levels may provide a way of 
quantifying any variability. 
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Appendix A: Information sheet 
 
 
 
PROFESSOR T A ROCKALL 
Consultant Surgeon 
 
Departments of Colorectal and Minimal Access 
Surgery 
 
Tel:  01483 402769 (secretary)  
Fax: 01483 464157 
Email:  ldunn@royalsurrey.nhs.uk 
 
Egerton Road 
Guildford 
Surrey 
GU2 7XX 
 
 
 
PATIENT INFORMATION SHEET 
 
Trial Title: The Stress Response in Laparoscopic 
Colorectal Surgery and its role in the Development of the 
Enhanced Recovery Program. 
 
Thank you for reading this information sheet. 
 
You are being invited to take part in a research trial, which will also contribute to 
a postgraduate degree (MD) for the chief investigator.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to 
others about the trial if you wish.  
 
If there is anything that is unclear or you would like more information please do 
not hesitate to ask.  Take time to decide whether or not you wish to take part. 
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What is the purpose of the trial? 
 
Until relatively recently tummy operations were performed requiring a large cut. 
Consequently this required a long stay in hospital after the operation because of 
the cut and the pain relief required. Laparoscopic (keyhole) surgery has 
become the gold standard for patients undergoing major bowel surgery.  
 
The use of laparoscopic surgery has been shown to reduce the length of time in 
hospital after an operation. Patients can have far smaller cuts and have a 
reduced need for pain relief after the operation. What is currently unknown is 
the correct type of pain relief to have after the operation, which fluid to use 
during surgery, and how this affects the levels of various substances released 
as a result of the surgery. 
 
Why have I been chosen? 
 
All patients with large bowel disease who are suitable for laparoscopic surgery 
and who meet the required inclusion criteria are being invited to participate. We 
are planning to recruit 128 patients. 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You 
are still free to withdraw at any time without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
 
What will happen to me if I take part? 
 
In order to determine which method of pain relief/fluids is best you will be 
assigned to a group receiving one of the treatments. To ensure that the groups 
are the same you will be allocated to a group randomly (as if tossing a coin).  
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There are two methods of pain relief commonly used after surgery of this kind 
and you will be assigned to one of these. In one method a painkiller (morphine) 
is given via a pump controlled by you. In the other method a spinal anaesthetic 
is used- where a painkiller is introduced into your spine by a needle just before 
surgery. During the operation you will also receive fluids through your vein. 
These will either be Hartmann’s (a salt-containing water) or Volulyte® (a 
mixture of water and starch). All these methods are currently used but we don’t 
know which is best. 
 
You will have blood drawn for later analysis. This will be drawn by the chief 
investigator prior to commencement of the anaesthetic and also during the 
period following the operation. This will be taken from a central venous line 
(long thin plastic tube) placed in your neck at the time of surgery at four time 
intervals after surgery. The central venous line is not being placed for the 
benefit of this study; it is a normal standard of care for all patients undergoing 
bowel resections. On one subsequent occasion (second day) after your 
operation you will have blood taken from a vein in your arm, as the line in your 
neck will now have been removed. 
  
Throughout the trial, you will have contact details of the investigators and 
doctors involved, and you may ask for advice or help at any time. 
 
Your personal information will be held in password-protected files, identical to 
your standard files. Only your doctors and the investigator will have access to 
your information, and this will not be shared with anyone else.  
 
What are the benefits? 
 
You will receive a high level of care and vigilance throughout the study by the 
team looking after you and the chief investigator.  
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What are the side effects? 
 
The different types of pain relief and fluids we will be using are currently in use 
within the hospital. There are some side effects associated with their use. 
Spinal pain relief can cause itching, headaches or rarely nerve damage. 
Morphine, which is given via the patient controlled pump, can cause itching, 
sickness and drowsiness. Additional hospital information sheets are included 
with this information sheet. 
 
Volulyte® (a mixture of starch and water) can cause itching, tissue swelling and 
rarely allergic reactions. Hartmann’s (a salt containing water) can cause tissue 
swelling and may require greater volumes to be given. 
 
Will my taking part in the study be kept confidential?  
 
Yes. All the information about your participation in this study will be kept 
confidential.   
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak 
with the researchers who will do their best to answer your questions.  If you 
remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure.  Details can be obtained from the hospital. 
  
If you are harmed and this is due to someone’s negligence then you may have 
grounds for a legal action for compensation against the NHS but you may have 
to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
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What will happen to the results of the research trial? 
 
The information from this trial will lead to publications within peer-reviewed 
journals, but this will be anonymous. Your personal information will never be 
used. 
 
Who is organising and funding the research?   
 
The study is fully funded by the Minimal Access Therapy Training Unit, 
Guildford. 
 
Who has reviewed the study?  
 
Ethical approval has been obtained from the Brighton West research ethics 
committee. 
 
If you are interested in participating, or you wish to get more information, please 
contact me. 
 
Mr. Andrew Day 
Royal Surrey County Hospital 
Egerton Road 
Guildford 
GU2 7XX  
Tel: 01483 402769   
Email: ldunn1@nhs.uk 
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Appendix B: Consent form 
 
 
CONSENT FORM 
 
 
Title of Project: The Stress Response in Laparoscopic Colorectal Surgery and its                   
role in the Development of the Enhanced Recovery Program. 
 
Name of Researcher:  Andrew Day       Please initial  
 
1. I confirm that I have read and understand the patient information      
for the above trial. I have had the opportunity to consider  
 the information, ask questions and have had these answered  
 satisfactorily.             __________
           
2. I understand that my participation is voluntary and that I am free to  
 withdraw from the trial at any time, and that my medical care will  
 not be affected in any way.           __________ 
 
3. I understand that relevant sections of my medical notes and data  
 collected during the study, may be looked at by individuals from 
 regulatory authorities or from the NHS Trust, where it is relevant 
 to my taking part in this research. I give permission for these  
 individuals to have access to my records.          __________
        
 
4.   I agree to take part in the above trial.          __________ 
 
                                                            
________________________ _______________________       ________________      
Name of Patient Signature      Date  
 
 
 
_________________________ _______________________       ________________ 
Name of Person taking consent Signature      Date 
(if different from researcher) 
 
 
_________________________ _______________________      ________________ 
Researcher Date  Signature 
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Appendix C: Data collection sheet 
Stress response trial data collection 
 
Patient Details: 
 
PMH:      DH: 
 
 
WEIGHT HEIGHT BSA 
ENEMA 
NA  /  1  
PRELOAD 
0  /  1  /  2 
ABDO CIRCUM 
DATE START SURGERY STOP SURGERY 
 
 
Surgery:       Pre-op BP: 
 
 
Antibiotics:      DOSA: Y / N 
 
Group: Sp-Vol  /  Sp-Har  /  PCA-Vol / PCA-Har 
 
ASA:     Control bloods taken: Y  /  N 
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MUST Nutritional Score 
 
BMI (kg/m2): 
>20 
>30 
18.5-20 
<18.5 
0 
0 
1 
2 
Score: 
 
Unplanned weight loss in last 3-6 mths: 
< 5% 
5-10% 
>10% 
0 
1 
2 
Score: 
 
Acute disease effect score: 
If patient is acutely ill 
and no nutritional 
intake for >5 days 
2  
 
Total (above 3 added): 
 
 
0 
1 
>2 
Low risk 
Medium risk 
High risk 
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P-POSSUM 
 
AGE GCS UREA 
HR HB (g/dl) WBC 
POTASSIUM SODIUM SYSTOLIC BP 
NO. PROCEDURES BLOOD LOSS MODE 
 
Elective  /  Emergency 
 
 
Respiratory: 
No SOB 
SOB on exertion or 
COPD on CXR 
Limiting SOB (1 
flight) or mod. COPD 
on CXR 
SOB at rest or 
fibrosis/consolidation 
 
Cardiac Signs: 
No Failure 
Diuretics/Digoxin/An
tianginal/AntiBP 
Peripheral 
oedema/Warfarin/Bor
derline cardiomegaly 
Raised 
JVP/Cardiomegaly 
 
ECG: 
Normal AF (60-90) 
Another abnormal 
rhythm/>5 EVS/min/q 
waves/ST-T changes 
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Operative Severity: 
 
Minor Moderate 
Major (bowel 
resection) 
Major+ (APR) 
 
Peritoneal Soiling: 
 
None Serous Fluid Local pus 
Free 
Faeces/pus/blood 
 
Cancer: 
 
None Primary Nodal disease Distant Mets 
 
 
Physiologic Score: 
 
Operative Score: 
 
Combined POSSUM Score: 
 
Predicted morbidity rate: 
 
Predicted Mortality rate (POSSUM): 
 
Predicted Mortality rate (P-POSSUM): 
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GA given as required: 
 
CV Oxygen sats at 25 mins: 
 
Volume of fluid given in theatre: 
 
Post-op analgesia prescribed: 
 
Post-op fluids prescribed (8hrs/12hrs): 
 
Post-op antibiotics: 
 
RECOVERY: 
 
Time in: 
 
Time out: 
 
Spinal analgesia level on assessment: 
 
 
TIME PAIN SCORE AT REST PAIN SCORE ON 
MOVEMENT 
   
   
 
CV O2 Sats: 
 
Time 25 Mins Recovery 6 hrs 24hrs 
Measurement     
If <60% give 500ml bolus- rpt CvO2 sats after bolus are=  
 
Time in evening: 
Pain score at rest:   Pain score on movement: 
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BREAKTHROUGH ANALGESIA?: 
 
 
3hr bloods to be taken at: 
 
 Taken:  Y  /  N 
 
6hr bloods to be taken at: 
 
 Taken:  Y  /  N 
 
12hr bloods to be taken at: 
 
 Taken:  Y  /  N 
 
24hr bloods to be taken at: 
 
 Taken:  Y  /  N 
 
48hr bloods to be taken at: 
 
 Taken:  Y  /  N 
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TAR Database Details 
 
Diagnosis:        Age: 
 
Pre-op DXT/Chemo:  Yes   /   No 
Curative Procedure:  Yes  /   No 
NHS  /  PP 
Surgeon: Cons  /  SpR 
Analgesia:  Spinal  /  PCA  
Anaesthetist: Scott  /  Stoneham  /  Fawcet  /  Dickinson / other 
 
Operation details: 
 
 Ports/incision? 
 
 
 
 
 
 
 
 
Post-op care:  ITU  /  HDU  /  Ward 
 
Anaesthetic start time: 
 
Operation start time: 
 
Operation end time: 
 
Complications: 
Splenic flexure mobilized?: 
 
 
Conversion and reason: 
 
 
Stoma and reason: 
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Post-op Day 
 
Fluids up to midnight: 
IVI given Oral fluid given Total fluid given 
UO Balance WCC: 
CRP: 
Crit: 
Hb: 
 
 
Fluids from midnight to 08:00: 
IVI given Oral fluid given Total fluid given 
UO Balance  
 
 
Time: 
 
SV cvc 02: 
 
24hr Bloods taken:  Y  /  N 
 
Pain at rest: 
 
Pain on movement: 
 
Weight: 
 
Abdo Circumference:     TWOC?: 
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AM: 
 
HR BP SATS 
TEMP BS BOWELS OPEN 
VOMITING/Nausea ANTI-EMETICS FLATUS 
 
 
 
PM MEASUREMENTS: 
 
HR BP SATS 
TEMP BS BOWELS OPEN 
 
PAIN AT REST PAIN ON MOVEMENT NORMAL DIET? 
BREAKTHROUGH 
ANALGESIA: 
REGULAR 
ANALGESIA: 
Para: 
Voltarol: 
Tramadol: 
FLATUS 
 
 
 
Amount of morphine from PCA: 
 
?stopped:  
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Complications?: 
 
 
 
 
Total post-op IVI: 
 
Total amount of Paracetamol: 
 
Total amount of voltarol: 
 
Total amount of tramadol: 
 
If tramadol was for breakthrough- How much?: 
 
Total amount of morphine from PCA: 
 
Total amount of morphine as breakthrough: 
 
Total amount of cyclizine: 
 
Total amount of ondansetron: 
 
 
Time to opening bowels: 
 
Time to first passing flatus: 
 
Time to bowel sounds: 
 
Time to tolerate meal: 
 
Time medically fit for discharge: 
 
Time left hospital: 
 
Length of stay: 
 296 
 
Appendix D: Blood request form 
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Appendix E: Additional blood results data 
E.1: Glucose 
Table E.1: Percentage change of postoperative glucose levels from the 
preoperative level for the four groups. Median values with interquartile 
ranges. p-value for multiple groups determined by an Independent-
samples Kruskal-Wallis test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
0.14 
(-0.22-
0.31) 
0.09 
(-0.18-0.23) 
0.2 
(0.02-0.38) 
0.15 
(-0.24-0.66) 
0.281 
6 hours 
0.05 
(-0.18-
0.38) 
0.04 
(-0.19-0.15) 
0.16 
(-0.02-
0.32) 
0.06 
(-0.27-0.52) 
0.227 
12 hours 
0.21 
(-0.1-0.43) 
0.16 
(-0.02-0.4) 
0.24 
(-0.04-
0.48) 
0.11 
(-0.19-0.46) 
0.720 
24 hours 
0.17 
(0.01-0.46) 
0.22 
(-0.06-0.39) 
0.18 
(-0.11-
0.54) 
0.2 
(-0.2-0.53) 
0.876 
48 hours 
0.19 
(-0.22-0.5) 
0.2 
(-0.3-0.42) 
0.29 
(-0.11-
0.58) 
0.05 
(-0.23-0.49) 
0.60 
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Table E.2: Percentage change of postoperative glucose levels from the 
preoperative level for the combined analgesia and fluid groups. Median 
values with interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
0.1 
(-0.2-
0.28) 
0.2 
(-0.15-
0.44) 
0.075 
0.18 
(-0.06-
0.36) 
0.09 
(-0.22-0.35) 
0.433 
6 hours 
0.04 
(-0.18-
0.23) 
0.1 
(-0.12-
0.32) 
0.225 
0.1 
(-0.09-
0.33) 
0.06 
(-0.24-0.22) 
0.094 
12 hours 
0.18 
(-0.07-
0.42) 
0.14 
(-0.05-
0.46) 
0.967 
0.23 
(-0.05-
0.45) 
0.13 
(-0.13-0.45) 
0.350 
24 hours 
0.19 
(-0.01-
0.45) 
0.19 
(-0.11-
0.53) 
0.90 
0.18 
(0.002-
0.48) 
0.21 
(-0.18-0.47) 
0.534 
48 hours 
0.19 
(-0.23-
0.44) 
0.17 
(-0.11-
0.56) 
0.719 
0.2 
(-0.11-
0.56) 
0.09 
(-0.24-0.46) 
0.418 
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E.2: Insulin 
Table E.3: Percentage change of insulin levels from the preoperative level 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.38 
(-0.81-0.08) 
-0.42 
(-0.87-0.04) 
-0.21 
(-0.66-0.38) 
-0.61 
(-0.87-0.22) 
0.344 
6 hours 
-0.67 
(-0.85- -
0.34) 
-0.69 
(-0.91- -
0.24) 
-0.48 
(-0.75- -
0.14) 
-0.77 
(-0.91-0.03) 
0.547 
12 hours 
-0.48 
(-0.71-0.11) 
-0.3 
(-0.87-0.24) 
-0.33 
(-0.7- -0.06) 
-0.52 
(-0.82-0.09) 
0.807 
24 hours 
0.63 
(-0.2-2.82) 
0.52 
(-0.63-3.21) 
0.59 
(-0.4-4.54) 
0.21 
(-0.67-1.83) 
0.625 
48 hours 
1.1 
(-0.47-3.36) 
0.66 
(-0.51-2.68) 
0.84 
(-0.42-7.33) 
0.47 
(-0.63-1.06) 
0.647 
 
Table E.4: Percentage change of insulin levels from the preoperative level 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
-0.41 
(-0.85-
0.04) 
-0.36 
(-0.77-
0.34) 
0.352 
-0.28 
(-0.71-
0.24) 
-0.43 
(-0.87-0.07) 
0.147 
6 hours 
-0.67 
(-0.86- -
0.31) 
-0.53 
(-0.88- -
0.09) 
0.459 
-0.54 
(-0.81- -
0.21) 
-0.73 
(-0.91- -
0.09) 
0.232 
12 hours 
-0.4 
(-0.79-
0.13) 
-0.38 
(-0.75-
0.00) 
0.827 
-0.38 
(-0.7- -
0.01) 
-0.39 
(-0.85-0.18) 
0.591 
24 hours 
0.52 
(-0.42-
2.88) 
0.35 
(-0.55-
2.86) 
0.827 
0.6 
(-0.29-
3.78) 
0.4 
(-0.62-2.46) 
0.204 
48 hours 
0.91 
(-0.5-
2.87) 
0.62 
(-0.57-
2.4) 
0.819 
0.87 
(-0.47-
3.36) 
0.56 
(-0.58-1.81) 
0.265 
  300 
E.3: IL-4 
Table E.5: Percentage change of IL-4 levels from the preoperative level for 
the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.3 
(-0.5- -
0.2) 
-0.4 
(-0.6- 0) 
-0.3 
(-0.7- -
0.03) 
-0.3 
(-0.6-0.2) 
0.655 
6 hours 
-0.01 
(-0.4-0.9) 
0 
(-0.5-0.3) 
-0.03 
(-0.5-0.3) 
-0.1 
(-0.6-0.3) 
0.810 
12 hours 
-0.08 
(-0.4-0.5) 
-0.2 
(-0.6-0.2) 
0.06 
(-0.5-0.4) 
0.1 
(-0.3-1) 
0.416 
24 hours 
0 
(-0.3-0.4) 
-0.2 
(-0.6-0.5) 
-0.07 
(-0.5-0.6) 
-0.1 
(-0.4-0.2) 
0.764 
48 hours 
-0.3 
(-0.7-0.3) 
-0.2 
(-0.4-0.7) 
-0.2 
(-0.7-0.2) 
-0.2 
(-0.6-0.3) 
0.889 
 
Table E.6: Percentage change of IL-4 levels from the preoperative level for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours -0.3 
(-0.5-0) 
-0.3 
(-0.7-0) 0.904 
-0.3 
(-0.6- -
0.1) 
-0.3 
(-0.6-0) 0.844 
6 hours 
0 
(-0.4-
0.4) 
-0.1 
(-0.5-
0.3) 
0.649 -0.01 
(-0.4-0.5) 
0 
(-0.6-0.2) 0.405 
12 hours 
-0.1 
(-0.4-
0.5) 
0.1 
(-0.3-
0.7) 
0.441 -0.07 
(-0.4-0.5) 
-0.2 
(-0.4-0.5) 0.830 
24 hours 
-0.04 
(-0.5-
0.4) 
-0.1 
(-0.4-
0.4) 
0.880 0 
(-0.4-0.4) 
-0.1 
(-0.5-0.3) 0.412 
48 hours 
-0.2 
(-0.6-
0.3) 
-0.2 
(-0.6-
0.2) 
0.563 -0.2 
(-0.7-0.2) 
-0.2 
(-0.6-0.3) 0.648 
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E.4: IL-8 
Table E.7: Percentage change of IL-8 levels from the preoperative level for 
the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.57 
(-0.81- -
0.17) 
-0.69 
(-0.87- -
0.37) 
-0.4 
(-0.84- -
0.21) 
-0.78 
(-0.89- -
0.45) 
0.272 
6 hours 
-0.6 
(-0.87- 
0.63) 
-0.72 
(-0.88- -
0.21) 
-0.54 
(-0.86- -
0.05) 
-0.72 
(-0.88- -
0.27) 
0.542 
12 hours 
-0.64 
(-0.88-1.02) 
-0.54 
(-0.93-0.2) 
0 
(-0.86-1.26) 
-0.59 
(-0.87-0.3) 
0.336 
24 hours 
-0.1 
(-0.8-0.93) 
-0.63 
(-0.93- -
0.05) 
-0.15 
(-0.89-3.89) 
-0.21 
(-0.86-0.36) 
0.121 
48 hours 
-0.58 
(-0.87-0.29) 
-0.84 
(-0.95- -
0.54) 
-0.67 
(-0.91- -
0.12) 
-0.85 
(-0.93- -
0.45) 
0.101 
 
Table E.8: Percentage change of IL-8 levels from the preoperative level for 
the combined analgesia and fluid groups. Median values with interquartile 
ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
-0.65 
(-0.84- 
-0.28) 
-0.69 
(-0.85- 
-0.33) 
0.848 
-0.5 
(-0.83- -
0.18) 
-0.73 
(-0.88- -
0.44) 
0.054 
6 hours 
-0.66 
(-0.88-
0.03) 
-0.7 
(-0.88- 
-0.19) 
0.682 -0.58 
(-0.86-0.09) 
-0.72 
(-0.88- -
0.28) 
0.182 
12 hours 
-0.59 
(-0.9- 
0.58) 
-0.49 
(-0.86-
0.63) 
0.440 -0.08 
(-0.86-1.07) 
-0.55 
(-0.9-0.25) 0.095 
24 hours 
-0.34 
(-0.86-
0.49) 
-0.19 
(-0.87-
1.21) 
0.472 -0.15 
(-0.83-2.63) 
-0.44 
(-0.88-0.18) 0.038 
48 hours 
-0.74 
(-0.91- 
-0.21) 
-0.78 
(-0.92- 
-0.35) 
0.615 -0.65 
(-0.88-0.05) 
-0.85 
(-0.94- -
0.47) 
0.017 
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E.5: IL-10 
Table F.9: Percentage change of IL-10 levels from the preoperative level 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.31 
(-0.58- -
0.11) 
-0.24 
(-0.39- -
0.01) 
-0.1 
(-0.3-0.02) 
-0.2 
(-0.4-0.32) 
0.102 
6 hours 
0.06 
(-0.38-0.63) 
-0.06 
(-0.47-0.33) 
0.1 
(-0.23-0.5) 
0.01 
(-0.37-0.44) 
0.765 
12 hours 
0.34 
(-0.27-1.3) 
0.05 
(-0.11-0.4) 
0.48 
(0.04-1.17) 
0.08 
(-0.3-0.8) 
0.130 
24 hours 
0.03 
(-0.31-0.91) 
-0.24 
(-0.52-0.36) 
0.31 
(-0.21-
0.99) 
-0.15 
(-0.38-0.68) 
0.071 
48 hours 
-0.25 
(-0.62-0.51) 
-0.4 
(-0.69- -
0.14) 
-0.26 
(-0.53-
0.08) 
-0.51 
(-0.66- -
0.01) 
0.412 
 
Table E.10: Percentage change of IL-10 levels from the preoperative level 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
-0.29 
(-0.55- 
-0.02) 
-0.17 
(-0.35-
0.04) 
0.027 -0.23 
(-0.55-0) 
-0.21 
(-0.39-0.02) 
0.417 
6 hours 
-0.03 
(-0.38-
0.37) 
0.04 
(-0.29-
0.45) 
0.584 
0.07 
(-0.33-
0.49) 
-0.04 
(-0.37-0.38) 
0.368 
12 hours 
0.2 
(-0.15-
0.81) 
0.28 
(-0.15-
0.97) 
0.775 
0.44 
(-0.1-1.2) 
0.07 
(-0.22-0.53) 
0.02 
24 hours 
-0.21 
(-0.4-
0.75) 
0.05 
(-0.36-
0.96) 
0.326 
0.13 
(-0.26-
0.99) 
-0.23 
(-0.43-0.45) 
0.016 
48 hours 
-0.33 
(-0.67-
0.29) 
-0.37 
(-0.64-
0.01) 
0.758 
-0.26 
(-0.6-0.25) 
-0.48 
(-0.68- -
0.06) 
0.094 
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E.6: IL-12 
Table E.11: Percentage change of IL-12 levels from the preoperative level 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.48 
(-0.65- -
0.26) 
-0.30 
(-0.49- -
0.08) 
-0.35 
(-0.49- -
0.18) 
-0.34 
(-0.57-0) 
0.185 
6 hours 
-0.27 
(-0.58-0.2) 
-0.27 
(-0.5-0.1) 
-0.14 
(-0.29-0.16) 
-0.26 
(-0.47-0.09) 
0.687 
12 hours 
0.29 
(-0.37-0.95) 
0.12 
(-0.37-0.47) 
0.24 
(-0.13-0.8) 
0.08 
(-0.36-0.63) 
0.263 
24 hours 
-0.13 
(-0.6-0.6) 
-0.39 
(-0.63- -
0.02) 
0.22 
(-0.36-0.64) 
-0.35 
(-0.58-0.48) 
0.115 
48 hours 
-0.32 
(-0.78-0.25) 
-0.55 
(-0.79- -
0.35) 
-0.42 
(-0.76- -
0.04) 
-0.55 
(-0.73- -
0.23) 
0.396 
 
Table E.12: Percentage change of IL-12 levels from the preoperative level 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
-0.37 
(-0.61- 
-0.12) 
-0.34 
(-0.54- 
-0.12) 
0.319 
-0.37 
(-0.58- -
0.19) 
-0.32 
(-0.56- -
0.05) 
0.127 
6 hours 
-0.27 
(-0.55-
0.11) 
-0.23 
(-0.36-
0.12) 
0.486 
-0.17 
(-0.43-0.17) 
-0.26 
(-0.47-0.09) 
0.372 
12 hours 
0.21 
(-0.37-
0.81) 
0.21 
(-0.28-
0.70) 
0.640 
0.26 
(-0.2-0.83) 
0.1 
(-0.35-0.48) 
0.058 
24 hours 
-0.28 
(-0.61-
0.44) 
-0.16 
(-0.47-
0.57) 
0.347 
0.11 
(-0.46-0.64) 
-0.36 
(-0.61-0.12) 
0.025 
48 hours 
-0.47 
(-0.78- 
-0.09) 
-0.47 
(-0.73- 
-0.12) 
0.938 
-0.39 
(-0.77-0.18) 
-0.55 
(-0.77- -0.3) 
0.099 
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E.7: IFN-γ 
Table E.13: Percentage change of IFN-γ levels from the preoperative level 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.43 
(-0.63- -
0.04) 
-0.17 
(-0.48-0) 
-0.28 
(-0.52-
0.08) 
-0.11 
(-0.36-0.23) 
0.111 
6 hours 
0 
(-0.38-0.27) 
-0.20 
(-0.5-0.15) 
-0.22 
(-0.46-
0.02) 
-0.06 
(-0.43-0.47) 
0.517 
12 hours 
-0.13 
(-0.40-0.82) 
-0.15 
(-0.37-0.18) 
0.17 
(-0.16-
1.02) 
0 
(-0.31-0.71) 
0.199 
24 hours 
-0.27 
(-0.53-1.1) 
-0.29 
(-0.46-0.25) 
0 
(-0.33-
0.39) 
-0.11 
(-0.32-0.28) 
0.515 
48 hours 
-0.14 
(-0.66-0) 
-0.32 
(-0.75- -
0.04) 
-0.21 
(-0.67-0.44 
-0.28 
(-0.71-0) 
0.688 
Table E.14: Percentage change of IFN-γ levels from the preoperative level 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
-0.32 
(-0.55-
0) 
-0.23 
(-0.44-
0.15) 
0.065 
-0.33 
(-0.56-0) 
-0.17 
(-0.44-0.16) 
0.115 
6 hours 
-0.09 
(-0.48-
0.26) 
-0.13 
(-0.45-
0.24) 
0.932 
-0.13 
(-0.4-0.19) 
-0.08 
(-0.46-0.26) 
0.955 
12 hours 
-0.14 
(-0.38-
0.32) 
0.10 
(-0.26-
0.89) 
0.118 
0.1 
(-0.29-
0.89) 
-0.1 
(-0.32-0.3) 
0.155 
24 hours 
-0.27 
(-0.46-
0.28) 
0 
(-0.32-
0.31) 
0.235 
-0.02 
(-0.46-
0.56) 
-0.22 
(-0.41-0.26) 
0.368 
48 hours 
-0.29 
(-0.72- 
-0.03) 
-0.28 
(-0.69-
0.12) 
0.543 
-0.14 
(-0.66-
0.15) 
-0.30 
(-0.73- -
0.03) 
0.288 
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E.8: TNF-α 
Table E.15: Percentage change of TNF-α levels from the preoperative level 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. The sub-table shows the comparisons between the groups. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-0.38 
(-0.46- -
0.15) 
-0.06 
(-0.51-0) 
0 
(-0.37-
0.61) 
-0.18 
(-0.48-0.33) 
0.460 
6 hours 
-0.11 
(-0.44-0.61) 
0.10 
(-0.09-1.38) 
0.15 
(0-1.69) 
0 
(-0.44-0.25) 
0.032* 
12 hours 
-0.06 
(-0.27-0.65) 
0 
(-0.42-1.34) 
0.43 
(-0.13-
2.05) 
-0.17 
(-0.41-0.52) 
0.241 
24 hours 
0 
(-0.38-0.48) 
0 
(-0.49-0.55) 
0.56 
(0-3.40) 
0.13 
(-0.25-1.68) 
0.066 
48 hours 
-0.27 
(-0.52-0.26) 
-0.28 
(-0.64-0) 
0.22 
(-0.18-
2.10) 
-0.47 
(-0.61-0.18) 
0.141 
*Pairwise comparisons at six hours 
  p 
Spi/Vol 
Spi/Hart 0.371 
PCA/Vol 0.06 
PCA/Hart 1 
Spi/Hart 
PCA/Vol 1 
PCA/Hart 0.891 
PCA/Vol PCA/Hart 0.189 
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Table E.16: Percentage change of TNF-α levels from the preoperative level 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
-0.29 
(-0.48-
0) 
-0.09 
(-0.42-
0.45) 
0.193 
-0.26 
(-0.42-
0.37) 
-0.15 
(-0.48-0.06) 
0.855 
6 hours 
0 
(-0.31-
0.90) 
0.02 
(0-
0.58) 
0.399 
0 
(-0.23-
0.81) 
0 
(-0.26-0.57) 
0.759 
12 hours 
-0.03 
(-0.39-
1.09) 
0.25 
(-0.30-
1.02) 
0.581 
0.07 
(-0.14-
1.34) 
-0.75 
(-0.41-0.85) 
0.158 
24 hours 
0 
(-0.44-
0.49) 
0.35 
(-0.11-
2.16) 
0.022 0.23 
(-0.20-1.4) 
0 
(-0.28-1.07) 
0.262 
48 hours 
-0.28 
(-0.52-
0.12) 
-0.06 
(-0.51-
1.56) 
0.477 
-0.03 
(-0.44-
1.56) 
-0.37 
(-0.61-0.12) 
0.137 
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E.9: VEGF 
Table E.17: Percentage change of VEGF levels from the preoperative level 
for the four groups. Median values with interquartile ranges. p-value for 
multiple groups determined by an Independent-samples Kruskal-Wallis 
test. The sub-table shows the comparisons between the groups. 
Post-operation 
time 
Spinal/ 
Volulyte 
Spinal/ 
Hartmann’s 
PCA/ 
Volulyte 
PCA/ 
Hartmann’s 
p-
value 
3 hours 
-.47 
(-0.60- -
0.31) 
-0.23 
(-0.39- -
0.05) 
-0.22 
(-0.35- -
0.09) 
-0.33 
(-0.49- -
0.08) 
0.004* 
6 hours 
-0.23 
(-0.47-0.17) 
-0.22 
(-0.37-0.26) 
-0.11 
(-0.30-0.09) 
-0.19 
(-0.37-0.07) 
0.814 
12 hours 
0.49 
(-0.37-0.99) 
0.14 
(-0.14-0.47) 
0.28 
(0.02-0.97) 
0.13 
(-0.34-0.6) 
0.307 
24 hours 
-0.08 
(-0.43-1.29) 
-0.22 
(-0.45-0.47) 
0.36 
(-0.25-0.73) 
-0.02 
(-0.42-0.66) 
0.319 
48 hours 
-0.16 
(-0.59-0.48) 
-0.43 
(-0.64- -
0.10) 
-0.26 
(-0.48-0.02) 
-0.46 
(-0.66- -
0.18) 
0.206 
*Pairwise comparisons at three hours 
  p 
Spi/Vol 
Spi/Hart 0.01 
PCA/Vol 0.008 
PCA/Hart 0.115 
Spi/Hart 
PCA/Vol 1 
PCA/Hart 1 
PCA/Vol PCA/Hart 1 
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Table E.18: Percentage change of VEGF levels from the preoperative level 
for the combined analgesia and fluid groups. Median values with 
interquartile ranges. 
Post-operation 
time Spinal PCA 
p-
value Volulyte Hartmann’s 
p-
value 
3 hours 
 -0.34 
(-0.54- 
-0.13) 
-0.27 
(-0.42- 
-0.09) 
0.09 
-0.33 
(-0.52- -
0.12) 
-0.28 
(-0.46- -
0.05) 
0.106 
6 hours 
-0.22 
(-0.42-
0.22) 
-0.14 
(-0.32-
0.07) 
0.560 
-0.14 
(-0.42-0.12) 
-0.21 
(-0.37-0.22) 
0.834 
12 hours 
0.26 
(-0.26-
0.81) 
0.21 
(-0.23-
0.72) 
0.773 
0.35 
(-0.15-0.96) 
0.13 
(-0.27-0.57) 
0.084 
24 hours 
-0.15 
(-0.45-
0.64) 
0.07 
(-0.36-
0.72) 
0.353 
0.09 
(-0.37-0.75) 
-0.18 
(-0.45-0.49) 
0.109 
48 hours 
-0.35 
(-0.62-
0.08) 
-0.38 
(-0.60- 
-0.01) 
0.792 
-0.19 
(-0.51-0.09) 
-0.44 
(-0.64- -
0.16) 
0.034 
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